cmd_id,cuis_selected,preferred,har_manual,X2nd_har,X3rd_har,final,final_cui
1,C0206158;C0282403,Premenopause Hormone replacement therapy,Hormone Therapy,,,Hormone Therapy,C0279025
1,C0206158;C0282402,Premenopause Hormone replacement therapy,Premenopause,Menopausal Status,,Menopausal Status,C1513126
2,C0206158;C1518422;C0282403,Premenopause Negation Hormone replacement therapy,Hormone Therapy,,,Hormone Therapy,C0279025
2,C0206158;C1518422;C0282402,Premenopause Negation Hormone replacement therapy,Premenopause,Menopausal Status,,Menopausal Status,C1513126
3,C0232970;C0282402;C1518423,Postmenopausal state Hormone replacement therapy Negation,Hormone Therapy,,,Hormone Therapy,C0279025
3,C0232970;C0282402;C1518422,Postmenopausal state Hormone replacement therapy Negation,Postmenopausal state,Menopausal Status,,Menopausal Status,C1513126
4,C3815594;C0043210;C0439810,Subject is Randomized Woman Total,Gender,,,Gender,C0079399
5,C0232970;C0282402;C0521116,Postmenopausal state Hormone replacement therapy Current (present time),Hormone Therapy,Hormone Therapy,,Hormone Therapy,C0279025
5,C0232970;C0282402;C0521116,Postmenopausal state Hormone replacement therapy Current (present time),Postmenopausal state,Menopausal Status,,Menopausal Status,C1513126
6,C0282402;C0025320,Hormone replacement therapy Menopause,Hormone Therapy,,,Hormone Therapy,C0279025
6,C0282402;C0025320,Hormone replacement therapy Menopause,Menopausal Status,,,Menopausal Status,C1513126
7,C1444637;C2003901;eitheror,In the past Never (frequency) Either one or other,NA TO BE DELETED,,,NA TO BE DELETED,NA
8,C0001948;C0332174,Alcohol consumption Weekly,Alcohol consumption,,,Alcohol consumption,C0001948
9,C0026606;C0332174;C0439259,Physical activity Weekly kilocalorie,Physical activity,,,Physical activity,C0026606
10,C0042874;C0034656;C1514756,Vitamin E Randomization Receive,Vitamin E,,,Vitamin E,C0042874
11,C0053396;C0034656;C1514756,Beta Carotene Randomization Receive,Beta Carotene,,,Beta Carotene,C0053396
12,C0232970;C0279025;C1518423,Postmenopausal state Hormone Therapy Negation,Hormone Therapy,,,Hormone Therapy,C0279025
12,C0232970;C0279025;C1518422,Postmenopausal state Hormone Therapy Negation,Postmenopausal state,Menopausal Status,,Menopausal Status,C1513126
13,C0232970;C1524063;C0279025;C0521117,Postmenopausal state Use of Hormone Therapy Current (present time),Hormone Therapy,,,Hormone Therapy,C0279025
13,C0232970;C1524063;C0279025;C0521116,Postmenopausal state Use of Hormone Therapy Current (present time),Postmenopausal state,Menopausal Status,,Menopausal Status,C1513126
14,C0241889;C0677898,Family history invasive cancer,Family history,,,Family history,C0241889
14,C0241889;C0677898,Family history invasive cancer,invasive cancer,,,invasive cancer,C0677898
15,C1513126;C1524063;C0279025,Menopausal Status Use of Hormone Therapy,Hormone Therapy,,,Hormone Therapy,C0279025
15,C1513126;C1524063;C0279025,Menopausal Status Use of Hormone Therapy,Menopausal Status,,,Menopausal Status,C1513126
16,C0001779;C0439234;C666666666,Age year NA,Age-Years,,,Age-Years,C1510829
17,C0026606;C0439259;C0332174,Physical activity kilocalorie Weekly,Physical activity,,,Physical activity,C0026606
18,C0232970;C0279025,Postmenopausal state Hormone Therapy,Hormone Therapy,,,Hormone Therapy,C0279025
18,C0232970;C0279025,Postmenopausal state Hormone Therapy,Postmenopausal state,Menopausal Status,,Menopausal Status,C1513126
19,C0241889;C0030551;C0027051,Family history parent Myocardial Infarction,Family history,,,Family history,C0241889
19,C0241889;C0030551;C0027051,Family history parent Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
20,C0301532;C0457083,Multivitamin preparation Usage,Multivitamin preparation,,,Multivitamin preparation,C0301532
21,C0439234;C1277690;10 year risk,year Coronary heart disease risk 10 year risk,Coronary heart disease,,,Coronary heart disease,C0010068
21,C0439234;C1277690;10 year risk,year Coronary heart disease risk 10 year risk,Risk,,,Risk,C0035647
22,C0522498;C2003901,Rare Never (frequency),NA TO BE DELETED,,,NA TO BE DELETED,NA
23,C1444637;C2003901,In the past Never (frequency),NA TO BE DELETED,,,NA TO BE DELETED,NA
24,C1513126;C0279025,Menopausal Status Hormone Therapy,Hormone Therapy,,,Hormone Therapy,C0279025
24,C1513126;C0279025,Menopausal Status Hormone Therapy,Menopausal Status,,,Menopausal Status,C1513126
25,C0004096;C0750546;C0011900,Asthma newly Diagnosis,Asthma,,,Asthma,C0004096
26,C0015259;C4321352,Exercise Frequency,Exercise,Physical activity,,Physical activity,C0026606
27,C0006560;C1441604,C-reactive protein High sensitivity,C-Reactive Protein,,,C-Reactive Protein,NA
28,C0015259;C0558293;C0205172,Exercise Once a week More,Exercise,Physical activity,,Physical activity,C0026606
29,C0025320;C0279025,Menopause Hormone Therapy,Hormone Therapy,,,Hormone Therapy,C0279025
29,C0025320;C0279025,Menopause Hormone Therapy,Menopausal Status,,,Menopausal Status,C1513126
30,C0279025;C0232970,Hormone Therapy Postmenopausal state,Hormone Therapy,,,Hormone Therapy,C0279025
30,C0279025;C0232970,Hormone Therapy Postmenopausal state,Postmenopausal state,Menopausal Status,,Menopausal Status,C1513126
31,C0149931;C0850708,Migraine Disorders History of disease,Medical History,,,Medical History,C0262926
31,C0149931;C0850708,Migraine Disorders History of disease,Migraine Disorders,,,Migraine Disorders,C0149931
32,C0154723;C1518422,Migraine with Aura Negation,Migraine Disorders,,,Migraine Disorders,C0149931
33,C0455512;C1518422,H/O: migraine Negation,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
33,C0455512;C1518422,H/O: migraine Negation,Medical History,,,Medical History,C0262926
34,C0043210;C1510829;C0205172,Woman Age-Years More,Age-Years,,,Age-Years,C1510829
35,C0043210;C1510829;C0439092,Woman Age-Years Less Than,Gender,,,Gender,C0079399
36,C0017654;C0011849;C0443288,Glomerular Filtration Rate Diabetes Mellitus Restricted,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
36,C0017654;C0011849;C0443288,Glomerular Filtration Rate Diabetes Mellitus Restricted,Glomerular Filtration Rate,,,Glomerular Filtration Rate,C0017654
37,C0241863;C0449438,diabetic Status,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
38,C1518422;C0241863,Negation diabetic,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
39,C0005680;C1518422,Black race Negation,Racial group,,,Racial group,C0034510
40,C0241863;C1518422,diabetic Negation,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
41,C0043157;C1518422,Caucasians Negation,Racial group,,,Racial group,C0034510
42,C0086409;C1518422,Hispanics Negation,Racial group,,,Racial group,C0034510
43,C1533021;C3853635,Hispanic white racial group Race,Racial group,,,Racial group,C0034510
44,C0524620;C1518422,Metabolic Syndrome X Negation,Metabolic Syndrome X,,,Metabolic Syndrome X,C0524620
45,C0011849;C1518422,Diabetes Mellitus Negation,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
46,C1442488;C0011849,Baseline Diabetes Mellitus,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
47,C1551358;C0011849,Incident Diabetes Mellitus,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
48,C3811844;C0205081;C0205082,Estimated Glomerular Filtration Rate Moderate (severity modifier) Severe (severity modifier),Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
49,C3811844;C0442805;C0205307,Estimated Glomerular Filtration Rate Increase Normal,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
50,C3811844;C2945599,Estimated Glomerular Filtration Rate Mild (qualifier value),Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
51,C0004057;C1442488,Aspirin Baseline,Aspirin,,,Aspirin,C0004057
52,C0004057;C1442488;C1518422,Aspirin Baseline Negation,Aspirin,,,Aspirin,C0004057
53,C0004238;C1518422,Atrial Fibrillation Negation,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
54,C0005910;C3898900,Body Weight Healthy,Body Weight,,,Body Weight,C0005910
55,C0007222;C1518422,Cardiovascular Diseases Negation,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
56,C0014939;C1518422,Estrogens Negation,Estrogens,,,Estrogens,C0014939
57,C0439175;C1561607,% of total Overall,NA TO BE DELETED,,,NA TO BE DELETED,NA
58,C0314603;C0449820,Genetic Score,Genetic,,,Genetic,C0314603
59,C1412761;C0314603;C0035647;C0449820,BCL2A1 gene Genetic Risk Score,BCL2A1 gene,Genotype,,Genotype,C0017431
59,C1412761;C0314603;C0035647;C0449820,BCL2A1 gene Genetic Risk Score,Risk,,,Risk,C0035647
60,C0005516;C0016026;C0205251;C0919505,Biological Markers Fibroblast Growth Factor low Fibroblast Growth Factor Gene Family,Fibroblast Growth Factor Gene Family,,,Fibroblast Growth Factor Gene Family,C0919505
61,C0005516;C0016026;C0205251;C3163633,Biological Markers Fibroblast Growth Factor low Elevated,Fibroblast Growth Factor,,,Fibroblast Growth Factor,C0016026
62,C0005516;C0016026;C0919505;C0205250;C3163633,Biological Markers Fibroblast Growth Factor Fibroblast Growth Factor Gene Family High Elevated,Fibroblast Growth Factor,,,Fibroblast Growth Factor,C0016026
63,C0005516;C0919505;C0016026;C0205250;C3163633,Biological Markers Fibroblast Growth Factor Gene Family Fibroblast Growth Factor High Elevated,Fibroblast Growth Factor Gene Family,,,Fibroblast Growth Factor Gene Family,C0919505
64,C0016026;C3811844,Fibroblast Growth Factor Estimated Glomerular Filtration Rate,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
65,C0035647;C0683312,Risk Categories,risk factors,,,risk factors,C0035648
66,C0001645;C1516879,Adrenergic beta-Antagonists Enrollment,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
67,C0001645;C1518422,Adrenergic beta-Antagonists Negation,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
68,C0001645;C3274571,Adrenergic beta-Antagonists Clinical Study Follow-up,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
69,C0003015;C1516879,Angiotensin-Converting Enzyme Inhibitors Enrollment,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
70,C0003015;C3274571,Angiotensin-Converting Enzyme Inhibitors Clinical Study Follow-up,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
71,C0004057;C1516879,Aspirin Enrollment,Aspirin,,,Aspirin,C0004057
72,C0004057;C3274571,Aspirin Clinical Study Follow-up,Aspirin,,,Aspirin,C0004057
73,C0004238;C0016385,Atrial Fibrillation Cardiac Flutter,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
74,C0005910;C0850293,Body Weight electrophysiological studies,Body Weight,,,Body Weight,C0005910
75,C0012265;C1516879,Digoxin Enrollment,Digoxin,Digitalis glycosides,CARDIAC THERAPY,CARDIAC THERAPY,NA
76,C0012265;C3274571,Digoxin Clinical Study Follow-up,Digoxin,Digitalis glycosides,CARDIAC THERAPY,CARDIAC THERAPY,NA
77,C0032821;C1516879,Potassium Enrollment,Potassium,,,Potassium,C0032821
78,C0043031;C1516879,Warfarin Enrollment,Warfarin,Vitamin K antagonists,Antithrombotic Agents,Antithrombotic Agents,C1704311
79,C0043031;C3274571,Warfarin Clinical Study Follow-up,Warfarin,,Antithrombotic Agents,Antithrombotic Agents,C1704311
80,C0304490;C3274571,Potassium Sparing Diuretics Clinical Study Follow-up,Potassium Sparing Diuretics,Diuretics,,Diuretics,C0012798
81,C0354100;C3274571,Loop Diuretics Clinical Study Follow-up,Loop Diuretics,Diuretics,,Diuretics,C0012798
82,C0360714;C1516879,Hydroxymethylglutaryl-CoA Reductase Inhibitors Enrollment,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
83,C0360714;C3274571,Hydroxymethylglutaryl-CoA Reductase Inhibitors Clinical Study Follow-up,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
84,C0521942;C3274571,Angiotensin II receptor antagonist Clinical Study Follow-up,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
85,C0541746;C1516879,Thiazides Enrollment,Loop Diuretics,Diuretics,,Diuretics,C0012798
86,C0541746;C3274571,Thiazides Clinical Study Follow-up,Loop Diuretics,Diuretics,,Diuretics,C0012798
87,C0034656;C0040223,Randomization Time,NA TO BE DELETED,,,NA TO BE DELETED,NA
88,C0040223;C4303340;C1444662,Time Warfarin therapy Discontinued,Warfarin,,Antithrombotic Agents,Antithrombotic Agents,C1704311
89,C1861172;C4330837,Venous Thromboembolism Number of Events,Thromboembolism,,,Thromboembolism,C0040038
90,C0012634;C0333482;C0205210,Disease atherosclerotic Clinical,atherosclerotic,,,atherosclerotic,C0333482
91,C0015663;C0202042,Fasting Plasma Glucose Measurement,Plasma Glucose Measurement,Glucose,,Glucose,C0017725
92,C0037369;C2003901,Smoking Never (frequency),Smoking Status,,,Smoking Status,C1519386
93,C0428883;C0439475,Diastolic blood pressure mmHg,Blood Pressure,,,Blood Pressure,C0005823
94,C0439475;C0871470,mmHg Systolic Pressure,Blood Pressure,,,Blood Pressure,C0005823
95,C0455271;C0567349,Urine albumin/creatinine ratio measurement milligram/millimole (mg/mmol),Urine albumin/creatinine ratio measurement,,,Urine albumin/creatinine ratio measurement,C0455271
96,C2926735;C0011849;C0439234,Duration Diabetes Mellitus year,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
97,"C0456689	  ;C1305855",Kilogram Per Square Meter Body mass index,Body mass index,,,Body mass index,C1305855
98,C1305855;C0456689,Body mass index NA,Body mass index,,,Body mass index,C1305855
99,C2926735;C0011849,Duration Diabetes Mellitus,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
100,C0019139;C1516879,"Heparin, Low-Molecular-Weight Enrollment",heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
101,C0021398;C1320528;C1318493;C0002997,"Economic Inflation Time of symptom onset Inflation procedure Angioplasty, Balloon, Coronary","Angioplasty, Balloon, Coronary",,,"Angioplasty, Balloon, Coronary",C0002997
102,C0034656;C1320528,Randomization Time of symptom onset,NA TO BE DELETED,,,NA TO BE DELETED,NA
103,C0205094;C1518422,Anterior Negation,Anterior myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
104,C0205156;C0439242,Previous milliliter,NA TO BE DELETED,,,NA TO BE DELETED,NA
105,C0205421;C0678226;C3538919;C1532338,Deferred Due to Low Risk Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
106,C0439673;eitheror;C1518422,Unknown Either one or other Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
107,C0455488;C0262512,H/O: diabetes mellitus History of present illness,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
107,C0455488;C0262512,H/O: diabetes mellitus History of present illness,Medical History,,,Medical History,C0262926
108,C0678226;C3538919;C0522486;C1532338,Due to Low Risk Delay time Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
109,C0884358;C0918012;C1532338,Performed Index Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
110,C0884358;C1532338,Performed Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
111,C1320528;C1318493;C0002997,"Time of symptom onset Inflation procedure Angioplasty, Balloon, Coronary","Angioplasty, Balloon, Coronary",,,"Angioplasty, Balloon, Coronary",C0002997
112,C1515974;C0021308,Anatomic Site Infarction,Infarction Anatomic Site ,,,Infarction Anatomic Site ,NA
113,C1518422;C0337954,Negation Tertiary care hospital,NA TO BE DELETED,,,NA TO BE DELETED,NA
114,C1623258;C0449244;C1318493;C1514624;C0002997,"Electrocardiography Time of onset Inflation procedure Qualifying Angioplasty, Balloon, Coronary",Electrocardiography,,,Electrocardiography,C1623258
115,C1623258;C1318493;C1514624;C0002997;C0449244,"Electrocardiography Inflation procedure Qualifying Angioplasty, Balloon, Coronary Time of onset","Angioplasty, Balloon, Coronary",,,"Angioplasty, Balloon, Coronary",C0002997
116,C1881332;C1442488,Killip Class Baseline,Killip Class,,,Killip Class,C1881332
117,C2700280;C0035253,World Rest,Geographic Locations,,,Geographic Locations,C0017446
118,C0040223;C0564385;C3251812;C0449820;C0337954;C1518422,Time /hour Bleeding risk Score Tertiary care hospital Negation,Bleeding risk,,,Bleeding risk,C3251812
119,C0040223;C0564385;C3251812;C0449820;C1518422;C0337954,Time /hour Bleeding risk Score Negation Tertiary care hospital,Bleeding risk,,,Bleeding risk,C3251812
120,C0449820;C3251812,Score Bleeding risk,Bleeding risk,,,Bleeding risk,C3251812
121,C3251812;C0449820,Bleeding risk Score,Bleeding risk,,,Bleeding risk,C3251812
122,C3251812;C0449820;C0337954;C1518422,Bleeding risk Score Tertiary care hospital Negation,Bleeding risk,,,Bleeding risk,C3251812
123,C0009240;C0205307,Cognition Normal,Cognition,,,Cognition,C0009240
124,C0009240;C0221099,Cognition Impaired,Cognition,,,Cognition,C0009240
125,C1552646;C1709380,chi square P-Value,NA TO BE DELETED,,,NA TO BE DELETED,NA
126,C0040223;C0205435;C0574032,Time First (number) Infusion procedures,Infusion procedures,,,Infusion procedures,C0574032
127,C3854607;C0015815,T-Score Structure of neck of femur,Structure of neck of femur,,,Structure of neck of femur,C0015815
128,C0006560;C0439269,C-reactive protein mg/dL,C-Reactive Protein,,,C-Reactive Protein,NA
129,C0023824;C0439269,LDL Cholesterol Lipoproteins mg/dL,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
130,C0086582;C0079399,Males Gender,Gender,,,Gender,C0079399
131,C0439269;C1518422;C0023822,mg/dL Negation High Density Lipoprotein Cholesterol,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
132,C0439475;C0005823,mmHg Blood Pressure,Blood Pressure,,,Blood Pressure,C0005823
133,C0456689,Kilogram Per Square Meter,NA TO BE DELETED,,,NA TO BE DELETED,NA
134,C1549445;C3241966,Yes - Yes/no indicator Current Smoker,Smoking Status,,,Smoking Status,C1519386
135,C0005910;C0439209,Body Weight Kilogram,Body Weight,,,Body Weight,C0005910
136,C0005938;C0015815,Bone Density Structure of neck of femur,Bone Density,,,Bone Density,C0005938
137,C0019552;C0005938,Hip structure Bone Density,Bone Density,,,Bone Density,C0005938
137,C0019552;C0005938,Hip structure Bone Density,Hip structure,,,Hip structure,C0019552
138,C0812399;C0439445,Creatinine clearance mL/min,Creatinine clearance,,,Creatinine clearance,C0812399
139,C3541401;C1514463,Bisphosphonate drugs affecting bone structure and mineralization Prior Therapy,Bisphosphonate drugs affecting bone structure and mineralization,,,Bisphosphonate drugs affecting bone structure and mineralization,C3541401
140,C0005823;C1442488,Blood Pressure Baseline,Blood Pressure,,,Blood Pressure,C0005823
141,C0011849;C0262926,Diabetes Mellitus Medical History,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
141,C0011849;C0262926,Diabetes Mellitus Medical History,Medical History,,,Medical History,C0262926
142,C0003015;C0521942,Angiotensin-Converting Enzyme Inhibitors Angiotensin II receptor antagonist,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
142,C0003015;C0521942,Angiotensin-Converting Enzyme Inhibitors Angiotensin II receptor antagonist,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
143,C0003015;C1518422;C0521942,Angiotensin-Converting Enzyme Inhibitors Negation Angiotensin II receptor antagonist,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
143,C0003015;C1518422;C0521942,Angiotensin-Converting Enzyme Inhibitors Negation Angiotensin II receptor antagonist,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
144,C0015663;C0202042;C0202045,"Fasting Plasma Glucose Measurement Glucose measurement, fasting",Glucose,,,Glucose,C0017725
144,C0015663;C0202042;C0202045,"Fasting Plasma Glucose Measurement Glucose measurement, fasting",Plasma Glucose Measurement,Glucose,,Glucose,C0017725
145,C0202042;C0202045,"Plasma Glucose Measurement Glucose measurement, fasting",Plasma Glucose Measurement,Glucose,,Glucose,C0017725
146,C0205156;C0007222;C1320716,Previous Cardiovascular Diseases Cardiovascular event,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
147,C0205156;C1320716,Previous Cardiovascular event,Cardiovascular event,,,Cardiovascular event,C1320716
148,C0205156;C1320716;C1518422,Previous Cardiovascular event Negation,Cardiovascular event,,,Cardiovascular event,C1320716
149,C0205156;C1518422;C0155668;C0741923;C1880008,Previous Negation Old myocardial infarction cardiac event Cardiovascular History,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
149,C0205156;C1518422;C0155668;C0741923;C1880008,Previous Negation Old myocardial infarction cardiac event Cardiovascular History,Medical History,,,Medical History,C0262926
149,C0205156;C1518422;C0155668;C0741923;C1880008,Previous Negation Old myocardial infarction cardiac event Cardiovascular History,Old myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
150,C0360714;C1518422,Hydroxymethylglutaryl-CoA Reductase Inhibitors Negation,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
151,C0455280;C0202045,"Plasma glucose result Glucose measurement, fasting",Plasma Glucose Measurement,Glucose,,Glucose,C0017725
152,C0521942;C0003015,Angiotensin II receptor antagonist Angiotensin-Converting Enzyme Inhibitors,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
152,C0521942;C0003015,Angiotensin II receptor antagonist Angiotensin-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
153,C0549183;C0017853,"Midline (qualifier value) Hemoglobin, Glycosylated","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
154,C1518422;C0003015;C0521942,Negation Angiotensin-Converting Enzyme Inhibitors Angiotensin II receptor antagonist,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
154,C1518422;C0003015;C0521942,Negation Angiotensin-Converting Enzyme Inhibitors Angiotensin II receptor antagonist,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
155,C0001779;C2939193,Age Median (qualifier value),Age-Years,,,Age-Years,C1510829
156,C0011570;C1518422,Mental Depression Negation,Mental state,,,Mental state,C0278060
157,C0017853;C2939193,"Hemoglobin, Glycosylated Median (qualifier value)","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
158,C0042036;C0486293,Urine Albumin To Creatinine Protein Ratio Measurement,Albumin To Creatinine Protein Ratio Measurement,,,Albumin To Creatinine Protein Ratio Measurement,C0486293
159,C0042036;C2347635;C0486293,Urine Population Median Albumin To Creatinine Protein Ratio Measurement,Albumin To Creatinine Protein Ratio Measurement,,,Albumin To Creatinine Protein Ratio Measurement,C0486293
160,C0429271;C0876920,Grip strength Median Statistical Measurement,Grip strength,,,Grip strength,C0429271
161,C0876920;C0205682,Median Statistical Measurement Waist-Hip Ratio,Waist-Hip Ratio,,,Waist-Hip Ratio,C0205682
162,C0013658;C0439234,Educational Status year,Educational Status,,,Educational Status,C0013658
163,C0017853;C2347635,"Hemoglobin, Glycosylated Population Median","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
164,C0019016;C0439093;C2348144,Hemoglobin A Greater Than Sample Median,Hemoglobin A,,,Hemoglobin A,C0019016
165,C0518015;C2348144,Hemoglobin measurement Sample Median,Hemoglobin,,,Hemoglobin,C0019046
166,C1442989;C1947933,Standard (qualifier) care activity,NA TO BE DELETED,,,NA TO BE DELETED,NA
167,C2348144;C0017853,"Sample Median Hemoglobin, Glycosylated","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
168,C2348144;C0518015,Sample Median Hemoglobin measurement,Hemoglobin,,,Hemoglobin,C0019046
169,C0001645;C0457083,Adrenergic beta-Antagonists Usage,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
170,C0001645;C0457083;C1518422,Adrenergic beta-Antagonists Usage Negation,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
171,C0001779;C1510829,Age Age-Years,Age-Years,,,Age-Years,C1510829
172,C0011849;C0205156,Diabetes Mellitus Previous,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
173,C0011849;C0205314,Diabetes Mellitus New,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
174,C0015684;C0032615,Fatty Acids Polyunsaturated Fatty Acids,Fatty Acids,,,Fatty Acids,C0015684
175,C0025598;C0457083,Metformin Usage,Metformin,Antidiabetics,,Antidiabetics,C0935929
176,C0025598;C0457083;C1518422,Metformin Usage Negation,Metformin,Antidiabetics,,Antidiabetics,C0935929
177,C0032042;C1696465,Placebos placebo,placebo,,,placebo,C1696465
178,C0032615;C1719844,Polyunsaturated Fatty Acids Omega,Fatty Acids,,,Fatty Acids,C0015684
179,C0205156;C1320716;C3538987,Previous Cardiovascular event Cardiovascular System Findings Domain,Cardiovascular event,,,Cardiovascular event,C1320716
180,C0360714;C0457083,Hydroxymethylglutaryl-CoA Reductase Inhibitors Usage,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
181,C0360714;C0457083;C1518422,Hydroxymethylglutaryl-CoA Reductase Inhibitors Usage Negation,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
182,C0457083;C0003015;C0521942,Usage Angiotensin-Converting Enzyme Inhibitors Angiotensin II receptor antagonist,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
182,C0457083;C0003015;C0521942,Usage Angiotensin-Converting Enzyme Inhibitors Angiotensin II receptor antagonist,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
183,C0457083;C0003015;C0521942;C1518422,Usage Angiotensin-Converting Enzyme Inhibitors Angiotensin II receptor antagonist Negation,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
183,C0457083;C0003015;C0521942;C1518422,Usage Angiotensin-Converting Enzyme Inhibitors Angiotensin II receptor antagonist Negation,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
184,C1320716;C0205156;C1518422,Cardiovascular event Previous Negation,Cardiovascular event,,,Cardiovascular event,C1320716
185,C1706778;C1719844,Allocation Omega,Omega,,,Omega,C1719844
186,C0039798;C0907402,therapeutic aspects Insulin Glargine,Insulin,,,Insulin,C0021641
187,C0205172;C1510829,More Age-Years,Age-Years,,,Age-Years,C1510829
188,C1561643;C1518422,Chronic Kidney Diseases Negation,Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
189,C0205160;D005968;C0003241,Negative Glutamate Decarboxylase Antibodies,Antibodies,,,Antibodies,C0003241
189,C0205160;D005968;C0003241,Negative Glutamate Decarboxylase Antibodies,Glutamate Decarboxylase,,,Glutamate Decarboxylase,D005968
190,D005968;C0003241;C1446409,Glutamate Decarboxylase Antibodies Positive,Glutamate Decarboxylase,,,Glutamate Decarboxylase,D005968
191,C0007222;C0019664,Cardiovascular Diseases History,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
191,C0007222;C0019664,Cardiovascular Diseases History,Medical History,,,Medical History,C0262926
192,C0681344;C0439234,formal education year,Educational Status,,,Educational Status,C0013658
193,C1442989;C1321567,Standard (qualifier) hyperglycemic agent,hyperglycemic agent,,,hyperglycemic agent,C1321567
194,C0003232;C1442488;C1518422,Antibiotics Baseline Negation,Antibiotics,,,Antibiotics,C0003232
195,C0021081;C1442488,Immunosuppressive Agents Baseline,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
196,C0021081;C1442488;C1518422,Immunosuppressive Agents Baseline Negation,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
197,C1442488;C0003232,Baseline Antibiotics,Antibiotics,,,Antibiotics,C0003232
198,C1442488;C0178602;C0239126,Baseline Dosage corticosteroid use,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
199,C1442488;C0239126;C2926735,Baseline corticosteroid use Duration,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
200,C0040223;C2709207,Time Rx therapy,Rx therapy,,,Rx therapy,C2709207
201,C0332152;C0027051,Before Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
202,C0332152;C0027051;C1518422,Before Myocardial Infarction Negation,Myocardial Infarction,,,Myocardial Infarction,C0027051
203,C0450429;C1515974,Location Anatomic Site,NA TO BE DELETED,,,NA TO BE DELETED,NA
204,C1518422;C0011849,Negation Diabetes Mellitus,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
205,C0022116;C2348867,Ischemia Global,Ischemia,,,Ischemia,C0022116
206,C0205289;C1261287;C1301886,Maximal (qualifier value) Stenosis Diameter (qualifier value),Stenosis,,,Stenosis,C1261287
207,C1442488;C0005823,Baseline Blood Pressure,Blood Pressure,,,Blood Pressure,C0005823
208,C4687747;C0039155,Peak Pressure Gradient Systole,Gradient Systole,,,Gradient Systole,NA
209,C1518422;C0043157,Negation Caucasians,Racial group,,,Racial group,C0034510
210,C1998280;C4300252,International Prostate Symptom Score HRQOL method,International Prostate Symptom Score,,,International Prostate Symptom Score,C1998280
211,C0017725;C0015663,Glucose Fasting,Glucose,,,Glucose,C0017725
212,C0010068;C0262926,Coronary heart disease Medical History,Coronary heart disease,,,Coronary heart disease,C0010068
212,C0010068;C0262926,Coronary heart disease Medical History,Medical History,,,Medical History,C0262926
213,C0015031;C0086409,Ethnic group Hispanics,Racial group,,,Racial group,C0034510
214,C0020538;C0262926,Hypertensive disease Medical History,"Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
214,C0020538;C0262926,Hypertensive disease Medical History,Medical History,,,Medical History,C0262926
215,C0679646;C1561607,Participant Overall,NA TO BE DELETED,,,NA TO BE DELETED,NA
216,C1060325;C1272092,Genus Ada Impaired fasting glycaemia,Impaired fasting glycaemia,,,Impaired fasting glycaemia,C1272092
217,C1518422;C0018017,Negation objective (goal),NA TO BE DELETED,,,NA TO BE DELETED,NA
218,C0150312;C0439269,Present mg/dL,NA TO BE DELETED,,,NA TO BE DELETED,NA
219,C0332197;C0439269,Absent mg/dL,NA TO BE DELETED,,,NA TO BE DELETED,NA
220,C0038454;C4554100;C0332153,"Cerebrovascular accident Stroke, CTCAE Before",Cerebrovascular accident,,,Cerebrovascular accident,C0038454
220,C0038454;C4554100;C0332152,"Cerebrovascular accident Stroke, CTCAE Before","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
221,C0041004;C0444598,Triglycerides Middle,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
222,C0041004;C1522410,Triglycerides Highest,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
223,C1708760;C0041004,Lowest Triglycerides,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
224,C0041004;C0205172,Triglycerides More,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
225,C0041004;C0439090,Triglycerides Less Than or Equal to,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
226,C0439093;C0876920,Greater Than Median Statistical Measurement,NA TO BE DELETED,,,NA TO BE DELETED,NA
227,C0549183;C0547044;C0876920,Midline (qualifier value) Smaller Median Statistical Measurement,NA TO BE DELETED,,,NA TO BE DELETED,NA
228,C2946261;C0005516;C2347023,Level Biological Markers Biological Absorption,Biological Markers,,,Biological Markers,C0005516
229,C0079399;C1510829,Gender Age-Years,Age-Years,,,Age-Years,C1510829
229,C0079399;C1510829,Gender Age-Years,Gender,,,Gender,C0079399
230,C0286651;C4086581,atorvastatin Milligram per Dose,atorvastatin,,,atorvastatin,C0286651
231,C1442488;C0023824,Baseline LDL Cholesterol Lipoproteins,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
232,C1514983;C3887704,Stratification treatment - ActInformationManagementReason,NA TO BE DELETED,,,NA TO BE DELETED,NA
233,C0010068;C0074554,Coronary heart disease Simvastatin,Coronary heart disease,,,Coronary heart disease,C0010068
233,C0010068;C0074554,Coronary heart disease Simvastatin,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
234,C0010068;C1518422,Coronary heart disease Negation,Coronary heart disease,,,Coronary heart disease,C0010068
235,C0010068;C1532737,Coronary heart disease ezetimibe / Simvastatin,Coronary heart disease,,,Coronary heart disease,C0010068
235,C0010068;C1532737,Coronary heart disease ezetimibe / Simvastatin,ezetimibe / Simvastatin,HMG CoA reductase inhibitors in combition with other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
236,C0043157;C0074554,Caucasians Simvastatin,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
237,C0043157;C1518422;C0074554,Caucasians Negation Simvastatin,Racial group,,,Racial group,C0034510
238,C0043157;C1532737,Caucasians ezetimibe / Simvastatin,ezetimibe / Simvastatin,HMG CoA reductase inhibitors in combition with other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
238,C0043157;C1532737,Caucasians ezetimibe / Simvastatin,Racial group,,,Racial group,C0034510
239,C0074554;C1510829,Simvastatin Age-Years,Age-Years,,,Age-Years,C1510829
239,C0074554;C1510829,Simvastatin Age-Years,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
240,C0079399;C1532737,Gender ezetimibe / Simvastatin,ezetimibe / Simvastatin,HMG CoA reductase inhibitors in combition with other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
240,C0079399;C1532737,Gender ezetimibe / Simvastatin,Gender,,,Gender,C0079399
241,C0086287;C0074554,Females Simvastatin,Gender,,,Gender,C0079399
241,C0086287;C0074554,Females Simvastatin,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
242,C0086287;C1532737,Females ezetimibe / Simvastatin,ezetimibe / Simvastatin,HMG CoA reductase inhibitors in combition with other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
242,C0086287;C1532737,Females ezetimibe / Simvastatin,Gender,,,Gender,C0079399
243,C0086582;C0074554,Males Simvastatin,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
244,C0086582;C1532737,Males ezetimibe / Simvastatin,Gender,,,Gender,C0079399
245,C0439269;C0010068,mg/dL Coronary heart disease,Coronary heart disease,,,Coronary heart disease,C0010068
246,C0439269;C0074554,mg/dL Simvastatin,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
247,C0439269;C1532737,mg/dL ezetimibe / Simvastatin,ezetimibe / Simvastatin,HMG CoA reductase inhibitors in combition with other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
248,C0449438;C0010068,Status Coronary heart disease,Coronary heart disease,,,Coronary heart disease,C0010068
249,C0599755;C0079399;C0444667,Cohort Gender Whole,Gender,,,Gender,C0079399
250,C0599755;C0439751,Cohort Entire,NA TO BE DELETED,,,NA TO BE DELETED,NA
251,C1510829;C0074554,Age-Years Simvastatin,Age-Years,,,Age-Years,C1510829
251,C1510829;C0074554,Age-Years Simvastatin,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
252,C1510829;C1442488;C0023824,Age-Years Baseline LDL Cholesterol Lipoproteins,Age-Years,,,Age-Years,C1510829
252,C1510829;C1442488;C0023824,Age-Years Baseline LDL Cholesterol Lipoproteins,Age-Years,,,Age-Years,C1510829
253,C1510829;C1532737,Age-Years ezetimibe / Simvastatin,Age-Years,,,Age-Years,C1510829
254,C1510829;C1532737;C1442488;C0023824,Age-Years ezetimibe / Simvastatin Baseline LDL Cholesterol Lipoproteins,ezetimibe / Simvastatin,HMG CoA reductase inhibitors in combition with other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
254,C1510829;C1532737;C1442488;C0023824,Age-Years ezetimibe / Simvastatin Baseline LDL Cholesterol Lipoproteins,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
255,C1518422;C0010068;C0074554,Negation Coronary heart disease Simvastatin,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
256,C1518422;C0010068;C1532737,Negation Coronary heart disease ezetimibe / Simvastatin,Coronary heart disease,,,Coronary heart disease,C0010068
257,C0003593;C0439269,Apolipoproteins B mg/dL,Apolipoprotein A-I,,,Apolipoprotein A-I,C0085201
258,C0006560;C0876920;C0871420,C-reactive protein Median Statistical Measurement Standard deviation,C-Reactive Protein,,,C-Reactive Protein,NA
259,C0010068;C1549488,Coronary heart disease Amount type - Percentage,Coronary heart disease,,,Coronary heart disease,C0010068
260,C0011849;C1549488,Diabetes Mellitus Amount type - Percentage,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
261,C0023822;C0439269,High Density Lipoprotein Cholesterol mg/dL,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
262,C0025266;C1549488,Male population group Amount type - Percentage,Gender,,,Gender,C0079399
263,C0041004;C0876920;C0871420,Triglycerides Median Statistical Measurement Standard deviation,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
264,C0043157;C1549488,Caucasians Amount type - Percentage,Racial group,,,Racial group,C0034510
265,C0524620;C1549488,Metabolic Syndrome X Amount type - Percentage,Metabolic Syndrome X,,,Metabolic Syndrome X,C0524620
266,C0543421;C0439269,Total cholesterol mg/dL,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
267,C0004057;C0358591,Aspirin Proton Pump Inhibitors,Proton Pump Inhibitors,,,Proton Pump Inhibitors,C0358591
268,C0004057;C0358591;C1518422,Aspirin Proton Pump Inhibitors Negation,Aspirin,,,Aspirin,C0004057
269,C1518422;C0358591;C0004057,Negation Proton Pump Inhibitors Aspirin,Aspirin,,,Aspirin,C0004057
269,C1518422;C0358591;C0004057,Negation Proton Pump Inhibitors Aspirin,Proton Pump Inhibitors,,,Proton Pump Inhibitors,C0358591
270,C0004057;C1442488;C0457083,Aspirin Baseline Usage,Aspirin,,,Aspirin,C0004057
271,C0521362;C1545588;C0450442,gastrointestinal Protection Agent,gastrointestinal,,,gastrointestinal,C0521362
272,C0441471;C0521362;C0441994,Event gastrointestinal Lower - spatial qualifier,gastrointestinal,,,gastrointestinal,C0521362
273,C0441471;C3203348,Event Upper Gastrointestinal Tract,gastrointestinal,,,gastrointestinal,C0521362
274,C1548802;C0521362;C0441471,Body Site Modifier - Lower gastrointestinal Event,gastrointestinal,,,gastrointestinal,C0521362
275,C3203348;C0441471,Upper Gastrointestinal Tract Event,gastrointestinal,,,gastrointestinal,C0521362
276,C3665365;C1518422,"Arteriosclerotic cardiovascular disease, NOS Negation","Arteriosclerotic cardiovascular disease, NOS",,,"Arteriosclerotic cardiovascular disease, NOS",C3665365
277,C0205314;C0521362;D020011,New gastrointestinal protective agents,gastrointestinal,,,gastrointestinal,C0521362
278,C0521362;D020011;C0549178,gastrointestinal protective agents Continuous,gastrointestinal,,,gastrointestinal,C0521362
279,C0035970;C0017452,"Russia Georgia, USA",Geographic Locations,,,Geographic Locations,C0017446
280,C0205250;C2709270,High Natriuretic peptide,Natriuretic peptide,,,Natriuretic peptide,C2709270
281,C3898876;C0019664,Hospitalization Due to Heart Failure History,Hospitalization Due to Heart Failure History,Heart failure,,Heart failure,C0018801
281,C3898876;C0019664,Hospitalization Due to Heart Failure History,Medical History,,,Medical History,C0262926
282,C0332325;C1963138;C1518422,"Resistant (qualifier value) Hypertension, CTCAE Negation","Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
283,C1963138;C0332325,"Hypertension, CTCAE Resistant (qualifier value)","Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
284,C1518422;C0005680,Negation Black race,Racial group,,,Racial group,C0034510
285,C0004482;C0666743;C0205195,Azathioprine infliximab Combined,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
285,C0004482;C0666743;C0205195,Azathioprine infliximab Combined,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
286,C0010346;C0543467;C0205156,Crohn Disease Operative Surgical Procedures Previous,Crohn Disease,,,Crohn Disease,C0010346
286,C0010346;C0543467;C0205156,Crohn Disease Operative Surgical Procedures Previous,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
287,C0010346;C1279919,Crohn Disease Early,Crohn Disease,,,Crohn Disease,C0010346
288,C0010346;C1279919;C1518422,Crohn Disease Early Negation,Crohn Disease,,,Crohn Disease,C0010346
289,C0019664;C0021390;C1280464,History Inflammatory Bowel Diseases Manifestation of,Inflammatory Bowel Diseases,,,Inflammatory Bowel Diseases,C0021390
289,C0019664;C0021390;C1280464,History Inflammatory Bowel Diseases Manifestation of,Medical History,,,Medical History,C0262926
290,C0019664;C0021390;C1518422;C1280464,History Inflammatory Bowel Diseases Negation Manifestation of,Inflammatory Bowel Diseases,,,Inflammatory Bowel Diseases,C0021390
290,C0019664;C0021390;C1518422;C1280464,History Inflammatory Bowel Diseases Negation Manifestation of,Medical History,,,Medical History,C0262926
291,C0019664;C0741614,History bowel resection,bowel resection,,,bowel resection,C0741614
291,C0019664;C0741614,History bowel resection,Medical History,,,Medical History,C0262926
292,C0019664;C0741614;C1518422,History bowel resection Negation,bowel resection,,,bowel resection,C0741614
292,C0019664;C0741614;C1518422,History bowel resection Negation,Medical History,,,Medical History,C0262926
293,C0019993;C4086728,Hospitalization Past Year,NA TO BE DELETED,,,NA TO BE DELETED,NA
294,C0019993;C4086728;C1518422,Hospitalization Past Year Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
295,C0239126;C1442488;C1518422,corticosteroid use Baseline Negation,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
296,C1442488;C0239126,Baseline corticosteroid use,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
297,C0337438;C0376674,Glucose measurement Postprandial Period,Glucose,,,Glucose,C0017725
298,C0455280;C0015663,Plasma glucose result Fasting,Plasma Glucose Measurement,Glucose,,Glucose,C0017725
299,C0549183;C0876920;C2347635;C2348144;C2939193,Midline (qualifier value) Median Statistical Measurement Population Median Sample Median Median (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
300,C0001779;C0332239,Age Young,Age-Years,,,Age-Years,C1510829
301,C0001779;C0580836,Age Old,Age-Years,,,Age-Years,C1510829
302,C0002965;C0340288;C0948089;C0332185,"Angina, Unstable Stable angina Acute Coronary Syndrome Recent","Angina, Unstable",Angi Pectoris,,Angina Pectoris,C0002962
303,C0010055;C0205156,Coronary Artery Bypass Surgery Previous,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
304,C0018801;C0428772,Heart failure Left ventricular ejection fraction,Heart failure,,,Heart failure,C0018801
304,C0018801;C0428772,Heart failure Left ventricular ejection fraction,Left ventricular ejection fraction,,,Left ventricular ejection fraction,C0428772
305,C0018802;C0262926,Congestive heart failure Medical History,Congestive heart failure,Heart failure,,Heart failure,C0018801
305,C0018802;C0262926,Congestive heart failure Medical History,Medical History,,,Medical History,C0262926
306,C0077401;C1446409,Troponin I Positive,Troponin,,,Troponin,C0041199
307,C0205156;C0085532;C0242231,Previous Coronary angiography Coronary Stenosis,Coronary angiography,,,Coronary angiography,C0085532
307,C0205156;C0085532;C0242231,Previous Coronary angiography Coronary Stenosis,Coronary Stenosis,,,Coronary Stenosis,C0242231
308,C0241889;C1956346,Family history Coronary Artery Disease,Coronary Artery Disease,,,Coronary Artery Disease,C1956346
308,C0241889;C1956346,Family history Coronary Artery Disease,Family history,,,Family history,C0241889
309,C0332152;C0155668;C0027051;C0205156,Before Old myocardial infarction Myocardial Infarction Previous,Myocardial Infarction,,,Myocardial Infarction,C0027051
310,C0581603;C0205156;C2114427,Revascularization - action Previous previous coronary angioplasty,previous coronary angioplasty,,,previous coronary angioplasty,C2114427
310,C0581603;C0205156;C2114427,Revascularization - action Previous previous coronary angioplasty,Revascularization - action,,,Revascularization - action,C0581603
311,C0742343;C1536221,Acute Chest Syndrome Non ST elevation myocardial infarction,Acute Chest Syndrome,,,Acute Chest Syndrome,C0742343
311,C0742343;C1536221,Acute Chest Syndrome Non ST elevation myocardial infarction,Non ST elevation myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
312,C1532338;C0205156,Percutaneous Coronary Intervention Previous,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
313,C1532338;C1518422,Percutaneous Coronary Intervention Negation,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
314,C3811844;C0017654;C0812399;C0439445,Estimated Glomerular Filtration Rate Glomerular Filtration Rate Creatinine clearance mL/min,Creatinine clearance,,,Creatinine clearance,C0812399
314,C3811844;C0017654;C0812399;C0439445,Estimated Glomerular Filtration Rate Glomerular Filtration Rate Creatinine clearance mL/min,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
315,C0578022;C0028754,Finding of body mass index Obesity,Body mass index,,,Body mass index,C1305855
316,C0030705;C1510829,Patients Age-Years,Age-Years,,,Age-Years,C1510829
317,C0030705;C1510829;C2700149,Patients Age-Years Value Above Reference Range,Age-Years,,,Age-Years,C1510829
318,C0151280;C0205082;C0205081,"Creatinine clearance, ml/min Severe (severity modifier) Moderate (severity modifier)",Creatinine clearance,,,Creatinine clearance,C0812399
319,C0151280;C2945599,"Creatinine clearance, ml/min Mild (qualifier value)",Creatinine clearance,,,Creatinine clearance,C0812399
320,C0205307;C0151280,"Normal Creatinine clearance, ml/min",Creatinine clearance,,,Creatinine clearance,C0812399
321,C0812399;C0232804,Creatinine clearance Renal function,Renal function,,,Renal function,C0232804
322,C0003241;C0205258;C0666743,Antibodies Indeterminate infliximab,Antibodies,,,Antibodies,C0003241
322,C0003241;C0205258;C0666743,Antibodies Indeterminate infliximab,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
323,C0003241;C1334932;C0666743,Antibodies Negative Test Result infliximab,Antibodies,,,Antibodies,C0003241
323,C0003241;C1334932;C0666743,Antibodies Negative Test Result infliximab,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
324,C0003241;C1335447;C0666743,Antibodies Positive Laboratory Test Result infliximab,Antibodies,,,Antibodies,C0003241
324,C0003241;C1335447;C0666743,Antibodies Positive Laboratory Test Result infliximab,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
325,C0205156;C0666743;C3844738,Previous infliximab No Response - Disease Response,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
326,C0239126;C1442488,corticosteroid use Baseline,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
327,C0239126;C1518422;C1442488,corticosteroid use Negation Baseline,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
328,C1442488;C4048285,"Baseline C-Reactive Protein, human",C-Reactive Protein,,,C-Reactive Protein,NA
329,C1744706;C0666743,intolerance to substance infliximab,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
330,C1744706;C0666743;C3844738;C0205156,intolerance to substance infliximab No Response - Disease Response Previous,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
331,C4048285;C1442488,"C-Reactive Protein, human Baseline",C-Reactive Protein,,,C-Reactive Protein,NA
332,C0449238;C0872146,Duration (temporal concept) disease length,NA TO BE DELETED,,,NA TO BE DELETED,NA
333,C0030705;C0034656,Patients Randomization,NA TO BE DELETED,,,NA TO BE DELETED,NA
334,C0033860;C2926735;C0439234,Psoriasis Duration year,Psoriasis,,,Psoriasis,C0033860
335,C0449820;C4528685,Score Psoriasis Area and Severity Index Clinical Classification,Psoriasis Area and Severity Index Clinical Classification,Psoriasis,,Psoriasis,C0033860
336,C0879626;C1515119;C1444662,Adverse effects systemic therapy Discontinued,NA TO BE DELETED,,,NA TO BE DELETED,NA
337,C1442488;C0005902;C0439165,Baseline Body Surface Area Percent (qualifier value),Body Surface Area,,,Body Surface Area,C0005902
338,C1442488;C4528685,Baseline Psoriasis Area and Severity Index Clinical Classification,Psoriasis Area and Severity Index Clinical Classification,Psoriasis,,Psoriasis,C0033860
339,C1515119;C1514463,systemic therapy Prior Therapy,NA TO BE DELETED,,,NA TO BE DELETED,NA
340,C0003872;C1518422,"Arthritis, Psoriatic Negation","Arthritis, Psoriatic",,,"Arthritis, Psoriatic","C0003872	"
340,C0003872;C1518422,"Arthritis, Psoriatic Negation","Arthritis, Psoriatic",,,"Arthritis, Psoriatic",C0003872
341,C0006560;C1442488,C-reactive protein Baseline,C-Reactive Protein,,,C-Reactive Protein,NA
342,C0011849;C0449238,Diabetes Mellitus Duration (temporal concept),Diabetes Mellitus,,,Diabetes Mellitus,C0011849
343,C0013227;C0205156;C1518422,Pharmaceutical Preparations Previous Negation,Pharmaceutical Preparations,,,Pharmaceutical Preparations,C0013227
344,C0041004;C1442488,Triglycerides Baseline,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
345,C0202117;C1442488,Low density lipoprotein cholesterol measurement Baseline,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
346,C0264956;C1442488,Atheroma Baseline,Atheroma,,,Atheroma,C0264956
347,C0360714;C1442488,Hydroxymethylglutaryl-CoA Reductase Inhibitors Baseline,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
348,C0871470;C1442488,Systolic Pressure Baseline,Blood Pressure,,,Blood Pressure,C0005823
349,C0035647;C0449820,Risk Score,Risk,,,Risk,C0035647
350,C0278372;C0043237,Functional assessment World Health Organization,Functional assessment,,,Functional assessment,C0278372
351,C1442488;C3900196,Baseline 6 Minute Walk Functional Test,6 Minute Walk Functional Test,Physical activity,,Physical activity,C0026606
352,C1955473;C1518425,Others - Allergy Not Otherwise Specified,Others - Allergy,,,Others - Allergy,C1955473
353,C0003015;C0815017,Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists,Angiotensin Receptor Antagonists,,,Angiotensin Receptor Antagonists,C0815017
353,C0003015;C0815017,Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
354,C0003015;C0815017;C1518422,Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists Negation,Angiotensin Receptor Antagonists,,,Angiotensin Receptor Antagonists,C0815017
354,C0003015;C0815017;C1518422,Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists Negation,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
355,C0439269;C0428568;C0205172;C0205163;bothand,mg/dL Fasting blood glucose measurement More Equal BOTH AND,Fasting blood glucose,,,Fasting blood glucose,NA
356,C0439269;C0428568;C0439092,mg/dL Fasting blood glucose measurement Less Than,Fasting blood glucose,,,Fasting blood glucose,NA
357,C1305855;C0205172;bothand;C0205163,Body mass index More BOTH AND Equal,Body mass index,,,Body mass index,C1305855
358,C1305855;C0439092,Body mass index Less Than,Body mass index,,,Body mass index,C1305855
359,C1313937;C1518422,Family history of diabetes mellitus Negation,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
359,C1313937;C1518422,Family history of diabetes mellitus Negation,Family history,,,Family history,C0241889
360,C1510829;C0205172;bothand;C0205163,Age-Years More BOTH AND Equal,Age-Years,,,Age-Years,C1510829
361,C1510829;C0439092,Age-Years Less Than,Age-Years,,,Age-Years,C1510829
362,C0024117;C1518422,Chronic Obstructive Airway Disease Negation,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
363,C0013175;C1272706;C1532338,Drug Evaluation Interval Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
364,C0019664;C0027051,History Myocardial Infarction,Medical History,,,Medical History,C0262926
364,C0019664;C0027051,History Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
365,C0021308;C0475264,Infarction localization,Infarction Anatomic Site ,,,Infarction Anatomic Site ,NA
366,C0070166;C1272706;C1532338,clopidogrel Interval Percutaneous Coronary Intervention,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
367,C0184666;C1272706;C1507009,Hospital admission Interval Pain onset,Pain ,,,Pain ,NA
368,C1272706;C1532338,Interval Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
369,C2347958;C0041703,Resident (person) United States,Racial group,,,Racial group,C0034510
370,C0011860;C3665365;C1518422,"Diabetes Mellitus, Non-Insulin-Dependent Arteriosclerotic cardiovascular disease, NOS Negation",Diabetes Mellitus,,,Diabetes Mellitus,C0011849
371,C0007430;C0022877;C4534362,Catheterization Laboratory In-center,Catheterization,,,Catheterization,C0007430
372,C0006280;C0871261,Bronchodilator Agents Response process,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
373,C0024117;C0439793;C0449820,Chronic Obstructive Airway Disease Severities Score,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
374,C0117996;C0586793;C1518422;eitheror,Fluticasone propionate Inhaled steroids use Negation Either one or other,Inhaled steroids use,,,Inhaled steroids use,C0586793
375,C0117996;C0586793;eitheror,Fluticasone propionate Inhaled steroids use Either one or other,Fluticasone propionate,,,Fluticasone propionate,C0117996
376,C0457591;C0586793,Type of drug Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
377,C1518422;eitheror;C0586793,Negation Either one or other Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
378,C2348561;C2930696;C1710475,Study Population (group) tofacitinib Trial Phase,tofacitinib,Immunosuppressive Agents,,Immunosuppressive Agents,C0021081
379,C2930696;C1710475;C2348561,tofacitinib Trial Phase Study Population (group),tofacitinib,Immunosuppressive Agents,,Immunosuppressive Agents,C0021081
380,C2930696;C2348561,tofacitinib Study Population (group),tofacitinib,Immunosuppressive Agents,,Immunosuppressive Agents,C0021081
381,C0032042;C0742906,Placebos Elevated C-reactive protein,C-Reactive Protein,,,C-Reactive Protein,NA
382,C1872109;C0742906,certolizumab pegol Elevated C-reactive protein,certolizumab pegol,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
383,C1518422;C2826257;C0666743,Negation Prior Medication Usage infliximab,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
384,C4076075;C2826257,Infliximab therapy Prior Medication Usage,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
385,C0019664;C4554100,"History Stroke, CTCAE",Medical History,,,Medical History,C0262926
385,C0019664;C4554100,"History Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
386,C0085826;C0205156;C0205191;C1524063,Antiplatelet Agents Previous chronic Use of,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
387,C0205156;C0011849,Previous Diabetes Mellitus,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
388,C1697238;C1442488,NIH stroke scale Baseline,NIH stroke scale,"Stroke, CACTE",,"Stroke, CACTE",NA
389,C0337672;C0521116,Non-smoker Current (present time),Smoking Status,,,Smoking Status,C1519386
390,C0030705;C0003873;C0038013;C0003872,"Patients Rheumatoid Arthritis Ankylosing spondylitis Arthritis, Psoriatic",Ankylosing spondylitis,,,Ankylosing spondylitis,C0038013
390,C0030705;C0003873;C0038013;C0003872,"Patients Rheumatoid Arthritis Ankylosing spondylitis Arthritis, Psoriatic","Arthritis, Psoriatic",,,"Arthritis, Psoriatic","C0003872	"
390,C0030705;C0003873;C0038013;C0003872,"Patients Rheumatoid Arthritis Ankylosing spondylitis Arthritis, Psoriatic","Arthritis, Psoriatic",,,"Arthritis, Psoriatic",C0003872
390,C0030705;C0003873;C0038013;C0003872,"Patients Rheumatoid Arthritis Ankylosing spondylitis Arthritis, Psoriatic",Rheumatoid Arthritis,,,Rheumatoid Arthritis,C0003873
391,C0030705;C0038013;C0003872;C0003873;C1518422,"Patients Ankylosing spondylitis Arthritis, Psoriatic Rheumatoid Arthritis Negation",Ankylosing spondylitis,,,Ankylosing spondylitis,C0038013
391,C0030705;C0038013;C0003872;C0003873;C1518422,"Patients Ankylosing spondylitis Arthritis, Psoriatic Rheumatoid Arthritis Negation","Arthritis, Psoriatic",,,"Arthritis, Psoriatic","C0003872	"
391,C0030705;C0038013;C0003872;C0003873;C1518422,"Patients Ankylosing spondylitis Arthritis, Psoriatic Rheumatoid Arthritis Negation","Arthritis, Psoriatic",,,"Arthritis, Psoriatic",C0003872
391,C0030705;C0038013;C0003872;C0003873;C1518422,"Patients Ankylosing spondylitis Arthritis, Psoriatic Rheumatoid Arthritis Negation",Rheumatoid Arthritis,,,Rheumatoid Arthritis,C0003873
392,C0033860;C1518422,Psoriasis Negation,Psoriasis,,,Psoriasis,C0033860
393,C0033860;C1549445,Psoriasis Yes - Yes/no indicator,Psoriasis,,,Psoriasis,C0033860
394,C0025266;C1532338;C0205226,Male population group Percutaneous Coronary Intervention Primary,Gender,,,Gender,C0079399
394,C0025266;C1532338;C0205225,Male population group Percutaneous Coronary Intervention Primary,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
395,C0043210;C1532338;C0205225,Woman Percutaneous Coronary Intervention Primary,Gender,,,Gender,C0079399
395,C0043210;C1532338;C0205225,Woman Percutaneous Coronary Intervention Primary,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
396,C1882085;C1882086;C0428772,New York Heart Association Class II New York Heart Association Class III Left ventricular ejection fraction,Left ventricular ejection fraction,,,Left ventricular ejection fraction,C0428772
396,C1882085;C1882086;C0428772,New York Heart Association Class II New York Heart Association Class III Left ventricular ejection fraction,New York Heart Association Class,,,New York Heart Association Class,C1882083
397,C0011849;C0150312,Diabetes Mellitus Present,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
398,C0011849;C0332197;C0011816,Diabetes Mellitus Absent Dextromethorphan,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
399,C0074554;C1696465,Simvastatin placebo,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
400,C1704675;C1709380,Interaction P-Value,NA TO BE DELETED,,,NA TO BE DELETED,NA
401,C0027051;C0205156,Myocardial Infarction Previous,Myocardial Infarction,,,Myocardial Infarction,C0027051
402,C0085201;C0456603,Apolipoprotein A-I Ratio,Apolipoprotein A-I,,,Apolipoprotein A-I,C0085201
403,C0205156;C0581603,Previous Revascularization - action,Revascularization - action,,,Revascularization - action,C0581603
404,C0205156;C1963138,"Previous Hypertension, CTCAE","Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
405,C0439268;C4048285,"Microgram per Milliliter C-Reactive Protein, human",C-Reactive Protein,,,C-Reactive Protein,NA
406,C0439294;C4048285,"Kilogram per Cubic Meter C-Reactive Protein, human",C-Reactive Protein,,,C-Reactive Protein,NA
407,C0337671;C3241966,Smoking Status,Smoking Status,,,Smoking Status,C1519386
408,C0205307;C1561643;C2945599,Normal Chronic Kidney Diseases Mild (qualifier value),Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
409,C1561643;C0205081,Chronic Kidney Diseases Moderate (severity modifier),Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
410,C0428883;C0439475;C0442592;C0439092,Diastolic blood pressure mmHg Clinic Less Than,Blood Pressure,,,Blood Pressure,C0005823
411,C0428883;C0439475;C4534363;C0439092,Diastolic blood pressure mmHg At home Less Than,Blood Pressure,,,Blood Pressure,C0005823
412,C0428883;C0442592;C0439475;C0205172,Diastolic blood pressure Clinic mmHg More,Blood Pressure,,,Blood Pressure,C0005823
413,C0439475;C0442592;C0871470;C0439092,mmHg Clinic Systolic Pressure Less Than,Blood Pressure,,,Blood Pressure,C0005823
414,C0439475;C0871470;C4534363;C0439092,mmHg Systolic Pressure At home Less Than,Blood Pressure,,,Blood Pressure,C0005823
415,C0442592;C0871470;C0439475;C0205172,Clinic Systolic Pressure mmHg More,Blood Pressure,,,Blood Pressure,C0005823
416,C0871470;C4534363;C0439475;C0205172,Systolic Pressure At home mmHg More,Blood Pressure,,,Blood Pressure,C0005823
417,C4534363;C0428883;C0439475;C0205172,At home Diastolic blood pressure mmHg More,Blood Pressure,,,Blood Pressure,C0005823
418,C0205156;C1956346,Previous Coronary Artery Disease,Coronary Artery Disease,,,Coronary Artery Disease,C1956346
419,C0041004;C0428471,Triglycerides HDL - High density lipoprotein cholesterol level result,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
420,C0017887;C0522082,Nitroglycerin Normal glucose level,Glucose,,,Glucose,C0017725
420,C0017887;C0522082,Nitroglycerin Normal glucose level,Nitroglycerin,,,Nitroglycerin,C0017887
421,C0522082;C0271650,Normal glucose level Impaired glucose tolerance,Glucose,,,Glucose,C0017725
421,C0522082;C0271650,Normal glucose level Impaired glucose tolerance,Impaired glucose tolerance,,,Impaired glucose tolerance,C0271650
422,C1706005;C0271650,CD40LG wt Allele Impaired glucose tolerance,CD40LG wt Allele,Genotype,,Genotype,C0017431
422,C1706005;C0271650,CD40LG wt Allele Impaired glucose tolerance,Impaired glucose tolerance,,,Impaired glucose tolerance,C0271650
423,C1306889;C1704436;C1442488,Peripheral arterial occlusive disease Peripheral Arterial Diseases Baseline,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
423,C1306889;C1704436;C1442488,Peripheral arterial occlusive disease Peripheral Arterial Diseases Baseline,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
423,C1306889;C1704436;C1442488,Peripheral arterial occlusive disease Peripheral Arterial Diseases Baseline,Peripheral arterial occlusive disease,,,Peripheral arterial occlusive disease,C1306889
424,C1704436;C1518422;C1442488,Peripheral Arterial Diseases Negation Baseline,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
424,C1704436;C1518422;C1442488,Peripheral Arterial Diseases Negation Baseline,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
425,C0010592;C0332268,Cyclosporine Lacking,Cyclosporins,,,Cyclosporins,C0010594
426,C0025677;C0332268,Methotrexate Lacking,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
427,C1514463;C0205373,Prior Therapy Systemic,NA TO BE DELETED,,,NA TO BE DELETED,NA
428,C1514463;C0332268;C0205373,Prior Therapy Lacking Systemic,NA TO BE DELETED,,,NA TO BE DELETED,NA
429,C0205250;C1619634;C0006560;;bothand,High erythrocyte sedimentation rate result C-reactive protein NA BOTH AND,C-reactive protein,,,C-reactive protein,C0006560
429,C0205250;C1619634;C0006560;;bothand,High erythrocyte sedimentation rate result C-reactive protein NA BOTH AND,erythrocyte sedimentation rate result,,,erythrocyte sedimentation rate result,C1619634
430,C0205250;C1619634;C0006560;eitheror,High erythrocyte sedimentation rate result C-reactive protein Either one or other,C-reactive protein,,,C-reactive protein,C0006560
430,C0205250;C1619634;C0006560;eitheror,High erythrocyte sedimentation rate result C-reactive protein Either one or other,erythrocyte sedimentation rate result,,,erythrocyte sedimentation rate result,C1619634
431,C0449820;C0012634;C0449279,Score Disease Extent of disease,NA TO BE DELETED,,,NA TO BE DELETED,NA
432,C0449820;C0457451,Score Severity score,NA TO BE DELETED,,,NA TO BE DELETED,NA
433,C1619634;C0205307;C0006560,erythrocyte sedimentation rate result Normal C-reactive protein,erythrocyte sedimentation rate result,,,erythrocyte sedimentation rate result,C1619634
434,C0011900;C0918012,Diagnosis Index,NA TO BE DELETED,,,NA TO BE DELETED,NA
435,C0205390;C0679823,Phase participation,NA TO BE DELETED,,,NA TO BE DELETED,NA
436,C0441471;C1532338;C0918012,Event Percutaneous Coronary Intervention Index,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
437,C0520886;C1518422;C0948089,ST segment elevation (finding) Negation Acute Coronary Syndrome,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
437,C0520886;C1518422;C0948089,ST segment elevation (finding) Negation Acute Coronary Syndrome,ST segment elevation (finding),,,ST segment elevation (finding),C0520886
438,C0004057;C0332152,Aspirin Before,Aspirin,,,Aspirin,C0004057
439,C0004057;C0332152;C1518422,Aspirin Before Negation,Aspirin,,,Aspirin,C0004057
440,C0041199;C0205307,Troponin Normal,Troponin,,,Troponin,C0041199
441,C0041199;C3163633,Troponin Elevated,Troponin,,,Troponin,C0041199
442,C0520887;C0520886,ST segment depression (finding) ST segment elevation (finding),ST segment elevation (finding),,,ST segment elevation (finding),C0520886
443,C0520887;C0520886;C1518422,ST segment depression (finding) ST segment elevation (finding) Negation,ST segment depression (finding),,,ST segment depression (finding),C0520887
444,C1280500;C1561607,Effect Overall,NA TO BE DELETED,,,NA TO BE DELETED,NA
445,C0001645;C0445204,Adrenergic beta-Antagonists Preoperative,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
446,C0001645;C1518422;C0445204,Adrenergic beta-Antagonists Negation Preoperative,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
447,C0010055;C0018826;C0559956;C0332288,Coronary Artery Bypass Surgery Heart Valves Replacement Without,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
447,C0010055;C0018826;C0559956;C0332288,Coronary Artery Bypass Surgery Heart Valves Replacement Without,Heart Valves Replacement,,,Heart Valves Replacement,NA
448,C0002598;C0205156;C1524063,Amiodarone Previous Use of,Amiodarone,"Antiarrhythmics, class III",CARDIAC THERAPY,CARDIAC THERAPY,NA
449,C0003195;C0205156;C1524063,Anti-Arrhythmia Agents Previous Use of,Anti-Arrhythmia Agents,,,Anti-Arrhythmia Agents,C0003195
450,C0018801;C0243161,Heart failure criteria,Heart failure,,,Heart failure,C0018801
451,C0225860;C1301886,Left atrial structure Diameter (qualifier value),Left atrial structure,,,Left atrial structure,C0225860
452,C0439228;C1321500,day Conversion of cardiac rhythm to sinus rhythm,Conversion of cardiac rhythm to sinus rhythm,,,Conversion of cardiac rhythm to sinus rhythm,C1321500
453,C0034656;C3653316,Randomization Vitamin K antagonists,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
454,C0034656;C3653316;C1518422,Randomization Vitamin K antagonists Negation,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
455,C2003901;C3653316,Never (frequency) Vitamin K antagonists,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
456,C3653316;C0205156;C1518422,Vitamin K antagonists Previous Negation,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
457,C3653316;C0596545,Vitamin K antagonists Experience,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
458,C3653316;C3887636,Vitamin K antagonists Ever,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
459,C0002598;C1518422,Amiodarone Negation,Amiodarone,"Antiarrhythmics, class III",CARDIAC THERAPY,CARDIAC THERAPY,NA
460,C0004057;C1518422,Aspirin Negation,Aspirin,,,Aspirin,C0004057
461,C0358591;C1518422,Proton Pump Inhibitors Negation,Proton Pump Inhibitors,,,Proton Pump Inhibitors,C0358591
462,C0005847;C1306577,Blood Vessel Death (finding),Blood Vessel,,,Blood Vessel,C0005847
463,C0013922;C0205373;C4554100,"Embolism Systemic Stroke, CTCAE",Embolism,,,Embolism,C0013922
463,C0013922;C0205373;C4554100,"Embolism Systemic Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
464,C0019080;C0205164,Hemorrhage Major,Hemorrhage,,,Hemorrhage,C0019080
465,C0439810;C1306577,Total Death (finding),NA TO BE DELETED,,,NA TO BE DELETED,NA
466,C0018801;C1518422,Heart failure Negation,Heart failure,,,Heart failure,C0018801
467,C0038454;C1518422,Cerebrovascular accident Negation,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
468,C1956346;C1518422,Coronary Artery Disease Negation,Coronary Artery Disease,,,Coronary Artery Disease,C1956346
469,C0011849;C1171304,Diabetes Mellitus diabetes risk,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
469,C0011849;C1171304,Diabetes Mellitus diabetes risk,diabetes risk,,,diabetes risk,C1171304
470,C0001779;C1709380,Age P-Value,Age-Years,,,Age-Years,C1510829
471,C0027362;C1709380;C1704675,Human Age Group P-Value Interaction,Age-Years,,,Age-Years,C1510829
472,C0439508;C0441471,per year Event,NA TO BE DELETED,,,NA TO BE DELETED,NA
473,C2985465;C0009667,Hazard Ratio Confidence Intervals,NA TO BE DELETED,,,NA TO BE DELETED,NA
474,C0038454;C0040038,Cerebrovascular accident Thromboembolism,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
474,C0038454;C0040038,Cerebrovascular accident Thromboembolism,Thromboembolism,,,Thromboembolism,C0040038
475,C1306577;C1558950,Death (finding) Adverse Event Associated with Vascular,NA TO BE DELETED,,,NA TO BE DELETED,NA
476,C0003209;C1549445,Anti-Inflammatory Agents Yes - Yes/no indicator,Anti-Inflammatory Agents,,,Anti-Inflammatory Agents,C0003209
477,C0003209;C2003901,Anti-Inflammatory Agents Never (frequency),Anti-Inflammatory Agents,,,Anti-Inflammatory Agents,C0003209
478,C0025677;C1442488,Methotrexate Baseline,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
479,C0025677;C1518422;C1442488,Methotrexate Negation Baseline,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
480,C0025677;C4055380,Methotrexate Biologic Disease-Modifying Antirheumatic Drug,"Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
480,C0025677;C4055381,Methotrexate Biologic Disease-Modifying Antirheumatic Drug,Methotrexate,Immunosuppressive Agents,,Immunosuppressive Agents,C0021081
481,C0025677;C4055380;C1518422,Methotrexate Biologic Disease-Modifying Antirheumatic Drug Negation,"Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
481,C0025677;C4055380;C1518423,Methotrexate Biologic Disease-Modifying Antirheumatic Drug Negation,Methotrexate,Immunosuppressive Agents,,Immunosuppressive Agents,C0021081
482,C0429706;C1882327,Forced expiratory volume in 1 second finding Percent of Predicted Value,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
483,C1442488;C2964552;C0034380,Baseline Total score Quality of life,Quality of life,,,Quality of life,C0034380
484,C4086268;C0205156;C0439234,Exacerbation Previous year,NA TO BE DELETED,,,NA TO BE DELETED,NA
485,C4086268;C0439234;C0205156,Exacerbation year Previous,NA TO BE DELETED,,,NA TO BE DELETED,NA
486,C0332132;C0027051,Prior diagnosis Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
487,C1442488;C0439593;C0242896,Baseline Short duration Anticholinergic Agents,Anticholinergic Agents,,,Anticholinergic Agents,C0242896
488,C1442488;C1561566,"Baseline FEV1, CTCAE","FEV1, CTCAE",Forced expiratory volume function,,Forced expiratory volume function,C0016529
489,C1442488;C3887460;C3887704,Baseline Cardiovascular treatment - ActInformationManagementReason,Cardiovascular system,,,Cardiovascular system,C0007226
490,C0002962;C0155626,Angina Pectoris Acute myocardial infarction,Angina Pectoris,Angi Pectoris,,Angina Pectoris,C0002962
490,C0002962;C0155626,Angina Pectoris Acute myocardial infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
491,C0332287;LABA ;C0586793,In addition to long-acting beta agonist  Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
491,C0332287;LABA ;C0586793,In addition to long-acting beta agonist  Inhaled steroids use,long-acting beta agonist,,,long-acting beta agonist,NA
492,C1518422;C0586793,Negation Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
493,LABA ;C1518422,long-acting beta agonist  Negation,long-acting beta agonist,,,long-acting beta agonist,NA
494,C0017853;C1442488,"Hemoglobin, Glycosylated Baseline","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
495,C0015663;C0857690,Fasting plasma insulin,Insulin,,,Insulin,C0021641
496,C0086528;C0086409,Latinos Hispanics,Racial group,,,Racial group,C0034510
497,C0006558;C0015663,C-Peptide Fasting,C-Peptide,,,C-Peptide,C0006558
498,C0006558;C0376674,C-Peptide Postprandial Period,C-Peptide,,,C-Peptide,C0006558
499,C0015663;C0021641,Fasting Insulin,Insulin,,,Insulin,C0021641
500,C0015663;C0033362;C0439284,Fasting Proinsulin Picomole per Liter,Proinsulin,,,Proinsulin,C0033362
501,C0021641;C0376674,Insulin Postprandial Period,Insulin,,,Insulin,C0021641
502,C0033362;C0376674,Proinsulin Postprandial Period,Proinsulin,,,Proinsulin,C0033362
503,C0205199;C0918012;C0920563,Composite Index Insulin Sensitivity,Insulin Sensitivity,,,Insulin Sensitivity,C0920563
504,C0454664;C0017853,"Country Hemoglobin, Glycosylated","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
505,C0743223;C0918012,Disposition Index,NA TO BE DELETED,,,NA TO BE DELETED,NA
506,C0918012;C0221102;C0021641,Index Excretory function Insulin,Insulin,,,Insulin,C0021641
507,C4033634;C0376674,Blood Indices Postprandial Period,Blood Indices,,,Blood Indices,C4033634
508,C0021641;C0418981,Insulin Medical therapy,Insulin,,,Insulin,C0021641
509,C0021641;C0418981;C1524062,Insulin Medical therapy Additional,Insulin,,,Insulin,C0021641
510,C2348561;C0439810,Study Population (group) Total,NA TO BE DELETED,,,NA TO BE DELETED,NA
511,C0024117;C0439793,Chronic Obstructive Airway Disease Severities,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
512,C0024117;C1292730,Chronic Obstructive Airway Disease Condition severity,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
513,C1514463;C0586793;C1707479;LABA,Prior Therapy Inhaled steroids use Concomitant Therapy NA,Inhaled steroids use,,,Inhaled steroids use,C0586793
513,C1514463;C0586793;C1707479;LABA,Prior Therapy Inhaled steroids use Concomitant Therapy NA,long-acting beta agonist,,,long-acting beta agonist,NA
514,to add;C0586793,LABA Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
514,to add;C0586793,LABA Inhaled steroids use,long-acting beta agonist,,,long-acting beta agonist,NA
515,C0035448;C0521143,Rheumatoid Factor Seropositive,Rheumatoid Factor,,,Rheumatoid Factor,C0035448
516,C0035448;C0521144,Rheumatoid Factor Seronegative,Rheumatoid Factor,,,Rheumatoid Factor,C0035448
517,C0205156;C0281481;C0237753,Previous anti-tumor necrosis factor therapy Numbers,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
518,C0205156;C4055380;C0457454,Previous Biologic Disease-Modifying Antirheumatic Drug Discontinuation (procedure),Biologic Disease-Modifying Antirheumatic Drug,,,Biologic Disease-Modifying Antirheumatic Drug,C4055380
519,C0445356;C1280519,Unrelated (finding) Effectiveness,NA TO BE DELETED,,,NA TO BE DELETED,NA
520,C0340288;C1518422;C4255010,Stable angina Negation Non-ST Elevated Myocardial Infarction,Non-ST Elevated Myocardial Infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
520,C0340288;C1518422;C4255010,Stable angina Negation Non-ST Elevated Myocardial Infarction,Stable angina,,,Stable angina,C0340288
521,C0241863;C1549445,diabetic Yes - Yes/no indicator,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
522,C1120149;C0332152,thienopyridine Before,thienopyridine,,,thienopyridine,C1120149
523,C1120149;C0332152;C1518422,thienopyridine Before Negation,thienopyridine,,,thienopyridine,C1120149
524,C0013404;C1518422,Dyspnea Negation,Dyspnea,,,Dyspnea,C0013404
525,C0013404;C1549445,Dyspnea Yes - Yes/no indicator,Dyspnea,,,Dyspnea,C0013404
526,C0518015;C1442488,Hemoglobin measurement Baseline,Hemoglobin,,,Hemoglobin,C0019046
527,C0518015;C1442488;C4321351,Hemoglobin measurement Baseline Low Level,Hemoglobin,,,Hemoglobin,C0019046
528,C0518015;C1561607,Hemoglobin measurement Overall,Hemoglobin,,,Hemoglobin,C0019046
529,C1280500;C0126174,Effect Losartan,Angiotensin Receptor Antagonists,,,Angiotensin Receptor Antagonists,C0815017
530,C0014442;C0003018;C0017432,Enzymes Angiotensins Genotype,Angiotensins,,,Angiotensins,C0003018
530,C0014442;C0003018;C0017431,Enzymes Angiotensins Genotype,Enzymes,,,Enzymes,C0014442
530,C0014442;C0003018;C0017433,Enzymes Angiotensins Genotype,Genotype,,,Genotype,C0017431
531,C0752046;C0022709,Single Nucleotide Polymorphism Peptidyl-Dipeptidase A,Peptidyl-Dipeptidase A,,,Peptidyl-Dipeptidase A,C0022709
531,C0752046;C0022709,Single Nucleotide Polymorphism Peptidyl-Dipeptidase A,Single Nucleotide Polymorphism,,,Single Nucleotide Polymorphism,C0752046
532,C0235974;C0007131,Pancreatic carcinoma Non-Small Cell Lung Carcinoma,Non-Small Cell Lung Carcinoma,,,Non-Small Cell Lung Carcinoma,C0007131
532,C0235974;C0007131,Pancreatic carcinoma Non-Small Cell Lung Carcinoma,Pancreatic carcinoma,,,Pancreatic carcinoma,C0235974
533,C1442488;C0017853,"Baseline Hemoglobin, Glycosylated","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
534,C0043237;C0456387;C1442488,World Health Organization Class Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
535,C1442488;C0429886,Baseline Walking distance,Walking (activity),Physical activity,,Physical activity,C0026606
536,C1442488;C0005910,Baseline Body Weight,Body Weight,,,Body Weight,C0005910
537,C1442488;C0428568,Baseline Fasting blood glucose measurement,Fasting blood glucose,,,Fasting blood glucose,NA
538,C4013784;C1518422,"Hypertension, severe Negation","Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
539,C0023822;C1518422,High Density Lipoprotein Cholesterol Negation,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
540,C0006826;C0205177,Malignant Neoplasms Active,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
541,C0019664;C0630906,History vinyltriethoxysilane,Medical History,,,Medical History,C0262926
541,C0019664;C0630906,History vinyltriethoxysilane,vinyltriethoxysilane,,,vinyltriethoxysilane,C0630906
542,C0037369;C0521116,Smoking Current (present time),Smoking Status,,,Smoking Status,C1519386
543,C0070939;C0231220,phosphoethanolamine Symptomatic,phosphoethanolamine,,,phosphoethanolamine,C0070939
544,C1518422;C0037369,Negation Smoking,Smoking Status,,,Smoking Status,C1519386
545,C3811844;C0439445,Estimated Glomerular Filtration Rate mL/min,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
546,C0015127;C0475224,Etiology aspects Ischemic,Etiology aspect,,,Etiology aspect,NA
547,C0015127;C0475224;C1518422,Etiology aspects Ischemic Negation,Ischemic,,,Ischemic,C0475224
548,C1510829;C0876920,Age-Years Median Statistical Measurement,Age-Years,,,Age-Years,C1510829
549,C0042373;C1518422;C3830527,Vascular Diseases Negation Detectable,Vascular Diseases,,,Vascular Diseases,C0042373
550,C0042373;C3830527,Vascular Diseases Detectable,Vascular Diseases,,,Vascular Diseases,C0042373
551,C3166866;C0035647;C0449820,Framingham Risk Score,Risk,,,Risk,C0035647
552,C0444504;C1306620,Statistical mean Systolic blood pressure measurement,Blood Pressure,,,Blood Pressure,C0005823
553,C0070166;C3539076;C2926735,clopidogrel Pretreatment Duration,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
554,C0003015;C1524063,Angiotensin-Converting Enzyme Inhibitors Use of,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
555,C0018801;C1963159,"Heart failure Left Ventricular Systolic Dysfunction, CTCAE 3.0",Heart failure,,,Heart failure,C0018801
555,C0018801;C1963159,"Heart failure Left Ventricular Systolic Dysfunction, CTCAE 3.0","Left Ventricular Systolic Dysfunction, CTCAE 3.0",,,"Left Ventricular Systolic Dysfunction, CTCAE 3.0",C1963159
556,C0030705;C1561607,Patients Overall,NA TO BE DELETED,,,NA TO BE DELETED,NA
557,C0001948;C1442488,Alcohol consumption Baseline,Alcohol consumption,,,Alcohol consumption,C0001948
558,C0003364;C1442488,Antihypertensive Agents Baseline,Antihypertensive Agents,,,Antihypertensive Agents,C0003364
559,C0037369;C1442488,Smoking Baseline,Smoking Status,,,Smoking Status,C1519386
560,C2926735;C0242350,Duration Erectile dysfunction,Erectile dysfunction,,,Erectile dysfunction,C0242350
560,C2926735;C0242350,Duration Erectile dysfunction,Erectile dysfunction,,,Erectile dysfunction,D007172
561,C0001641;C1514463,Adrenergic alpha-Antagonists Prior Therapy,Adrenergic alpha-Antagonists,,,Adrenergic alpha-Antagonists,C0001641
562,C0005001;C0574785;C0457451,Benign prostatic hypertrophy Lower Urinary Tract Symptoms Severity score,Benign prostatic hypertrophy,,,Benign prostatic hypertrophy,C0005001
563,C1514463;C0242350,Prior Therapy Erectile dysfunction,Erectile dysfunction,,,Erectile dysfunction,C0242350
563,C1514463;C0242350,Prior Therapy Erectile dysfunction,Erectile dysfunction,,,Erectile dysfunction,D007172
564,C1998280;C0205081,International Prostate Symptom Score Moderate (severity modifier),International Prostate Symptom Score,,,International Prostate Symptom Score,C1998280
565,C1998280;C0205082,International Prostate Symptom Score Severe (severity modifier),International Prostate Symptom Score,,,International Prostate Symptom Score,C1998280
566,C0242350;C0205081;C0205082,Erectile dysfunction Moderate (severity modifier) Severe (severity modifier),Erectile dysfunction,,,Erectile dysfunction,C0242350
566,C0242350;C0205081;C0205082,Erectile dysfunction Moderate (severity modifier) Severe (severity modifier),Erectile dysfunction,,,Erectile dysfunction,D007172
567,C0242350;C2945599,Erectile dysfunction Mild (qualifier value),Erectile dysfunction,,,Erectile dysfunction,C0242350
567,C0242350;C2945599,Erectile dysfunction Mild (qualifier value),Erectile dysfunction,,,Erectile dysfunction,D007172
568,C2945599;C0242350,Mild (qualifier value) Erectile dysfunction,Erectile dysfunction,,,Erectile dysfunction,C0242350
568,C2945599;C0242350,Mild (qualifier value) Erectile dysfunction,Erectile dysfunction,,,Erectile dysfunction,D007172
569,C0281481;C1514463,anti-tumor necrosis factor therapy Prior Therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
570,C0011849;C0524620;C1549445,Diabetes Mellitus Metabolic Syndrome X Yes - Yes/no indicator,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
571,C0907402;C0359086,Insulin Glargine oral hypoglycemic,oral hypoglycemic,,,oral hypoglycemic,C0359086
572,C0907402;C4553624;C0359086;C0205172;C0585361,Insulin Glargine With meals oral hypoglycemic More Twice a day,Insulin,,,Insulin,C0021641
573,C0907402;C4553624;C0359086;C0332173,Insulin Glargine With meals oral hypoglycemic Daily,Insulin,,,Insulin,C0021641
574,C0907402;C4553624;C0359086;C0585361,Insulin Glargine With meals oral hypoglycemic Twice a day,Insulin,,,Insulin,C0021641
575,C1441604;C0006560;C1442488,High sensitivity C-reactive protein Baseline,C-Reactive Protein,,,C-Reactive Protein,NA
576,C1707479;C0021081,Concomitant Therapy Immunosuppressive Agents,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
577,C0003374;C0457083;C1549445,Antimalarials Usage Yes - Yes/no indicator,Antimalarials,,,Antimalarials,C0003374
578,C0021081;C0457083;C1549445,Immunosuppressive Agents Usage Yes - Yes/no indicator,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
579,C0038317;C0178602,Steroids Dosage,Steroids,,,Steroids,C0038317
580,C0038317;C1549445,Steroids Yes - Yes/no indicator,Steroids,,,Steroids,C0038317
581,C4055380;C0205156;C1518422,Biologic Disease-Modifying Antirheumatic Drug Previous Negation,"Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
582,C4055380;C0521983,Biologic Disease-Modifying Antirheumatic Drug Absence of therapeutic response,"Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
583,C0439475;C0428883,mmHg Diastolic blood pressure,Blood Pressure,,,Blood Pressure,C0005823
584,C0286651;C0178602,atorvastatin Dosage,atorvastatin,,,atorvastatin,C0286651
585,C1565489;C0205081,Renal Insufficiency Moderate (severity modifier),Renal Insufficiency,,,Renal Insufficiency,C1565489
586,C2945599;C1565489,Mild (qualifier value) Renal Insufficiency,Renal Insufficiency,,,Renal Insufficiency,C1565489
587,C1442488;C0545082;C0439231,Baseline Visit month,NA TO BE DELETED,,,NA TO BE DELETED,NA
588,C1565489;C2945599,Renal Insufficiency Mild (qualifier value),Renal Insufficiency,,,Renal Insufficiency,C1565489
589,C0029355;C0543467,Orthopedics Operative Surgical Procedures,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
589,C0029355;C0543467,Orthopedics Operative Surgical Procedures,Orthopedics,,,Orthopedics,C0029355
590,C0228134;C0002903,Spinal epidural space Anesthesia procedures,Anesthesia procedures,,,Anesthesia procedures,C0002903
591,C0442120;C0543467,Intraperitoneal Operative Surgical Procedures,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
592,C1523987;C0002903,Alternative Anesthesia procedures,Anesthesia procedures,,,Anesthesia procedures,C0002903
593,C1523987;C0543467,Alternative Operative Surgical Procedures,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
594,C0004057;C0457083;C1442488;C1518422,Aspirin Usage Baseline Negation,Aspirin,,,Aspirin,C0004057
595,C0018799;C1518422,Heart Diseases Negation,Heart Diseases,Cardiovascular Diseases,,Cardiovascular Diseases,C0007222
596,C1442488;C0004057;C0457083,Baseline Aspirin Usage,Aspirin,,,Aspirin,C0004057
597,C1442488;C1518422;C0004057;C0457083,Baseline Negation Aspirin Usage,Aspirin,,,Aspirin,C0004057
598,C0586793;C0869039,Inhaled steroids use Unit dose,Inhaled steroids use,,,Inhaled steroids use,C0586793
599,C1510829;C0001792,Age-Years Elderly (population group),Age-Years,,,Age-Years,C1510829
600,C0038257;C0332152,"Stent, device Before","Stent, device",,,"Stent, device",C0038257
601,C0038454;C4554100;C0007787;C0332152,"Cerebrovascular accident Stroke, CTCAE Transient Ischemic Attack Before",Cerebrovascular accident,,,Cerebrovascular accident,C0038454
601,C0038454;C4554100;C0007787;C0332152,"Cerebrovascular accident Stroke, CTCAE Transient Ischemic Attack Before","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
601,C0038454;C4554100;C0007787;C0332152,"Cerebrovascular accident Stroke, CTCAE Transient Ischemic Attack Before",Transient Ischemic Attack,,,Transient Ischemic Attack,C0007787
602,C0007787;C4554100,"Transient Ischemic Attack Stroke, CTCAE",Transient Ischemic Attack,,,Transient Ischemic Attack,C0007787
603,C0007787;C4554100;C1518422,"Transient Ischemic Attack Stroke, CTCAE Negation","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
604,C0011702;C1518422,Desmosine Negation,Desmosine,,,Desmosine,C0011702
605,C0037369;C1518422,Smoking Negation,Smoking Status,,,Smoking Status,C1519386
606,C0332152;C1536220,Before ST segment elevation myocardial infarction,ST segment elevation myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
607,C0332152;C1536220;C1518422,Before ST segment elevation myocardial infarction Negation,ST segment elevation myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
608,C0439231;C0027051,month Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
609,C1120149;C1549445,thienopyridine Yes - Yes/no indicator,thienopyridine,,,thienopyridine,C1120149
610,C1442488;C1120149,Baseline thienopyridine,thienopyridine,,,thienopyridine,C1120149
611,C1120149;C1518422,thienopyridine Negation,thienopyridine,,,thienopyridine,C1120149
612,C0302353;C1532563,Serum potassium measurement Millimole per Liter,potassium measurement,Potassium,,Potassium,C0032821
613,C0439475;C1306620,mmHg Systolic blood pressure measurement,Blood Pressure,,,Blood Pressure,C0005823
614,C3811844;C0001925,Estimated Glomerular Filtration Rate Albuminuria,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
615,C0005680;1,Black race ethnicity- other,Racial group,,,Racial group,C0034510
616,C0521942;C0003015;C0332287,Angiotensin II receptor antagonist Angiotensin-Converting Enzyme Inhibitors In addition to,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
616,C0521942;C0003015;C0332287,Angiotensin II receptor antagonist Angiotensin-Converting Enzyme Inhibitors In addition to,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
617,C0034656;C1510829,Randomization Age-Years,Age-Years,,,Age-Years,C1510829
618,C0683519;C1880008,disease history Cardiovascular History,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
618,C0683519;C1880008,disease history Cardiovascular History,Medical History,,,Medical History,C0262926
619,C0213771;C0073992,tiotropium salmeterol,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
619,C0213771;C0073992,tiotropium salmeterol,long-acting beta agonist,,,long-acting beta agonist,NA
620,C0332293;C3538919;C0586793,Treated with Low Risk Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
621,C0521114;C4086268,Infrequent Exacerbation,NA TO BE DELETED,,,NA TO BE DELETED,NA
622,C3538919;C0586793;C0332288,Low Risk Inhaled steroids use Without,Inhaled steroids use,,,Inhaled steroids use,C0586793
623,C4086268;C0332183,Exacerbation Frequently,NA TO BE DELETED,,,NA TO BE DELETED,NA
624,C4319571;C0332293;C0586793,High risk Treated with Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
625,C4319571;C0586793;C0332288,High risk Inhaled steroids use Without,Inhaled steroids use,,,Inhaled steroids use,C0586793
626,C3241966;C0337671,Current Smoker Former smoker,Smoking Status,,,Smoking Status,C1519386
627,C0017654;C0444686,Glomerular Filtration Rate Calculated,Glomerular Filtration Rate,,,Glomerular Filtration Rate,C0017654
628,C0439475;C0444504;C1442488;C3844320;C1306620,mmHg Statistical mean Baseline One day Systolic blood pressure measurement,Blood Pressure,,,Blood Pressure,C0005823
629,C0876920;C0205172,Median Statistical Measurement More,NA TO BE DELETED,,,NA TO BE DELETED,NA
630,C0876920;C0439092,Median Statistical Measurement Less Than,NA TO BE DELETED,,,NA TO BE DELETED,NA
631,C0021641;C0332325,Insulin Resistant (qualifier value),Insulin,,,Insulin,C0021641
632,C0150312;C2939420,Present Metastatic Neoplasm,Metastatic Neoplasm,,,Metastatic Neoplasm,C2939420
633,C0035647;C0449820;C3166866,Risk Score Framingham,Risk,,,Risk,C0035647
634,C0240320;C1524062,medication use Additional,NA TO BE DELETED,,,NA TO BE DELETED,NA
635,C0030193;C0205081;C0205082,Pain Moderate (severity modifier) Severe (severity modifier),Pain score,,,Pain score,C0582148
636,C0030193;C2945599,Pain Mild (qualifier value),Pain score,,,Pain score,C0582148
637,C0030705;C0439810,Patients Total,NA TO BE DELETED,,,NA TO BE DELETED,NA
638,C0205081;C0205082;C0582148,Moderate (severity modifier) Severe (severity modifier) Pain score,Pain score,,,Pain score,C0582148
639,C0582148;C2945599,Pain score Mild (qualifier value),Pain score,,,Pain score,C0582148
640,C0022661;C0205088,"Kidney Failure, Chronic End-stage",Kidney Failure,"Rel Failure, CTCAE",,"Renal Failure, CTCAE",C1963154
641,C0205088;C0035078,End-stage Kidney Failure,Kidney Failure,"Rel Failure, CTCAE",,"Renal Failure, CTCAE",C1963154
642,C1565489;C0205082,Renal Insufficiency Severe (severity modifier),Renal Insufficiency,,,Renal Insufficiency,C1565489
643,"C0034656	  ;C0040223",Randomisation Time,NA TO BE DELETED,,,NA TO BE DELETED,NA
644,C0070939;C0149871,phosphoethanolamine Deep Vein Thrombosis,Deep Vein Thrombosis,,,Deep Vein Thrombosis,C0149871
644,C0070939;C0149871,phosphoethanolamine Deep Vein Thrombosis,phosphoethanolamine,,,phosphoethanolamine,C0070939
645,C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335,Moderate (severity modifier) Severe (severity modifier) Moderation Moderate Extremity Pain Borg Category-Ratio 10 Perceived Exertion Score 3 Severe Extremity Pain Borg Category-Ratio 10 Perceived Exertion Score 5 Moderate Response Moderate Level,Borg Category-Ratio 10 Perceived Exertion Score 3,,,Borg Category-Ratio 10 Perceived Exertion Score 3,C4049706
646,C0205307;C0231683;C0439166;C2347086;C4553972,Normal Gait normal Percent normal Mean Percent of Normal How Often Felt Normal question,NA TO BE DELETED,,,NA TO BE DELETED,NA
647,C0441471;C0918012,Event Index,NA TO BE DELETED,,,NA TO BE DELETED,NA
648,C1565489;C0441889,Renal Insufficiency Levels (qualifier value),Renal Insufficiency,,,Renal Insufficiency,C1565489
649,C0007222;C0205191,Cardiovascular Diseases chronic,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
650,C0205191;C0007222,chronic Cardiovascular Diseases,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
651,C1561643;C1442488;C1306673,Chronic Kidney Diseases Baseline Stage,Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
652,C0001779;C0002965,"Age Angina, Unstable",Age-Years,,,Age-Years,C1510829
652,C0001779;C0002965,"Age Angina, Unstable","Angina, Unstable",Angi Pectoris,,Angina Pectoris,C0002962
653,C0019993;C1549995,Hospitalization Primary Reason,NA TO BE DELETED,,,NA TO BE DELETED,NA
654,C0439269;C0202117,mg/dL Low density lipoprotein cholesterol measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
655,C0439269;C0392885,mg/dL High density lipoprotein measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
656,C0439269;C0428475,mg/dL Triglyceride level - finding,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
657,C0439269;C0543421,mg/dL Total cholesterol,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
658,C0441471;C1514624,Event Qualifying,NA TO BE DELETED,,,NA TO BE DELETED,NA
659,C0023779;C1524063;C1707479,Lipids Use of Concomitant Therapy,Lipids Concomitant Therapy,,,Lipids Concomitant Therapy,NA
660,C0023779;C1707479,Lipids Concomitant Therapy,Lipids Concomitant Therapy,,,Lipids Concomitant Therapy,NA
661,C0023822;C1442488,High Density Lipoprotein Cholesterol Baseline,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
662,C0023824;C1442488,LDL Cholesterol Lipoproteins Baseline,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
663,C0205171;C0360714,Singular Hydroxymethylglutaryl-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
664,C0360714;C0027996;C1449704,Hydroxymethylglutaryl-CoA Reductase Inhibitors Niacin Fibrates,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
664,C0360714;C0027996;C1449705,Hydroxymethylglutaryl-CoA Reductase Inhibitors Niacin Fibrates,Niacin,,,Niacin,C0027996
665,C0360714;C0332307;C0521115,Hydroxymethylglutaryl-CoA Reductase Inhibitors Type - attribute Simultaneous,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
666,C0360714;C0521115,Hydroxymethylglutaryl-CoA Reductase Inhibitors Simultaneous,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
667,C0360714;C1142985,Hydroxymethylglutaryl-CoA Reductase Inhibitors ezetimibe,ezetimibe,Other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
667,C0360714;C1142985,Hydroxymethylglutaryl-CoA Reductase Inhibitors ezetimibe,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
668,C0011849;C0439591,Diabetes Mellitus Long duration,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
669,C0011849;C0439593,Diabetes Mellitus Short duration,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
670,C0017853;C0205250;C1442488,"Hemoglobin, Glycosylated High Baseline","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
671,C0017853;C0205251;C1442488,"Hemoglobin, Glycosylated low Baseline","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
672,C1305855;C0205250;C1442488,Body mass index High Baseline,Body mass index,,,Body mass index,C1305855
673,C1305855;C0205251;C1442488,Body mass index low Baseline,Body mass index,,,Body mass index,C1305855
674,C0205092;C1457887;C1442488,Unilateral Symptoms Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
675,C0238767;C1442488,Bilateral Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
676,C3639721;C0205250,Unified Parkinson's Disease Rating Scale High,Unified Parkinson's Disease Rating Scale,,,Unified Parkinson's Disease Rating Scale,C3639721
677,C3639721;C0205251;C1442488,Unified Parkinson's Disease Rating Scale low Baseline,Unified Parkinson's Disease Rating Scale,,,Unified Parkinson's Disease Rating Scale,C3639721
678,C0006826;C0205156,Malignant Neoplasms Previous,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
679,C0011900;C0149871,Diagnosis Deep Vein Thrombosis,Deep Vein Thrombosis,,,Deep Vein Thrombosis,C0149871
680,C0040223;C0460097,Time Within therapeutic range,NA TO BE DELETED,,,NA TO BE DELETED,NA
681,C0018824;C1518422,Heart valve disease Negation,Heart valve disease,,,Heart valve disease,C0018824
682,C0012798;C1442488;C0457083,Diuretics Baseline Usage,Diuretics,,,Diuretics,C0012798
683,C0018810;C1442488,heart rate Baseline,heart rate,,,heart rate,C0018810
684,C0034656;C0039798,Randomization therapeutic aspects,NA TO BE DELETED,,,NA TO BE DELETED,NA
685,C0332307;C0344434,Type - attribute Atrial Fibrillation by ECG Finding,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
686,C1442488;C3541930,"Baseline Beta blocking agents, antiglaucoma preparations and miotics","Beta blocking agents, antiglaucoma preparations and miotics",,,"Beta blocking agents, antiglaucoma preparations and miotics",C3541930
687,C0213771;C1518422,tiotropium Negation,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
688,C0281481;C1518422,anti-tumor necrosis factor therapy Negation,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
689,C0282416;C1561607,Overall Publication Type Overall,NA TO BE DELETED,,,NA TO BE DELETED,NA
690,C0332157;C0281481,Exposure to anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
691,C1561607;C1257890,Overall Population Group,NA TO BE DELETED,,,NA TO BE DELETED,NA
692,C0162643;C0281481,treatment failure anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
693,C0281481;C1518422;C0205156,anti-tumor necrosis factor therapy Negation Previous,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
694,--;C0449261,SABA- short acting beta agonist Reversibility,SABA- short acting beta agonist Reversibility,,,SABA- short acting beta agonist Reversibility,NA
695,C0024117;C0521117,Chronic Obstructive Airway Disease Severity of illness,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
696,C1710181;C0444506;C0444504,Standard Error Trough Statistical mean,NA TO BE DELETED,,,NA TO BE DELETED,NA
697,C0024117;C0205081,Chronic Obstructive Airway Disease Moderate (severity modifier),Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
698,C0024117;C0205082,Chronic Obstructive Airway Disease Severe (severity modifier),Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
699,C0024117;C0449238,Chronic Obstructive Airway Disease Duration (temporal concept),Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
700,C0086582;C0086287;eitheror,Males Females Either one or other,Gender,,,Gender,C0079399
701,C0205081;C0024117,Moderate (severity modifier) Chronic Obstructive Airway Disease,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
702,C0205082;C0024117,Severe (severity modifier) Chronic Obstructive Airway Disease,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
703,C0337671;C3241966;eitheror,Former smoker Current Smoker Either one or other,Smoking Status,,,Smoking Status,C1519386
704,C0456603;C3714541;C0429706,Ratio Forced Vital Capacity Forced expiratory volume in 1 second finding,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
704,C0456603;C3714541;C0429706,Ratio Forced Vital Capacity Forced expiratory volume in 1 second finding,Forced Vital Capacity,,,Forced Vital Capacity,C3714541
705,C0001613;C1518422,Adrenal Cortex Negation,Adrenal Cortex,,,Adrenal Cortex,C0001613
706,C0005775;C0205094,Blood Circulation Anterior,Blood Circulation,,,Blood Circulation,C0005775
707,C0019664;C0948008,History Ischemic stroke,Ischemic stroke,"Stroke, CTCAE",,"Stroke, CTCAE",C4554100
707,C0019664;C0948008,History Ischemic stroke,Medical History,,,Medical History,C0262926
708,C0455527;C0262926,H/O: hypertension Medical History,"Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
708,C0455527;C0262926,H/O: hypertension Medical History,Medical History,,,Medical History,C0262926
709,C0025598;C0444917,Metformin Duration of therapy,Metformin,Antidiabetics,,Antidiabetics,C0935929
710,C1305855;C1442488,Body mass index Baseline,Body mass index,,,Body mass index,C1305855
711,C0574785;C1442488;C0457451,Lower Urinary Tract Symptoms Baseline Severity score,Lower Urinary Tract Symptoms,,,Lower Urinary Tract Symptoms,C0574785
712,C1442488;C0242350;C0457451,Baseline Erectile dysfunction Severity score,Erectile dysfunction,,,Erectile dysfunction,C0242350
712,C1442488;C0242350;C0457451,Baseline Erectile dysfunction Severity score,Erectile dysfunction,,,Erectile dysfunction,D007172
713,C0038257;C0237753,"Stent, device Numbers","Stent, device",,,"Stent, device",C0038257
714,C0443225;C1257890,Full Population Group,NA TO BE DELETED,,,NA TO BE DELETED,NA
715,C0443225;C3258257,Full Total population,NA TO BE DELETED,,,NA TO BE DELETED,NA
716,C0948089;C1518422,Acute Coronary Syndrome Negation,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
717,C0039798;C0742343,therapeutic aspects Acute Chest Syndrome,Acute Chest Syndrome,,,Acute Chest Syndrome,C0742343
718,C0205081;C0205082,Moderate (severity modifier) Severe (severity modifier),NA TO BE DELETED,,,NA TO BE DELETED,NA
719,C0332307;C0742343,Type - attribute Acute Chest Syndrome,Acute Chest Syndrome,,,Acute Chest Syndrome,C0742343
720,C1096021;C1554184,antiplatelet therapy Dual,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
721,C1565489;C2946261,Renal Insufficiency Level,Renal Insufficiency,,,Renal Insufficiency,C1565489
722,C1831808;C0032042;C0150103;C0178602,apixaban Placebos MATCHING Dosage,Antithrombotic Agents,,,Antithrombotic Agents,C1704311
723,C3537184;C1518422,Non-ST Elevation Myocardial Infarction by ECG Finding Negation,Non-ST Elevated Myocardial Infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
724,C0004057;C1720467,Aspirin Only - dosing instruction fragment,Aspirin,,,Aspirin,C0004057
725,C0070166;C0004057,clopidogrel Aspirin,Aspirin,,,Aspirin,C0004057
725,C0070166;C0004057,clopidogrel Aspirin,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
726,C3540778;C1518422,Glucocorticoid inhalants for obstructive airway disease Negation,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
727,C3641272;C0205082;C3844638,Very severe Severe (severity modifier) Either,NA TO BE DELETED,,,NA TO BE DELETED,NA
728,C0011849;C1549445,Diabetes Mellitus Yes - Yes/no indicator,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
729,C0023189;C1442488;C0444504,Least-Squares Analysis Baseline Statistical mean,NA TO BE DELETED,,,NA TO BE DELETED,NA
730,C0277814;C1306620,Sitting position Systolic blood pressure measurement,Blood Pressure,,,Blood Pressure,C0005823
731,C0444504;C1319894,Statistical mean Sitting diastolic blood pressure,Blood Pressure,,,Blood Pressure,C0005823
732,C1305855;C1319441;C1518422,Body mass index Body mass index 40+ - severely obese Negation,Body mass index,,,Body mass index,C1305855
733,C1561643;C3272907;C0205450;C1306673,Chronic Kidney Diseases Percent Change From Baseline Four Stage,Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
734,C1561643;C3272907;C0441771,Chronic Kidney Diseases Percent Change From Baseline Stage level 3,Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
735,C0086582;C0086287;C0079399,Males Females Gender,Gender,,,Gender,C0079399
736,C3714496;C0205082;C2945599;C0205081,Chronic obstructive pulmonary disease of horses Severe (severity modifier) Mild (qualifier value) Moderate (severity modifier),Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
737,C0286651;C1524063,atorvastatin Use of,atorvastatin,,,atorvastatin,C0286651
738,C0007222;C0850708,Cardiovascular Diseases History of disease,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
738,C0007222;C0850708,Cardiovascular Diseases History of disease,Medical History,,,Medical History,C0262926
739,C0013227;C2003888,Pharmaceutical Preparations Lower (action),Pharmaceutical Preparations,,,Pharmaceutical Preparations,C0013227
740,C0443258;C0850708,Microvascular History of disease,Medical History,,,Medical History,C0262926
740,C0443258;C0850708,Microvascular History of disease,Microvascular disease,,,Microvascular disease,NA
741,C0650607;C0332307,Basal insulin Type - attribute,Insulin,,,Insulin,C0021641
742,C0001779;C1442488,Age Baseline,Age-Years,,,Age-Years,C1510829
743,C0003980;C0030168,Asia Pacific Islands,Geographic Locations,,,Geographic Locations,C0017446
744,C0005802;C1442488,Blood Glucose Baseline,Glucose,,,Glucose,C0017725
745,C0006823;C0041703,Canada United States,Geographic Locations,,,Geographic Locations,C0017446
746,C0010055;C0019664,Coronary Artery Bypass Surgery History,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
746,C0010055;C0019664,Coronary Artery Bypass Surgery History,Medical History,,,Medical History,C0262926
747,C0018802;C0019664,Congestive heart failure History,Congestive heart failure,Heart failure,,Heart failure,C0018801
747,C0018802;C0019664,Congestive heart failure History,Medical History,,,Medical History,C0262926
748,C0025885;C0007674;C0037713,Mexico Central America South America,Geographic Locations,,,Geographic Locations,C0017446
749,C0037369;C4555205,Smoking Ex-Smokers,Smoking Status,,,Smoking Status,C1519386
750,C0043129;C4289954;C0026068,Western Europe Australian/New Zealand Ethnicity Middle East,Racial group,,,Racial group,C0034510
751,C0221099;C4296962,Impaired Normal function,NA TO BE DELETED,,,NA TO BE DELETED,NA
752,C0239309;C0001737,eastern european Africa,Geographic Locations,,,Geographic Locations,C0017446
753,C0240016;C1442488,Insulin used Baseline,Insulin,,,Insulin,C0021641
754,C1561607;C1518681,Overall Outcome of Therapy,NA TO BE DELETED,,,NA TO BE DELETED,NA
755,C0006560;C0439268,C-reactive protein Microgram per Milliliter,C-Reactive Protein,,,C-Reactive Protein,NA
756,C0016658;C0019664,Fracture History,Fracture,,,Fracture,C0016658
756,C0016658;C0019664,Fracture History,Medical History,,,Medical History,C0262926
757,C0016658;C0019664;C1518422,Fracture History Negation,Fracture,,,Fracture,C0016658
757,C0016658;C0019664;C1518422,Fracture History Negation,Medical History,,,Medical History,C0262926
758,C0016157;C0015684,Fish Oils Fatty Acids,Fatty Acids,,,Fatty Acids,C0015684
759,C0360714;C0445204;C0032790,Hydroxymethylglutaryl-CoA Reductase Inhibitors Preoperative Postoperative Period,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
760,C0556216;C0205353,Fish intake Habitual,NA TO BE DELETED,,,NA TO BE DELETED,NA
761,C0010055;C0332152,Coronary Artery Bypass Surgery Before,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
762,C0010055;C0332152;C1518422,Coronary Artery Bypass Surgery Before Negation,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
763,C0027051;C1518422,Myocardial Infarction Negation,Myocardial Infarction,,,Myocardial Infarction,C0027051
764,C0034656;C1120149,Randomization thienopyridine,thienopyridine,,,thienopyridine,C1120149
765,C0034656;C4696290,Randomization Aspirin dose,Aspirin,,,Aspirin,C0004057
766,C0043157;C0220938,Caucasians White color,Racial group,,,Racial group,C0034510
767,C0241889;C0455471,Family history H/O: malignant neoplasm,Family history,,,Family history,C0241889
768,C0241889;C0455471;C1518422,Family history H/O: malignant neoplasm Negation,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
769,C0332132;C0027051;C1518422,Prior diagnosis Myocardial Infarction Negation,Myocardial Infarction,,,Myocardial Infarction,C0027051
770,C0332152;C1532338;C1518422,Before Percutaneous Coronary Intervention Negation,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
771,C0521116;C0543414,Current (present time) Tobacco use,Smoking Status,,,Smoking Status,C1519386
772,C0521116;C0543414;C1518422,Current (present time) Tobacco use Negation,Smoking Status,,,Smoking Status,C1519386
773,C1532338;C0332152,Percutaneous Coronary Intervention Before,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
774,C3146298;C1532338,Indication Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
775,C0418981;C1518422,Medical therapy Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
776,C0418981;C1549445,Medical therapy Yes - Yes/no indicator,NA TO BE DELETED,,,NA TO BE DELETED,NA
777,C0232100;C0205164;C1518422,Exsanguination Major Negation,Exsanguination,,,Exsanguination,C0232100
778,C0003015;C0457083,Angiotensin-Converting Enzyme Inhibitors Usage,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
779,C0004153;C0226003,Atherosclerosis Structure of large artery,Atherosclerosis,,,Atherosclerosis,C0004153
780,C0035647;C0205081,Risk Moderate (severity modifier),Risk,,,Risk,C0035647
781,C0038454;C1710306,Cerebrovascular accident TOAST Classification,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
782,C0205258;C3536725,Indeterminate Undetermined,NA TO BE DELETED,,,NA TO BE DELETED,NA
783,C0248719;C0034656;C1696465,telmisartan Randomization placebo,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
784,C0332174;C1518422,Weekly Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
785,C0449820;C1277291,Score Stroke risk,Stroke risk,,,Stroke risk,C1277291
786,C3272281;C3538919,American College of Cardiology/American Heart Association Lesion Complexity Score A Low Risk,American College of Cardiology/American Heart Association Lesion Complexity Score A,,,American College of Cardiology/American Heart Association Lesion Complexity Score A,C3272281
787,C0034656;C4554100,"Randomization Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
788,C1320716;C0205164,Cardiovascular event Major,Cardiovascular event,,,Cardiovascular event,C1320716
789,C1306673;C0024117,Stage Chronic Obstructive Airway Disease,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
790,C0025677;C1549445,Methotrexate Yes - Yes/no indicator,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
791,C0034656;C2360800;C0030705,Randomization Number of patients Patients,NA TO BE DELETED,,,NA TO BE DELETED,NA
792,C0087113;C0439230,Treatment Effectiveness week,NA TO BE DELETED,,,NA TO BE DELETED,NA
793,C1442488;C0025677;C1524063;C1549445,Baseline Methotrexate Use of Yes - Yes/no indicator,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
794,C2360800;C0030705,Number of patients Patients,NA TO BE DELETED,,,NA TO BE DELETED,NA
795,C0001792;C1556094,Elderly (population group) Japanese race,Racial group,,,Racial group,C0034510
796,C0443225;C0936012;C1705195,Full Analysis set (group),NA TO BE DELETED,,,NA TO BE DELETED,NA
797,C2974540;C0869039,canagliflozin Unit dose,canagliflozin,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,Antidiabetics,Antidiabetics,C0935929
798,C0002460;C1515945;C0205430;C0439673;C3853635,American Indians American Indian or Alaska Native Mixed (qualifier value) Unknown Race,Racial group,,,Racial group,C0034510
799,C0005680;C0085756,Black race African American,Racial group,,,Racial group,C0034510
800,C0038766;C0178602;C1442488,Sulfonylurea Compounds Dosage Baseline,Sulfonylurea Compounds,Antidiabetics,,Antidiabetics,C0935929
801,C0038766;C0806909;C1442488;C0178602,Sulfonylurea Compounds Maximum Baseline Dosage,Sulfonylurea Compounds,Antidiabetics,,Antidiabetics,C0935929
802,C1442488;C3811844,Baseline Estimated Glomerular Filtration Rate,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
803,C3811844;C1442488,Estimated Glomerular Filtration Rate Baseline,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
804,C0035096;C1999216,Renin-angiotensin system Inhibitor,Renin-angiotensin system Inhibitor,,,Renin-angiotensin system Inhibitor,NA
805,C0037713;C0007674,South America Central America,Geographic Locations,,,Geographic Locations,C0017446
806,C0475224;C1314792,Ischemic Etiology,Etiology aspects,,,Etiology aspects,C0015127
806,C0475224;C1314792,Ischemic Etiology,Ischemia,,,Ischemia,C0022116
807,C0669479;C2348144,pro-brain natriuretic peptide (1-76) Sample Median,pro-brain natriuretic peptide (1-76),,,pro-brain natriuretic peptide (1-76),C0669479
808,C1314792;C0475224,Etiology Ischemic,Etiology aspect,,,Etiology aspect,NA
808,C1314792;C0475224,Etiology Ischemic,Ischemic,,,Ischemic,C0475224
809,C2348144;C1095989,Sample Median Brain natriuretic peptide measurement,Brain natriuretic peptide measurement,,,Brain natriuretic peptide measurement,C1095989
810,C0011849;C1408353,Diabetes Mellitus Undiagnosed,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
811,C0086715;C0017853,"Normal Range Hemoglobin, Glycosylated","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
812,C0682369;C0015177,"central europe Europe, Eastern",Geographic Locations,,,Geographic Locations,C0017446
813,C0551577;C3898876;C0872291;C2004062;C0521116,History of hospitalizations:Finding:Point in time:^Patient:Nominal:Reported Hospitalization Due to Heart Failure Time Interval History of previous events Current (present time),Heart failure,,,Heart failure,C0018801
813,C0551577;C3898876;C0872291;C2004062;C0521116,History of hospitalizations:Finding:Point in time:^Patient:Nominal:Reported Hospitalization Due to Heart Failure Time Interval History of previous events Current (present time),Medical History,,,Medical History,C0262926
814,C3898876;C1518422;C2004062,Hospitalization Due to Heart Failure Negation History of previous events,Heart failure,,,Heart failure,C0018801
814,C3898876;C1518422;C2004062,Hospitalization Due to Heart Failure Negation History of previous events,Medical History,,,Medical History,C0262926
815,C1579268;C1518422,Mineralocorticoid Receptor Antagonists Negation,Mineralocorticoid Receptor Antagonists,,,Mineralocorticoid Receptor Antagonists,C1579268
816,C0449261;C0001927;C1549488,Reversibility Albuterol Amount type - Percentage,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
817,C0024117;C0441767;C0521117,Chronic Obstructive Airway Disease Stage level 2 Severity of illness,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
818,C0024117;C0521117;C0441771;C0205450,Chronic Obstructive Airway Disease Severity of illness Stage level 3 Four,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
819,C1442488;C0443172,Baseline Changed status,NA TO BE DELETED,,,NA TO BE DELETED,NA
820,C3826872;C2825507,St. George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease Patients Last Observation Carried Forward Imputation Technique,Chronic Obstructive Pulmonary Disease,,,Chronic Obstructive Pulmonary Disease,NA
821,C3826872;C2964552,St. George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease Patients Total score,Chronic Obstructive Pulmonary Disease,,,Chronic Obstructive Pulmonary Disease,NA
822,C1442488;C0016529,Baseline Forced expiratory volume function,Forced expiratory volume function,,,Forced expiratory volume function,C0016529
823,C0281481;C2826257,anti-tumor necrosis factor therapy Prior Medication Usage,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
824,C1518422;C0281481;C2826257,Negation anti-tumor necrosis factor therapy Prior Medication Usage,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
825,C0444708;C0449820,Radiographic Score,Radiographic,,,Radiographic,C0444708
826,C0449820;C0444708,Score Radiographic,Radiographic,,,Radiographic,C0444708
827,C0242708;C1518422,"Antirheumatic Drugs, Disease-Modifying Negation","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
828,C0009678;C0232180,Congenital MeSH qualifier Cardiac shunt,Cardiac shunt,,,Cardiac shunt,C0232180
829,C0015176;C0043128,Europe Western Australia,Geographic Locations,,,Geographic Locations,C0017446
830,C0019682;C0152171;C0040549;C0013221;C0020519,HIV Idiopathic pulmonary hypertension Toxin Drug toxicity Hypersensitivity,Drug toxicity,,,Drug toxicity,C0013221
830,C0019682;C0152171;C0040549;C0013221;C0020517,HIV Idiopathic pulmonary hypertension Toxin Drug toxicity Hypersensitivity,HIV,,,HIV,C0019682
830,C0019682;C0152171;C0040549;C0013221;C0020520,HIV Idiopathic pulmonary hypertension Toxin Drug toxicity Hypersensitivity,Hypersensitivity,,,Hypersensitivity,C0020517
830,C0019682;C0152171;C0040549;C0013221;C0020518,HIV Idiopathic pulmonary hypertension Toxin Drug toxicity Hypersensitivity,Idiopathic pulmonary hypertension,,,Idiopathic pulmonary hypertension,C0152171
831,C0205245;C0456387;C0043237,Functional Class World Health Organization,Functional assessment,,,Functional assessment,C0278372
832,C1134681;C0031638,Endothelin receptor antagonist Phosphodiesterase Inhibitors,Endothelin receptor antagonist,,,Endothelin receptor antagonist,C1134681
832,C1134681;C0031638,Endothelin receptor antagonist Phosphodiesterase Inhibitors,Phosphodiesterase Inhibitors,CARDIAC THERAPY,,CARDIAC THERAPY,NA
833,C0009782;C1561607,Connective Tissue Diseases Overall,Connective Tissue Diseases,,,Connective Tissue Diseases,C0009782
834,C0026272;C1168098;C0205250,Mixed Connective Tissue Disease pulmonary arterial pressure High,Mixed Connective Tissue Disease,,,Mixed Connective Tissue Disease,C0026272
834,C0026272;C1168098;C0205250,Mixed Connective Tissue Disease pulmonary arterial pressure High,pulmonary arterial pressure,,,pulmonary arterial pressure,C1168098
835,C1168098;C1442488;C0205250,pulmonary arterial pressure Baseline High,pulmonary arterial pressure,,,pulmonary arterial pressure,C1168098
836,C1442488;C1457887,Baseline Symptoms,NA TO BE DELETED,,,NA TO BE DELETED,NA
837,C1457887;C1442488,Symptoms Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
838,C0017853;C0005823;C0428474,"Hemoglobin, Glycosylated Blood Pressure LDL - Low density lipoprotein cholesterol level result",Blood Pressure,,,Blood Pressure,C0005823
838,C0017853;C0005823;C0428473,"Hemoglobin, Glycosylated Blood Pressure LDL - Low density lipoprotein cholesterol level result","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
838,C0017853;C0005823;C0428475,"Hemoglobin, Glycosylated Blood Pressure LDL - Low density lipoprotein cholesterol level result",lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
839,C0017853;C0428473;C0005824,"Hemoglobin, Glycosylated LDL - Low density lipoprotein cholesterol level result Blood Pressure",Blood Pressure,,,Blood Pressure,C0005823
839,C0017853;C0428473;C0005823,"Hemoglobin, Glycosylated LDL - Low density lipoprotein cholesterol level result Blood Pressure","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
839,C0017853;C0428473;C0005825,"Hemoglobin, Glycosylated LDL - Low density lipoprotein cholesterol level result Blood Pressure",lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
840,C0035648;C0439064,risk factors Numerous,risk factors,,,risk factors,C0035648
841,C0205081;C0232804,Moderate (severity modifier) Renal function,Renal function,,,Renal function,C0232804
842,C0205082;C0232804,Severe (severity modifier) Renal function,Renal function,,,Renal function,C0232804
843,C0232804;C0205307;C2945599,Renal function Normal Mild (qualifier value),Renal function,,,Renal function,C0232804
844,C2599594;C0429706;C0586793;C1442488,post bronchodilator Forced expiratory volume in 1 second finding Inhaled steroids use Baseline,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
844,C2599594;C0429706;C0586793;C1442488,post bronchodilator Forced expiratory volume in 1 second finding Inhaled steroids use Baseline,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
844,C2599594;C0429706;C0586793;C1442488,post bronchodilator Forced expiratory volume in 1 second finding Inhaled steroids use Baseline,Inhaled steroids use,,,Inhaled steroids use,C0586793
845,C2599594;C0586793;C0429706;C1518422;C1442488,post bronchodilator Inhaled steroids use Forced expiratory volume in 1 second finding Negation Baseline,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
846,C2599594;C1442488,post bronchodilator Baseline,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
847,C2599594;C1442488;C0429706;C0205420;C0213771,post bronchodilator Baseline Forced expiratory volume in 1 second finding Concurrent tiotropium,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
847,C2599594;C1442488;C0429706;C0205420;C0213771,post bronchodilator Baseline Forced expiratory volume in 1 second finding Concurrent tiotropium,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
848,C0005823;C0243148,Blood Pressure control aspects,Blood Pressure,,,Blood Pressure,C0005823
849,C0007226;C0035647,Cardiovascular system Risk,Cardiovascular system,,,Cardiovascular system,C0007226
849,C0007226;C0035647,Cardiovascular system Risk,Risk,,,Risk,C0035647
850,C0007820;C0205171,Cerebrovascular Disorders Singular,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
851,C0011849;C0040223,Diabetes Mellitus Time,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
852,C0027978;C0028405;C0004340,New Zealand North America Australia,Geographic Locations,,,Geographic Locations,C0017446
853,C0038454;C0205156,Cerebrovascular accident Previous,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
854,C0043031;C1096489,Warfarin Treatment with Vitamin K antagonist,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
854,C0043031;C1096489,Warfarin Treatment with Vitamin K antagonist,Warfarin,,Antithrombotic Agents,Antithrombotic Agents,C1704311
855,C0205171;C1704436,Singular Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
855,C0205171;C1704436,Singular Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
856,C1956346;C0205171,Coronary Artery Disease Singular,Coronary Artery Disease,,,Coronary Artery Disease,C1956346
857,C0030705;C1442488;C0033687,Patients Baseline Proteinuria,Proteinuria,,,Proteinuria,C0033687
858,C0455271;C1442488;C0205307;C0030705,Urine albumin/creatinine ratio measurement Baseline Normal Patients,Urine albumin/creatinine ratio measurement,,,Urine albumin/creatinine ratio measurement,C0455271
859,C0730345;C0030705;C1442488,Microalbuminuria Patients Baseline,Microalbuminuria,,,Microalbuminuria,C0730345
860,C1275835;C0332119;C3841753;C1442488,"History of myocardial infarction Past history of Yes, stroke Baseline",Medical History,,,Medical History,C0262926
860,C1275835;C0332119;C3841753;C1442488,"History of myocardial infarction Past history of Yes, stroke Baseline",Myocardial Infarction,,,Myocardial Infarction,C0027051
860,C1275835;C0332119;C3841753;C1442488,"History of myocardial infarction Past history of Yes, stroke Baseline","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
861,C1442488;C1457887;C2926735,Baseline Symptoms Duration,NA TO BE DELETED,,,NA TO BE DELETED,NA
862,C0011849;C2926735,Diabetes Mellitus Duration,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
863,C0015031;C0034510,Ethnic group Racial group,Racial group,,,Racial group,C0034510
864,C0017654;C1306673,Glomerular Filtration Rate Stage,Glomerular Filtration Rate,,,Glomerular Filtration Rate,C0017654
865,C0018801;C0742742,Heart failure congestive,Heart failure,,,Heart failure,C0018801
866,C0018801;C0742742;C0262926,Heart failure congestive Medical History,Heart failure,,,Heart failure,C0018801
866,C0018801;C0742742;C0262926,Heart failure congestive Medical History,Medical History,,,Medical History,C0262926
867,C0020616;C0442027,Hypoglycemic Agents Oral,Hypoglycemic Agents,,,Hypoglycemic Agents,C0020616
868,C0238611;C0002460,alaskan American Indians,Racial group,,,Racial group,C0034510
869,C0337920;C0242191,Hawaiian population Pacific Islander Americans,Racial group,,,Racial group,C0034510
870,C1320716;C0205156,Cardiovascular event Previous,Cardiovascular event,,,Cardiovascular event,C1320716
871,C0018801;C0019664,Heart failure History,Heart failure,,,Heart failure,C0018801
871,C0018801;C0019664,Heart failure History,Medical History,,,Medical History,C0262926
872,C0034510;C1533021;C0005680;C0078988;1,Racial group Hispanic white racial group Black race Asians ethnicity- other,Racial group,,,Racial group,C0034510
873,C0041703;C1549445,United States Yes - Yes/no indicator,Geographic Locations,,,Geographic Locations,C0017446
874,C0086287;C0079399;C0086582,Females Gender Males,Gender,,,Gender,C0079399
875,C0205147;C0001737;C0003980;C0239309;C0043129;C0028405;C0037713;C0007674,regional Africa Asia eastern european Western Europe North America South America Central America,Geographic Locations,,,Geographic Locations,C0017446
876,C0243103;C0086409;C1518422,Ethnicity aspects Hispanics Negation,Racial group,,,Racial group,C0034510
877,C0677547;C0948089,days/week Acute Coronary Syndrome,Coronary heart disease,,,Coronary heart disease,C0010068
878,C0948089;C1536220;C4255010,Acute Coronary Syndrome ST segment elevation myocardial infarction Non-ST Elevated Myocardial Infarction,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
878,C0948089;C1536220;C4255010,Acute Coronary Syndrome ST segment elevation myocardial infarction Non-ST Elevated Myocardial Infarction,Non ST elevation myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
879,C0005847;C4049621,Blood Vessel Peritoneal Cancer Index,Blood Vessel,,,Blood Vessel,C0005847
879,C0005847;C4049621,Blood Vessel Peritoneal Cancer Index,Peritoneal Cancer Index,,,Peritoneal Cancer Index,C4049621
880,C0019134;C1720467,heparin Only - dosing instruction fragment,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
881,C0024671;C0070166,Mammography clopidogrel,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
881,C0024671;C0070166,Mammography clopidogrel,Mammography,,,Mammography,C0024671
882,C0168273;C1720467,bivalirudin Only - dosing instruction fragment,bivalirudin,Direct thrombin inhibitors,Antithrombotic Agents,Antithrombotic Agents,C1704311
883,C0184906;C1518422;C1522326,Bifurcation (procedure) Negation Treating,NA TO BE DELETED,,,NA TO BE DELETED,NA
884,C0043210;C0025266,Woman Male population group,Gender,,,Gender,C0079399
885,C0079399;C1706180;C0086287,"Gender Male Gender, Self Report Females",Gender,,,Gender,C0079399
886,C2700615;C1549445,North American (race) Yes - Yes/no indicator,Racial group,,,Racial group,C0034510
887,C0011849;C0019664,Diabetes Mellitus History,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
887,C0011849;C0019664,Diabetes Mellitus History,Medical History,,,Medical History,C0262926
888,C0019664;C0729790,History H/O: atrial fibrillation,atrial fibrillation,,,atrial fibrillation,NA
888,C0019664;C0729790,History H/O: atrial fibrillation,Medical History,,,Medical History,C0262926
889,C0041199;C0442818,Troponin Raised,Troponin,,,Troponin,C0041199
890,C0205094;C0027051;C1518422,Anterior Myocardial Infarction Negation,Anterior myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
891,C0205435;C0869039;C3469597,First (number) Unit dose Administration of medication,NA TO BE DELETED,,,NA TO BE DELETED,NA
892,C0332152;C0521942,Before Angiotensin II receptor antagonist,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
893,C0332152;C3541930;C0521942;C0004739,"Before Beta blocking agents, antiglaucoma preparations and miotics Angiotensin II receptor antagonist Barbados",Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
893,C0332152;C3541930;C0521942;C0004739,"Before Beta blocking agents, antiglaucoma preparations and miotics Angiotensin II receptor antagonist Barbados","Beta blocking agents, antiglaucoma preparations and miotics",,,"Beta blocking agents, antiglaucoma preparations and miotics",C3541930
893,C0332152;C3541930;C0521942;C0004739,"Before Beta blocking agents, antiglaucoma preparations and miotics Angiotensin II receptor antagonist Barbados",Geographic Locations,,,Geographic Locations,C0017446
894,C0684253;C0449243,Physiological reperfusion Timing,Physiological reperfusion,,,Physiological reperfusion,C0684253
895,C1523987;C0340293;C0027051,Alternative Anterior myocardial infarction Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
896,C2359859;C4086878,Medication timing Symptom Onset,NA TO BE DELETED,,,NA TO BE DELETED,NA
897,C2826257;C0001645;C0003015;C0815017;bothand,Prior Medication Usage Adrenergic beta-Antagonists Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists BOTH AND,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
897,C2826257;C0001645;C0003015;C0815017;bothand,Prior Medication Usage Adrenergic beta-Antagonists Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists BOTH AND,Angiotensin Receptor Antagonists,,,Angiotensin Receptor Antagonists,C0815017
897,C2826257;C0001645;C0003015;C0815017;bothand,Prior Medication Usage Adrenergic beta-Antagonists Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists BOTH AND,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
898,C3272266;C1532339,Thrombolysis in Myocardial Infarction Flow Percutaneous Coronary Intervention,Myocardial Infarction,,,Myocardial Infarction,C0027051
898,C3272266;C1532338,Thrombolysis in Myocardial Infarction Flow Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
898,C3272266;C1532340,Thrombolysis in Myocardial Infarction Flow Percutaneous Coronary Intervention,Thrombolysis,,,Thrombolysis,NA
899,eitheror;C0001645;C2826257;C0003015,Either one or other Adrenergic beta-Antagonists Prior Medication Usage Angiotensin-Converting Enzyme Inhibitors,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
899,eitheror;C0001645;C2826257;C0003015,Either one or other Adrenergic beta-Antagonists Prior Medication Usage Angiotensin-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
900,C0152035;C1515021,Chinese People Subgroup,Racial group,,,Racial group,C0034510
901,C0038454;C0332152,Cerebrovascular accident Before,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
902,C0449468;C1979874,Volume Contrast,NA TO BE DELETED,,,NA TO BE DELETED,NA
903,C0449820;C0035647;C0022660,"Score Risk Kidney Failure, Acute",Kidney Failure,"Rel Failure, CTCAE",,"Renal Failure, CTCAE",C1963154
903,C0449820;C0035647;C0022660,"Score Risk Kidney Failure, Acute",Risk,,,Risk,C0035647
904,C0012634;C0205091;C1542147,Disease Left Main,NA TO BE DELETED,,,NA TO BE DELETED,NA
905,C0038257;C1299432,"Stent, device Multi vessel coronary artery disease",Coronary Artery Disease,,,Coronary Artery Disease,C1956346
905,C0038257;C1299432,"Stent, device Multi vessel coronary artery disease","Stent, device",,,"Stent, device",C0038257
906,C0205314;C1322815,New Drug-Eluting Stents,Drug-Eluting Stents,,,Drug-Eluting Stents,C1322815
907,C1322815;C0332152,Drug-Eluting Stents Before,Drug-Eluting Stents,,,Drug-Eluting Stents,C1322815
908,C1322815;C1547052,Drug-Eluting Stents *Type - Kind of quantity,Drug-Eluting Stents,,,Drug-Eluting Stents,C1322815
909,C0038894;C0332307,Surgery specialty Type - attribute,Surgery specialty,,,Surgery specialty,C0038894
910,C0439190;C1532563,millimole Millimole per Liter,NA TO BE DELETED,,,NA TO BE DELETED,NA
911,C0439234;C1510829,year Age-Years,Age-Years,,,Age-Years,C1510829
912,C0543421;C1442488,Total cholesterol Baseline,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
913,C1441604;C4048285;C1442488,"High sensitivity C-Reactive Protein, human Baseline",C-Reactive Protein,,,C-Reactive Protein,NA
914,C0012634;C0457451,Disease Severity score,NA TO BE DELETED,,,NA TO BE DELETED,NA
915,C0281858;C0030193,global assessment Pain,Pain,,,Pain,C0030193
916,C0242708;C1707479,"Antirheumatic Drugs, Disease-Modifying Concomitant Therapy","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
917,C0018802;C0262926;C1518422,Congestive heart failure Medical History Negation,Congestive heart failure,Heart failure,,Heart failure,C0018801
917,C0018802;C0262926;C1518422,Congestive heart failure Medical History Negation,Medical History,,,Medical History,C0262926
918,C0262926;C0004238,Medical History Atrial Fibrillation,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
918,C0262926;C0004238,Medical History Atrial Fibrillation,Medical History,,,Medical History,C0262926
919,C3279454;C1518422,Renal dysfunction Negation,Renal dysfunction,,,Renal dysfunction,C3279454
920,C4554100;C0332152,"Stroke, CTCAE Before","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
921,C4554100;C0332152;C1518422,"Stroke, CTCAE Before Negation","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
922,"C0034656	  ;C0027051;C0439234",Randomisation Myocardial Infarction year,Myocardial Infarction,,,Myocardial Infarction,C0027051
923,C0034656;C0439234,Randomization year,NA TO BE DELETED,,,NA TO BE DELETED,NA
924,C0001925;C2984010,Albuminuria Macro,Albuminuria,,,Albuminuria,C0001925
925,C0001925;C3811161,Albuminuria Micro (prefix),Albuminuria,,,Albuminuria,C0001925
926,C0012634;C0332152,Disease Before,Medical History,,,Medical History,C0262926
927,C0085201;C0439269,Apolipoprotein A-I mg/dL,Apolipoprotein A-I,,,Apolipoprotein A-I,C0085201
928,C0871470;C0439475,Systolic Pressure mmHg,Blood Pressure,,,Blood Pressure,C0005823
929,C0871754;C1518422,Frail Negation,Fragility,,,Fragility,C0302113
930,C0019590;C2348331,Histamine Antagonists Dose Regimen,Histamine Antagonists,,,Histamine Antagonists,C0019590
931,C0014467;C0007584,eosinophil Cell Count,Eosinophil,,,Eosinophil,NA
932,C1442488;C0578022,Baseline Finding of body mass index,Body mass index,,,Body mass index,C1305855
933,C0442027;C0239126;C1442488,Oral corticosteroid use Baseline,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
934,C3540778;LABA ;C1518422,Glucocorticoid inhalants for obstructive airway disease long-acting beta agonist  Negation,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
934,C3540778;LABA ;C1518423,Glucocorticoid inhalants for obstructive airway disease long-acting beta agonist  Negation,long-acting beta agonist,,,long-acting beta agonist,NA
935,LABA ;C3540778,long-acting beta agonist  Glucocorticoid inhalants for obstructive airway disease,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
935,LABA ;C3540778,long-acting beta agonist  Glucocorticoid inhalants for obstructive airway disease,long-acting beta agonist,,,long-acting beta agonist,NA
936,C0004096;C0206132;C0439234,Asthma Age of Onset year,Asthma,,,Asthma,C0004096
937,C0002994;C1442488,Angioedema Baseline,Angioedema,,,Angioedema,C0002994
938,C0033774;C0457451,Pruritus Severity score,Pruritus,,,Pruritus,C0033774
939,C0041703;C1518422,United States Negation,Geographic Locations,,,Geographic Locations,C0017446
940,C0205156;C1718138,Previous Number of medications,NA TO BE DELETED,,,NA TO BE DELETED,NA
941,C0205373;C0281991,Systemic steroid use,Steroids,,,Steroids,C0038317
942,C1561536;C0449820;C0042109,*Activity (kind of quantity) Score Urticaria,Urticaria,,,Urticaria,C0042109
943,C0007222;C0027362,Cardiovascular Diseases Human Age Group,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
943,C0007222;C0027362,Cardiovascular Diseases Human Age Group,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
944,C0012634;C1518422;C0035647;C0850624;C1510829,Disease Negation Risk cardiovascular risk factor Age-Years,Age-Years,,,Age-Years,C1510829
944,C0012634;C1518422;C0035647;C0850624;C1510829,Disease Negation Risk cardiovascular risk factor Age-Years,cardiovascular risk factor,,,cardiovascular risk factor,C0850624
945,C0012634;C1518422;C0035647;C3887460;C0850624;C0027362,Disease Negation Risk Cardiovascular cardiovascular risk factor Human Age Group,Age-Years,,,Age-Years,C1510829
945,C0012634;C1518422;C0035647;C3887460;C0850624;C0027362,Disease Negation Risk Cardiovascular cardiovascular risk factor Human Age Group,cardiovascular risk factor,,,cardiovascular risk factor,C0850624
946,C0012634;C1518422;C3887460;C0850624;C0027362,Disease Negation Cardiovascular cardiovascular risk factor Human Age Group,Age-Years,,,Age-Years,C1510829
946,C0012634;C1518422;C3887460;C0850624;C0027362,Disease Negation Cardiovascular cardiovascular risk factor Human Age Group,cardiovascular risk factor,,,cardiovascular risk factor,C0850624
947,C0019993;C2004062;C0740304,Hospitalization History of previous events copd exacerbation,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
947,C0019993;C2004062;C0740304,Hospitalization History of previous events copd exacerbation,Medical History,,,Medical History,C0262926
948,C0027362;C2348001,Human Age Group Age Cohort,Age-Years,,,Age-Years,C1510829
949,C0034510;1,Racial group ethnicity- other,Racial group,,,Racial group,C0034510
950,C0035647;C3887460,Risk Cardiovascular,cardiovascular disorder risk,,,cardiovascular disorder risk,C1113685
951,C0037369;C0337671,Smoking Former smoker,Smoking Status,,,Smoking Status,C1519386
952,C0086409;C0086528;C1518424;C1518422,Hispanics Latinos Not Hispanic or Latino Negation,Racial group,,,Racial group,C0034510
953,C0086528;C0086409;C0015031,Latinos Hispanics Ethnic group,Racial group,,,Racial group,C0034510
954,C0205081;C0205082;C4086268;C0024117,Moderate (severity modifier) Severe (severity modifier) Exacerbation Chronic Obstructive Airway Disease,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
955,C0205082;C0205081;C0740304;C2004062,Severe (severity modifier) Moderate (severity modifier) copd exacerbation History of previous events,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
955,C0205082;C0205081;C0740304;C2004062,Severe (severity modifier) Moderate (severity modifier) copd exacerbation History of previous events,Medical History,,,Medical History,C0262926
956,C0243161;C3887460,criteria Cardiovascular,Cardiovascular system,,,Cardiovascular system,C0007226
957,C0551577;C0740304,History of hospitalizations:Finding:Point in time:^Patient:Nominal:Reported copd exacerbation,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
957,C0551577;C0740304,History of hospitalizations:Finding:Point in time:^Patient:Nominal:Reported copd exacerbation,Medical History,,,Medical History,C0262926
958,C0740304;C2004062;C0205081;C0205082,copd exacerbation History of previous events Moderate (severity modifier) Severe (severity modifier),Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
958,C0740304;C2004062;C0205081;C0205082,copd exacerbation History of previous events Moderate (severity modifier) Severe (severity modifier),Medical History,,,Medical History,C0262926
959,C1113685;C0007222,cardiovascular disorder risk Cardiovascular Diseases,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
959,C1113685;C0007222,cardiovascular disorder risk Cardiovascular Diseases,cardiovascular disorder risk,,,cardiovascular disorder risk,C1113685
960,C1510829;C0027362,Age-Years Human Age Group,Age-Years,,,Age-Years,C1510829
961,C1882327;C0429706,Percent of Predicted Value Forced expiratory volume in 1 second finding,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
962,C2004062;C0019993;C0740304,History of previous events Hospitalization copd exacerbation,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
962,C2004062;C0019993;C0740304,History of previous events Hospitalization copd exacerbation,Medical History,,,Medical History,C0262926
963,C2004062;C0205081;C0740304;C0205082,History of previous events Moderate (severity modifier) copd exacerbation Severe (severity modifier),Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
963,C2004062;C0205081;C0740304;C0205082,History of previous events Moderate (severity modifier) copd exacerbation Severe (severity modifier),Medical History,,,Medical History,C0262926
964,C4086268;C0701159;C0024117,Exacerbation Patient in hospital Chronic Obstructive Airway Disease,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
965,C0012634;C1518422;C0035647;C0027362;C0850624;C0007222,Disease Negation Risk Human Age Group cardiovascular risk factor Cardiovascular Diseases,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
965,C0012634;C1518422;C0035647;C0027362;C0850624;C0007222,Disease Negation Risk Human Age Group cardiovascular risk factor Cardiovascular Diseases,cardiovascular risk factor,,,cardiovascular risk factor,C0850624
966,C0085756;C1518422,African American Negation,Racial group,,,Racial group,C0034510
967,C0086287;C0043210,Females Woman,Gender,,,Gender,C0079399
968,C0586793;C1514463,Inhaled steroids use Prior Therapy,Inhaled steroids use,,,Inhaled steroids use,C0586793
969,C1514463;C1518422;LABA,Prior Therapy Negation NA,long-acting beta agonist,,,long-acting beta agonist,NA
970,C1514463;LABA,Prior Therapy NA,long-acting beta agonist,,,long-acting beta agonist,NA
971,C1518422;C1514463;LABA ;C0586793,Negation Prior Therapy long-acting beta agonist  Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
971,C1518422;C1514463;LABA ;C0586793,Negation Prior Therapy long-acting beta agonist  Inhaled steroids use,long-acting beta agonist,,,long-acting beta agonist,NA
972,LABA ;C1514463,long-acting beta agonist  Prior Therapy,long-acting beta agonist,,,long-acting beta agonist,NA
973,C0024119;C0439166;C2599594,Pulmonary function tests Percent normal post bronchodilator,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
973,C0024119;C0439166;C2599594,Pulmonary function tests Percent normal post bronchodilator,Pulmonary function tests,,,Pulmonary function tests,C0024119
974,C0009253;C0079399,Coitus Gender,Gender,,,Gender,C0079399
975,C0011849;C0262512,Diabetes Mellitus History of present illness,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
975,C0011849;C0262512,Diabetes Mellitus History of present illness,Medical History,,,Medical History,C0262926
976,C0012634;C0205156,Disease Previous,Medical History,,,Medical History,C0262926
977,C0020538;C1522326,Hypertensive disease Treating,"Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
978,C1963138;C1522326,"Hypertension, CTCAE Treating","Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
979,C0086440;C0581603;C0369773;C1518422,Hypolipidemic Agents Revascularization - action P Blood group antibodies Negation,Hypolipidemic Agents,,,Hypolipidemic Agents,C0086440
979,C0086440;C0581603;C0369773;C1518422,Hypolipidemic Agents Revascularization - action P Blood group antibodies Negation,P Blood group antibodies,,,P Blood group antibodies,C0369773
980,C0086440;C1518422,Hypolipidemic Agents Negation,Hypolipidemic Agents,,,Hypolipidemic Agents,C0086440
981,C0369773;C1518422,P Blood group antibodies Negation,P Blood group antibodies,,,P Blood group antibodies,C0369773
982,C0369773;C1549445,P Blood group antibodies Yes - Yes/no indicator,P Blood group antibodies,,,P Blood group antibodies,C0369773
983,C0581603;C0369773;C0085826;C0086440,Revascularization - action P Blood group antibodies Antiplatelet Agents Hypolipidemic Agents,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
983,C0581603;C0369773;C0085826;C0086440,Revascularization - action P Blood group antibodies Antiplatelet Agents Hypolipidemic Agents,Hypolipidemic Agents,,,Hypolipidemic Agents,C0086440
983,C0581603;C0369773;C0085826;C0086440,Revascularization - action P Blood group antibodies Antiplatelet Agents Hypolipidemic Agents,P Blood group antibodies,,,P Blood group antibodies,C0369773
983,C0581603;C0369773;C0085826;C0086440,Revascularization - action P Blood group antibodies Antiplatelet Agents Hypolipidemic Agents,Revascularization - action,,,Revascularization - action,C0581603
984,C1518422;C0085826,Negation Antiplatelet Agents,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
985,C1518422;C0877341,Negation coronary revascularization,coronary revascularization,,,coronary revascularization,C0877341
986,C1524063;C0085826,Use of Antiplatelet Agents,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
987,C0023822;C1532563,High Density Lipoprotein Cholesterol Millimole per Liter,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
988,C0023824;C1532563,LDL Cholesterol Lipoproteins Millimole per Liter,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
989,C0041004;C1532563,Triglycerides Millimole per Liter,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
990,C1305855;C0337664;C0337672;C0011849;C1549445;C1510829;C0086582;C0043210;C0023824;C4048285;C0202069;C0041005,"Body mass index Smoker Non-smoker Diabetes Mellitus Yes - Yes/no indicator Age-Years Males Woman LDL Cholesterol Lipoproteins C-Reactive Protein, human HDL cholesterol test Triglycerides",Age-Years,,,Age-Years,C1510829
990,C1305855;C0337664;C0337672;C0011849;C1549445;C1510829;C0086582;C0043210;C0023824;C4048285;C0202069;C0041004,"Body mass index Smoker Non-smoker Diabetes Mellitus Yes - Yes/no indicator Age-Years Males Woman LDL Cholesterol Lipoproteins C-Reactive Protein, human HDL cholesterol test Triglycerides",Body mass index,,,Body mass index,C1305855
990,C1305855;C0337664;C0337672;C0011849;C1549445;C1510829;C0086582;C0043210;C0023824;C4048285;C0202069;C0041008,"Body mass index Smoker Non-smoker Diabetes Mellitus Yes - Yes/no indicator Age-Years Males Woman LDL Cholesterol Lipoproteins C-Reactive Protein, human HDL cholesterol test Triglycerides",C-Reactive Protein,,,C-Reactive Protein,NA
990,C1305855;C0337664;C0337672;C0011849;C1549445;C1510829;C0086582;C0043210;C0023824;C4048285;C0202069;C0041004,"Body mass index Smoker Non-smoker Diabetes Mellitus Yes - Yes/no indicator Age-Years Males Woman LDL Cholesterol Lipoproteins C-Reactive Protein, human HDL cholesterol test Triglycerides",Diabetes Mellitus,,,Diabetes Mellitus,C0011849
990,C1305855;C0337664;C0337672;C0011849;C1549445;C1510829;C0086582;C0043210;C0023824;C4048285;C0202069;C0041006,"Body mass index Smoker Non-smoker Diabetes Mellitus Yes - Yes/no indicator Age-Years Males Woman LDL Cholesterol Lipoproteins C-Reactive Protein, human HDL cholesterol test Triglycerides",Gender,,,Gender,C0079399
990,C1305855;C0337664;C0337672;C0011849;C1549445;C1510829;C0086582;C0043210;C0023824;C4048285;C0202069;C0041007,"Body mass index Smoker Non-smoker Diabetes Mellitus Yes - Yes/no indicator Age-Years Males Woman LDL Cholesterol Lipoproteins C-Reactive Protein, human HDL cholesterol test Triglycerides",lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
990,C1305855;C0337664;C0337672;C0011849;C1549445;C1510829;C0086582;C0043210;C0023824;C4048285;C0202069;C0041004,"Body mass index Smoker Non-smoker Diabetes Mellitus Yes - Yes/no indicator Age-Years Males Woman LDL Cholesterol Lipoproteins C-Reactive Protein, human HDL cholesterol test Triglycerides",Smoking Status,,,Smoking Status,C1519386
991,C0011849;C1442488;C0362046,Diabetes Mellitus Baseline Prediabetes syndrome,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
992,C1442488;C0011849;C0362046,Baseline Diabetes Mellitus Prediabetes syndrome,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
993,C0015815;C0449820,Structure of neck of femur Score,Structure of neck of femur,,,Structure of neck of femur,C0015815
994,C0015815;C0449820;C0177804,Structure of neck of femur Score Bone Mineral Density Test,Bone Mineral Density Test,Bone Density,,Bone Density,C0005938
995,C0015815;C3854607,Structure of neck of femur T-Score,Structure of neck of femur,,,Structure of neck of femur,C0015815
996,C0016658;C0037949;C1518422,Fracture Vertebral column Negation,Fracture,,,Fracture,C0016658
996,C0016658;C0037949;C1518422,Fracture Vertebral column Negation,Vertebral column,,,Vertebral column,C0037949
997,C0016658;C0332152,Fracture Before,Fracture,,,Fracture,C0016658
998,C0016658;C0521329;C1518422,Fracture spinal Negation,Fracture,,,Fracture,C0016658
999,C0019552;C2964552,Hip structure Total score,Hip structure,,,Hip structure,C0019552
1000,C0019552;C2964552;C0177804,Hip structure Total score Bone Mineral Density Test,Bone Mineral Density Test,Bone Density,,Bone Density,C0005938
1001,C0024091;C0449820,Bone structure of lumbar vertebra Score,Bone structure of lumbar vertebra,,,Bone structure of lumbar vertebra,C0024091
1002,C0024091;C3854607,Bone structure of lumbar vertebra T-Score,Bone structure of lumbar vertebra,,,Bone structure of lumbar vertebra,C0024091
1003,C0449820;C3887615,Score Lumbar spine structure,Lumbar spine structure,,,Lumbar spine structure,C3887615
1004,C0449820;C3887615;C0177804,Score Lumbar spine structure Bone Mineral Density Test,Bone Mineral Density Test,Bone Density,,Bone Density,C0005938
1005,C0168634;C0337672,BaseLine dental cement Non-smoker,Smoking Status,,,Smoking Status,C1519386
1006,C0221690;C1518422,Syndesmophyte Negation,Syndesmophyte,,,Syndesmophyte,C0221690
1007,C0742906;C1518422,Elevated C-reactive protein Negation,C-Reactive Protein,,,C-Reactive Protein,NA
1008,C0023216;C4528685,Lower Extremity Psoriasis Area and Severity Index Clinical Classification,Lower Extremity,,,Lower Extremity,C0023216
1008,C0023216;C4528685,Lower Extremity Psoriasis Area and Severity Index Clinical Classification,Psoriasis Area and Severity Index Clinical Classification,Psoriasis,,Psoriasis,C0033860
1009,C4528685;C1140618,Psoriasis Area and Severity Index Clinical Classification Upper Extremity,Psoriasis Area and Severity Index Clinical Classification,Psoriasis,,Psoriasis,C0033860
1010,C0002598;C1442488,Amiodarone Baseline,Amiodarone,"Antiarrhythmics, class III",CARDIAC THERAPY,CARDIAC THERAPY,NA
1011,C0018801;C0231220,Heart failure Symptomatic,Heart failure,,,Heart failure,C0018801
1012,C0039798;C0443252;C3653316,therapeutic aspects Long-term Vitamin K antagonists,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1013,C0239307;C1561448,ethnic european Arab race,Racial group,,,Racial group,C0034510
1014,C0358591;C1442488,Proton Pump Inhibitors Baseline,Proton Pump Inhibitors,,,Proton Pump Inhibitors,C0358591
1015,C0022341;C0032659,Japan geographic population,Racial group,,,Racial group,C0034510
1016,C0032659;C1561607,geographic population Overall,Racial group,,,Racial group,C0034510
1017,C0010346;C2926735;C0439234,Crohn Disease Duration year,Crohn Disease,,,Crohn Disease,C0010346
1018,C0020885;C0009368,ileum Colon structure (body structure),ileum,,,ileum,C0020885
1019,C0449279;C0017189,Extent of disease Gastrointestinal tract structure,gastrointestinal,,,gastrointestinal,C0521362
1020,C0205156;C2603343;C2348561,Previous Study Study Population (group),NA TO BE DELETED,,,NA TO BE DELETED,NA
1021,C3815594;C0014245;C0449820,Subject is Randomized Endoscopy (procedure) Score,Endoscopy (procedure),,,Endoscopy (procedure),C0014245
1022,C0281481;C0162643,anti-tumor necrosis factor therapy treatment failure,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1023,C1518422;C0162643;C0281481,Negation treatment failure anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1024,C2348867;C0424093;C0024117,Global Initiative Chronic Obstructive Airway Disease,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1025,C0018787;C0019664,Heart History,Heart Diseases,Cardiovascular Diseases,,Cardiovascular Diseases,C0007222
1025,C0018787;C0019664,Heart History,Medical History,,,Medical History,C0262926
1026,C0586793;C1442488,Inhaled steroids use Baseline,Inhaled steroids use,,,Inhaled steroids use,C0586793
1027,C1442488;C0003811;C1518422,Baseline Cardiac Arrhythmia Negation,Cardiac Arrhythmia,,,Cardiac Arrhythmia,C0003811
1028,C1442488;C1549445;C0003811,Baseline Yes - Yes/no indicator Cardiac Arrhythmia,Cardiac Arrhythmia,,,Cardiac Arrhythmia,C0003811
1029,C0018026;C0024117;C0457451,Gold Chronic Obstructive Airway Disease Severity score,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1030,C0024117;C0457451;C0018026,Chronic Obstructive Airway Disease Severity score Gold,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1031,C0999593;LABA ;C1514463;eitheror,Lama long-acting beta agonist  Prior Therapy Either one or other,Lama,,,Lama,C0999593
1031,C0999593;LABA ;C1514463;eitheror,Lama long-acting beta agonist  Prior Therapy Either one or other,long-acting beta agonist,,,long-acting beta agonist,NA
1032,C0011849;C0332167,Diabetes Mellitus High risk of,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1033,C1518422;C4684790;C0008976,Negation Study Subject Enrolled Clinical Trials,NA TO BE DELETED,,,NA TO BE DELETED,NA
1034,C4684790;C0008976,Study Subject Enrolled Clinical Trials,NA TO BE DELETED,,,NA TO BE DELETED,NA
1035,C0010346;C0543467,Crohn Disease Operative Surgical Procedures,Crohn Disease,,,Crohn Disease,C0010346
1035,C0010346;C0543467,Crohn Disease Operative Surgical Procedures,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
1036,C0015176;C0022271,Europe Israel,Geographic Locations,,,Geographic Locations,C0017446
1037,C0017710;C0178602,Glucocorticoids Dosage,Glucocorticoids,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",Anti-Inflammatory Agents,Anti-Inflammatory Agents,C0003209
1038,C0205156;C0543467;C1518422,Previous Operative Surgical Procedures Negation,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
1039,C0239126;C1442488;C0439422,corticosteroid use Baseline milligram/day,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1040,C0368663;C1442488,aminosalicylate Baseline,aminosalicylate,Aminosalicylic acid and derivatives,ANTIMYCOBACTERIALS,ANTIMYCOBACTERIALS,NA
1041,C0368663;C1518422;C1442488,aminosalicylate Negation Baseline,aminosalicylate,Aminosalicylic acid and derivatives,ANTIMYCOBACTERIALS,ANTIMYCOBACTERIALS,NA
1042,C0543467;C0205156,Operative Surgical Procedures Previous,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
1043,C0543467;C1518422,Operative Surgical Procedures Negation,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
1044,C1442488;C0368663,Baseline aminosalicylate,aminosalicylate,Aminosalicylic acid and derivatives,ANTIMYCOBACTERIALS,ANTIMYCOBACTERIALS,NA
1045,C1442488;C1518422;C0368663,Baseline Negation aminosalicylate,aminosalicylate,Aminosalicylic acid and derivatives,ANTIMYCOBACTERIALS,ANTIMYCOBACTERIALS,NA
1046,C0025677;C1707479;C0869039,Methotrexate Concomitant Therapy Unit dose,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1047,C0623362;C0369718,Matrix Metalloproteinases N not otherwise specified Antibody,Matrix Metalloproteinases,,,Matrix Metalloproteinases,C0623362
1047,C0623362;C0369718,Matrix Metalloproteinases N not otherwise specified Antibody,N not otherwise specified Antibody,,,N not otherwise specified Antibody,C0369718
1048,C0025677;C0332157,Methotrexate Exposure to,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1049,C0038317;C1442488,Steroids Baseline,Steroids,,,Steroids,C0038317
1050,C0439231;C2926735;C0003873,month Duration Rheumatoid Arthritis,Rheumatoid Arthritis,,,Rheumatoid Arthritis,C0003873
1051,C0457451;C0022417;C0439679,Severity score Joints Erosive,NA TO BE DELETED,,,NA TO BE DELETED,NA
1052,C1442488;C0439679;C0022417,Baseline Erosive Joints,NA TO BE DELETED,,,NA TO BE DELETED,NA
1053,C0015176;C0017446,Europe Geographic Locations,Geographic Locations,,,Geographic Locations,C0017446
1054,C0017446;C0035253;C2700280,Geographic Locations Rest World,Geographic Locations,,,Geographic Locations,C0017446
1055,C0028405;C0017446,North America Geographic Locations,Geographic Locations,,,Geographic Locations,C0017446
1056,C0162643;C0281481;C0205156,treatment failure anti-tumor necrosis factor therapy Previous,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1057,C0205156;C0281481;C1518422,Previous anti-tumor necrosis factor therapy Negation,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1058,C0231174;C0205156;C0680095;C0281481;C0162643;C1518422,Failure (biologic function) Previous Personal failure anti-tumor necrosis factor therapy treatment failure Negation,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1059,C0231491;C1518422;C0281481;C0205156,Antagonist muscle action Negation anti-tumor necrosis factor therapy Previous,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1060,C0281481;C0162643;C0205156,anti-tumor necrosis factor therapy treatment failure Previous,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1061,C0281481;C0205156,anti-tumor necrosis factor therapy Previous,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1062,C1518422;C0205156;C0281481;C0162643,Negation Previous anti-tumor necrosis factor therapy treatment failure,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1063,C0034510;C0451528,Racial group Systemic lupus erythematosus disease activity index,"Lupus Erythematosus, Systemic",,,"Lupus Erythematosus, Systemic",C0024141
1063,C0034510;C0451528,Racial group Systemic lupus erythematosus disease activity index,Racia group ,,,Racia group ,NA
1064,C1442488;C0451528,Baseline Systemic lupus erythematosus disease activity index,"Lupus Erythematosus, Systemic",,,"Lupus Erythematosus, Systemic",C0024141
1065,C1514241;C2355607;C3897137,Positive Finding Anti dsDNA antibody (finding) Low Complement,Anti dsDNA antibody (finding),,,Anti dsDNA antibody (finding),C2355607
1066,C0205098;C0205108,Medial Distal (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
1067,C0205265;C3272266,Initially Thrombolysis in Myocardial Infarction Flow,Thrombolysis in Myocardial Infarction Flow,,,Thrombolysis in Myocardial Infarction Flow,C3272266
1068,C0449820;C0010075,Score Coronary Vessels,Coronary Vessels,,,Coronary Vessels,C0010075
1069,C1442488;C1881332,Baseline Killip Class,Killip Class,,,Killip Class,C1881332
1070,C3272266;C3853528,Thrombolysis in Myocardial Infarction Flow Final,Thrombolysis in Myocardial Infarction Flow,,,Thrombolysis in Myocardial Infarction Flow,C3272266
1071,C0012751;C1571704;C0023824,Distance Act Mood - Goal LDL Cholesterol Lipoproteins,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1072,C0360714;C0585943;C1518422,Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipid-lowering therapy Negation,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1072,C0360714;C0585943;C1518422,Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipid-lowering therapy Negation,Lipid-lowering therapy,,,Lipid-lowering therapy,C0585943
1073,C0011849;C0746890,Diabetes Mellitus new onset,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1074,C0457454;C1522538,Discontinuation (procedure) Leading,NA TO BE DELETED,,,NA TO BE DELETED,NA
1075,C1272092;C0011849;C0524620,Impaired fasting glycaemia Diabetes Mellitus Metabolic Syndrome X,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1075,C1272092;C0011849;C0524620,Impaired fasting glycaemia Diabetes Mellitus Metabolic Syndrome X,Impaired fasting glycaemia,,,Impaired fasting glycaemia,C1272092
1076,C0025677;C1696465,Methotrexate placebo,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1077,C0025677;C1872109,Methotrexate certolizumab pegol,certolizumab pegol,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
1077,C0025677;C1872109,Methotrexate certolizumab pegol,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1078,C0005847;C0205447,Blood Vessel One,Blood Vessel,,,Blood Vessel,C0005847
1079,C0005847;C0439064,Blood Vessel Numerous,Blood Vessel,,,Blood Vessel,C0005847
1080,C0006826;C0332152,Malignant Neoplasms Before,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1081,C0006826;C0332152;C1518422,Malignant Neoplasms Before Negation,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1082,C0018801;C0332152,Heart failure Before,Heart failure,,,Heart failure,C0018801
1083,C0018801;C0332152;C1518422,Heart failure Before Negation,Heart failure,,,Heart failure,C0018801
1084,C0038257;C0449788,"Stent, device Count of entities","Stent, device",,,"Stent, device",C0038257
1085,C0520886;C0520887,ST segment elevation (finding) ST segment depression (finding),ST segment depression (finding),,,ST segment depression (finding),C0520887
1085,C0520886;C0520887,ST segment elevation (finding) ST segment depression (finding),ST segment elevation (finding),,,ST segment elevation (finding),C0520886
1086,C1518422;C0520887;C0520886,Negation ST segment depression (finding) ST segment elevation (finding),ST segment depression (finding),,,ST segment depression (finding),C0520887
1086,C1518422;C0520887;C0520886,Negation ST segment depression (finding) ST segment elevation (finding),ST segment elevation (finding),,,ST segment elevation (finding),C0520886
1087,C1510829;C1305855,Age-Years Body mass index,Age-Years,,,Age-Years,C1510829
1087,C1510829;C1305855,Age-Years Body mass index,Body mass index,,,Body mass index,C1305855
1088,C0022271;C0043129,Israel Western Europe,Geographic Locations,,,Geographic Locations,C0017446
1089,C0022423;C0031831,Judgment Physicians,NA TO BE DELETED,,,NA TO BE DELETED,NA
1090,C0027051;C1956346,Myocardial Infarction Coronary Artery Disease,Coronary Artery Disease,,,Coronary Artery Disease,C1956346
1090,C0027051;C1956346,Myocardial Infarction Coronary Artery Disease,Myocardial Infarction,,,Myocardial Infarction,C0027051
1091,C0031831;C0022423,Physicians Judgment,NA TO BE DELETED,,,NA TO BE DELETED,NA
1092,C0205311;C0205322,Paroxysmal Persistent,NA TO BE DELETED,,,NA TO BE DELETED,NA
1093,C0017710;C0003211;C0032790,"Glucocorticoids Anti-Inflammatory Agents, Non-Steroidal Postoperative Period",Anti-Inflammatory Agents,,,Anti-Inflammatory Agents,C0003209
1093,C0017710;C0003211;C0032790,"Glucocorticoids Anti-Inflammatory Agents, Non-Steroidal Postoperative Period",Glucocorticoids,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",Anti-Inflammatory Agents,Anti-Inflammatory Agents,C0003209
1094,C0017710;C0003211;C0032790;C0042153,"Glucocorticoids Anti-Inflammatory Agents, Non-Steroidal Postoperative Period utilization qualifier",Anti-Inflammatory Agents,,,Anti-Inflammatory Agents,C0003209
1094,C0017710;C0003211;C0032790;C0042153,"Glucocorticoids Anti-Inflammatory Agents, Non-Steroidal Postoperative Period utilization qualifier",Glucocorticoids,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",Anti-Inflammatory Agents,Anti-Inflammatory Agents,C0003209
1095,C0017710;C0032790,Glucocorticoids Postoperative Period,Glucocorticoids,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",Anti-Inflammatory Agents,Anti-Inflammatory Agents,C0003209
1096,C0017710;C0032790;C0042153,Glucocorticoids Postoperative Period utilization qualifier,Glucocorticoids,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",Anti-Inflammatory Agents,Anti-Inflammatory Agents,C0003209
1097,C0034656;C0040808;C0449238,Randomization Treatment Protocols Duration (temporal concept),NA TO BE DELETED,,,NA TO BE DELETED,NA
1098,C0034656;C0449238;C0040808,Randomization Duration (temporal concept) Treatment Protocols,NA TO BE DELETED,,,NA TO BE DELETED,NA
1099,C0034656;C0449238;C0687676,Randomization Duration (temporal concept) Post,NA TO BE DELETED,,,NA TO BE DELETED,NA
1100,C0034656;C0683469,Randomization surgical methods,surgical methods,,,surgical methods,C0683469
1101,C0040808;C0449238,Treatment Protocols Duration (temporal concept),NA TO BE DELETED,,,NA TO BE DELETED,NA
1102,C0041199;C1442488,Troponin Baseline,Troponin,,,Troponin,C0041199
1103,C0042153;C0360714,utilization qualifier Hydroxymethylglutaryl-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1104,C0182537;C3842462;C1518422,pump (device) On pump Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1105,C0184661;C0543467,Interventional procedure Operative Surgical Procedures,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
1106,C0205156;C0027051,Previous Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
1107,C0449217;C0003506,aVR Replacement of aortic valve (procedure),aVR,,,aVR,C0449217
1107,C0449217;C0003506,aVR Replacement of aortic valve (procedure),Replacement of aortic valve (procedure),,,Replacement of aortic valve (procedure),C0003506
1108,C3842462;C1518422,On pump Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1109,C0205081;C0449295;C0231999;C0439092;eitheror,Moderate (severity modifier) Limitation Airflow Less Than Either one or other,Airflow,,,Airflow,C0231999
1110,C0205082;C1457868;C0231999;C0449295;eitheror,Severe (severity modifier) Worse Airflow Limitation Either one or other,Airflow,,,Airflow,C0231999
1111,C3540778;C1442488;C1518422;C0457083,Glucocorticoid inhalants for obstructive airway disease Baseline Negation Usage,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
1112,C3540778;C1705108;C0457083;C1442488,Glucocorticoid inhalants for obstructive airway disease Yes (indicator) Usage Baseline,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
1113,C0034656;C0360714;C1518422,Randomization Hydroxymethylglutaryl-CoA Reductase Inhibitors Negation,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1114,C0205081;C1561643,Moderate (severity modifier) Chronic Kidney Diseases,Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
1115,C0439536;C0205251;C0522510,Medium low With intensity,NA TO BE DELETED,,,NA TO BE DELETED,NA
1116,C0948008;C2004062,Ischemic stroke History of previous events,Ischemic stroke,"Stroke, CTCAE",,"Stroke, CTCAE",C4554100
1116,C0948008;C2004062,Ischemic stroke History of previous events,Medical History,,,Medical History,C0262926
1117,C0965129;C0178602,rosuvastatin Dosage,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1118,C4521761;C0439422,United States Military Commissioned Officer O8 milligram/day,Racial group,,,Racial group,C0034510
1119,C0011849;C0034656,Diabetes Mellitus Randomization,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1120,C0019664;C0027051;C0948008,History Myocardial Infarction Ischemic stroke,Medical History,,,Medical History,C0262926
1120,C0019664;C0027051;C0948008,History Myocardial Infarction Ischemic stroke,Myocardial Infarction,,,Myocardial Infarction,C0027051
1121,C0019664;C0948008;C0027051,History Ischemic stroke Myocardial Infarction,Medical History,,,Medical History,C0262926
1121,C0019664;C0948008;C0027051,History Ischemic stroke Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
1122,C0034656;C0585943,Randomization Lipid-lowering therapy,Lipid-lowering therapy,,,Lipid-lowering therapy,C0585943
1123,C0360714;bothand;C0585943,Hydroxymethylglutaryl-CoA Reductase Inhibitors BOTH AND Lipid-lowering therapy,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1123,C0360714;bothand;C0585943,Hydroxymethylglutaryl-CoA Reductase Inhibitors BOTH AND Lipid-lowering therapy,Lipid-lowering therapy,,,Lipid-lowering therapy,C0585943
1124,C0360714;C0087111,Hydroxymethylglutaryl-CoA Reductase Inhibitors Therapeutic procedure,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1125,C0360714;C0332288;C0585943,Hydroxymethylglutaryl-CoA Reductase Inhibitors Without Lipid-lowering therapy,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1125,C0360714;C0332288;C0585943,Hydroxymethylglutaryl-CoA Reductase Inhibitors Without Lipid-lowering therapy,Lipid-lowering therapy,,,Lipid-lowering therapy,C0585943
1126,C0360714;C4081854,Hydroxymethylglutaryl-CoA Reductase Inhibitors High intensity,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1127,C0360714;C4081854;C1518422,Hydroxymethylglutaryl-CoA Reductase Inhibitors High intensity Negation,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1128,C1518422;C0332132;C0027051;C0948008,Negation Prior diagnosis Myocardial Infarction Ischemic stroke,Ischemic stroke,"Stroke, CTCAE",,"Stroke, CTCAE",C4554100
1128,C1518422;C0332132;C0027051;C0948008,Negation Prior diagnosis Myocardial Infarction Ischemic stroke,Myocardial Infarction,,,Myocardial Infarction,C0027051
1129,C1561643;C0034656;C0205081,Chronic Kidney Diseases Randomization Moderate (severity modifier),Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
1130,C1561643;C0205081;C1518422,Chronic Kidney Diseases Moderate (severity modifier) Negation,Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
1131,C0025677;C3489764,Methotrexate ixekizumab,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1132,C1696465;C2945704;C0242708,"placebo Conventional Treatment Antirheumatic Drugs, Disease-Modifying","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1132,C1696465;C2945704;C0242708,"placebo Conventional Treatment Antirheumatic Drugs, Disease-Modifying",placebo,,,placebo,C1696465
1133,C2945691;C0242708;C2945704;C3489764,"past treatment Antirheumatic Drugs, Disease-Modifying Conventional Treatment ixekizumab","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1133,C2945691;C0242708;C2945704;C3489764,"past treatment Antirheumatic Drugs, Disease-Modifying Conventional Treatment ixekizumab",ixekizumab,Interleukin inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
1134,C2945704;C1696465;C0242708;C0332119,"Conventional Treatment placebo Antirheumatic Drugs, Disease-Modifying Past history of","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1134,C2945704;C1696465;C0242708;C0332119,"Conventional Treatment placebo Antirheumatic Drugs, Disease-Modifying Past history of",Medical History,,,Medical History,C0262926
1135,C3489764;C0025677,ixekizumab Methotrexate,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1136,C3489764;C2945704;C0242708,"ixekizumab Conventional Treatment Antirheumatic Drugs, Disease-Modifying","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1137,C3489764;C2945704;C0242708;C2945691,"ixekizumab Conventional Treatment Antirheumatic Drugs, Disease-Modifying past treatment",ixekizumab,Interleukin inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
1138,C0004096;C0024501;C0418981,Asthma Maintenance Medical therapy,Asthma,,,Asthma,C0004096
1139,C0004096;C1457887,Asthma Symptoms,Asthma,,,Asthma,C0004096
1140,C0349790;C0332181,Exacerbation of asthma Annual,Asthma,,,Asthma,C0004096
1141,C0586793;LABA ;eitheror;C1515021,Inhaled steroids use long-acting beta agonist  Either one or other Subgroup,Inhaled steroids use,,,Inhaled steroids use,C0586793
1141,C0586793;LABA ;eitheror;C1515021,Inhaled steroids use long-acting beta agonist  Either one or other Subgroup,long-acting beta agonist,,,long-acting beta agonist,NA
1142,C1442488;C2986411,Baseline Improvement,NA TO BE DELETED,,,NA TO BE DELETED,NA
1143,C1515021;C0586793,Subgroup Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
1144,C1561607;C2348561,Overall Study Population (group),NA TO BE DELETED,,,NA TO BE DELETED,NA
1145,C2733224;C2986411;C1442488;eitheror,Asthma control test score Improvement Baseline Either one or other,Asthma,,,Asthma,C0004096
1146,C3540778;LABA,Glucocorticoid inhalants for obstructive airway disease NA,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
1146,C3540778;LABA,Glucocorticoid inhalants for obstructive airway disease NA,long-acting beta agonist,,,long-acting beta agonist,NA
1147,C0205231;C0009319,Extensive Colitis,Colitis,,,Colitis,C0009319
1148,C0205231;C0009319;C1518422,Extensive Colitis Negation,Colitis,,,Colitis,C0009319
1149,C0239126;C1527392,corticosteroid use Immunomodulators,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1150,C0368663;C1518422,aminosalicylate Negation,aminosalicylate,Aminosalicylic acid and derivatives,ANTIMYCOBACTERIALS,ANTIMYCOBACTERIALS,NA
1151,C1527392;C0239126;C1518422,Immunomodulators corticosteroid use Negation,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1152,C0062152;C1707455;C1696465,HDL-triglyceride Comparison placebo,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1153,C0332152;C1518422;C0281481,Before Negation anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1154,C0332152;C4055380,Before Biologic Disease-Modifying Antirheumatic Drug,"Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1155,C0332152;C4055380;C1518422;C0281481,Before Biologic Disease-Modifying Antirheumatic Drug Negation anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1156,C0017446;C1709595,Geographic Locations Pooled Sample,Geographic Locations,,,Geographic Locations,C0017446
1157,C0035448;C0205160;C1525410,Rheumatoid Factor Negative Cyclic citrullinated peptide antibody,Cyclic citrullinated peptide antibody,,,Cyclic citrullinated peptide antibody,C1525410
1158,C0035448;C1525410;C1446409,Rheumatoid Factor Cyclic citrullinated peptide antibody Positive,Rheumatoid Factor,,,Rheumatoid Factor,C0035448
1159,C0281481;C2826257;C0278947,anti-tumor necrosis factor therapy Prior Medication Usage prior biologic therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1160,C0332152;C2826257;C1518422;C4055380,Before Prior Medication Usage Negation Biologic Disease-Modifying Antirheumatic Drug,"Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1161,C0439209;C1303013,Kilogram Baseline weight,Body Weight,,,Body Weight,C0005910
1162,C0549183;C2939193,Midline (qualifier value) Median (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
1163,C1514463;C0281481,Prior Therapy anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1164,C1518422;C0279936,Negation tumor necrosis factor therapy,tumor necrosis factor therapy,,,tumor necrosis factor therapy,C0279936
1165,C1518422;C0279936;C1514463,Negation tumor necrosis factor therapy Prior Therapy,tumor necrosis factor therapy,,,tumor necrosis factor therapy,C0279936
1166,C2700280;C0041703;C0015176;C1518422,World United States Europe Negation,Geographic Locations,,,Geographic Locations,C0017446
1167,C0025677;C0242708;bothand;C1523987,"Methotrexate Antirheumatic Drugs, Disease-Modifying BOTH AND Alternative","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1168,C0025677;C0242708;C1523987;bothand,"Methotrexate Antirheumatic Drugs, Disease-Modifying Alternative BOTH AND","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1169,C0025677;C1523987;C0242708;bothand,"Methotrexate Alternative Antirheumatic Drugs, Disease-Modifying BOTH AND",Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1170,C0242708;C1518422;C0025677,"Antirheumatic Drugs, Disease-Modifying Negation Methotrexate","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1171,C1706907;C0242708,"Background Antirheumatic Drugs, Disease-Modifying","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1172,C0018801;C1535947,Heart failure Normal Ventricular Ejection Fraction,Heart failure,,,Heart failure,C0018801
1172,C0018801;C1535947,Heart failure Normal Ventricular Ejection Fraction,Normal Ventricular Ejection Fraction,,,Normal Ventricular Ejection Fraction,C1535947
1173,C0086287;C1705498;C0043210,Females Female Phenotype Woman,Gender,,,Gender,C0079399
1174,C0455280;C0015663;C0202042,Plasma glucose result Fasting Plasma Glucose Measurement,Plasma Glucose Measurement,Glucose,,Glucose,C0017725
1175,C0595310;C0337438;C0029161,Blood glucose testing kit Glucose measurement Oral Glucose Tolerance Test,Glucose,,,Glucose,C0017725
1175,C0595310;C0337438;C0029161,Blood glucose testing kit Glucose measurement Oral Glucose Tolerance Test,Oral Glucose Tolerance Test,,,Oral Glucose Tolerance Test,C0029161
1176,C1334085;C1708411,IFNG gene IFNG wt Allele,Genotype,,,Genotype,C0017431
1177,C1706429;C1706428;C0086582,"Male, Self-Reported Male Phenotype Males",Gender,,,Gender,C0079399
1178,C0281481;C0205412;C1704632,anti-tumor necrosis factor therapy Inadequate (qualifier) Disease Response,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1179,C1518422;C0281481;C1514463,Negation anti-tumor necrosis factor therapy Prior Therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1180,C0205412;C1704632;C0281481,Inadequate (qualifier) Disease Response anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1181,C1257890;C1561607,Population Group Overall,NA TO BE DELETED,,,NA TO BE DELETED,NA
1182,C0278947;C0281481,prior biologic therapy anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1183,C0010055;C0027051;C4049621,Coronary Artery Bypass Surgery Myocardial Infarction Peritoneal Cancer Index,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
1183,C0010055;C0027051;C4049621,Coronary Artery Bypass Surgery Myocardial Infarction Peritoneal Cancer Index,Myocardial Infarction,,,Myocardial Infarction,C0027051
1184,C0010055;C0262926,Coronary Artery Bypass Surgery Medical History,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
1184,C0010055;C0262926,Coronary Artery Bypass Surgery Medical History,Medical History,,,Medical History,C0262926
1185,C0010055;C4049621;C0027052,Coronary Artery Bypass Surgery Peritoneal Cancer Index Myocardial Infarction,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
1185,C0010055;C4049621;C0027051,Coronary Artery Bypass Surgery Peritoneal Cancer Index Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
1185,C0010055;C4049621;C0027051,Coronary Artery Bypass Surgery Peritoneal Cancer Index Myocardial Infarction,Peritoneal Cancer Index,,,Peritoneal Cancer Index,C4049621
1186,C0011849;C1442488,Diabetes Mellitus Baseline,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1187,C0027051;C0205156;C1518422,Myocardial Infarction Previous Negation,Myocardial Infarction,,,Myocardial Infarction,C0027051
1188,C0086440;C4554605,Hypolipidemic Agents Non-Smokers -- population group,Hypolipidemic Agents,,,Hypolipidemic Agents,C0086440
1188,C0086440;C4554605,Hypolipidemic Agents Non-Smokers -- population group,Smoking Status,,,Smoking Status,C1519386
1189,C1532338;C0262926;C2936173,Percutaneous Coronary Intervention Medical History Percutaneous Transluminal Coronary Angioplasty,Medical History,,,Medical History,C0262926
1189,C1532338;C0262926;C2936173,Percutaneous Coronary Intervention Medical History Percutaneous Transluminal Coronary Angioplasty,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1189,C1532338;C0262926;C2936173,Percutaneous Coronary Intervention Medical History Percutaneous Transluminal Coronary Angioplasty,Percutaneous Transluminal Coronary Angioplasty,,,Percutaneous Transluminal Coronary Angioplasty,C2936173
1190,C1532338;C2936173;C0262926,Percutaneous Coronary Intervention Percutaneous Transluminal Coronary Angioplasty Medical History,Medical History,,,Medical History,C0262926
1190,C1532338;C2936173;C0262926,Percutaneous Coronary Intervention Percutaneous Transluminal Coronary Angioplasty Medical History,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1190,C1532338;C2936173;C0262926,Percutaneous Coronary Intervention Percutaneous Transluminal Coronary Angioplasty Medical History,Percutaneous Transluminal Coronary Angioplasty,,,Percutaneous Transluminal Coronary Angioplasty,C2936173
1191,C0038454;C0205156;C4554100,"Cerebrovascular accident Previous Stroke, CTCAE",Cerebrovascular accident,,,Cerebrovascular accident,C0038454
1191,C0038454;C0205156;C4554100,"Cerebrovascular accident Previous Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
1192,C0005767;C0750879,Blood Eosinophil count result,Eosinophil,,,Eosinophil,NA
1193,C0750879;C0005767,Eosinophil count result Blood,Eosinophil,,,Eosinophil,NA
1194,C0024117;C3641272,Chronic Obstructive Airway Disease Very severe,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1195,C1442488;C0750879;C0439378,Baseline Eosinophil count result cells/uL,Eosinophil,,,Eosinophil,NA
1196,C0011849;C1320657,Diabetes Mellitus Diabetes type,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1197,C0205081;C0205251,Moderate (severity modifier) low,NA TO BE DELETED,,,NA TO BE DELETED,NA
1198,C0241889;C4018905;C0010068,Family history Too early Coronary heart disease,Coronary heart disease,,,Coronary heart disease,C0010068
1198,C0241889;C4018905;C0010068,Family history Too early Coronary heart disease,Family history,,,Family history,C0241889
1199,C0264956;C0439165;C0449468,Atheroma Percent (qualifier value) Volume,Atheroma,,,Atheroma,C0264956
1200,C1442488;C0264956;C0449468,Baseline Atheroma Volume,Atheroma,,,Atheroma,C0264956
1201,C0070166;C1524063,clopidogrel Use of,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
1202,C0205091;C1542147;C0332293,Left Main Treated with,NA TO BE DELETED,,,NA TO BE DELETED,NA
1203,C0679199;C3887704;C0332307,strategy treatment - ActInformationManagementReason Type - attribute,NA TO BE DELETED,,,NA TO BE DELETED,NA
1204,C1524063;C1999375,Use of Ticagrelor,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
1205,C1956346;C0205360,Coronary Artery Disease Stable status,Coronary Artery Disease,,,Coronary Artery Disease,C1956346
1206,C3829066;C0017853,"Millimole per Mole Hemoglobin, Glycosylated","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
1207,C1518422;C0948089,Negation Acute Coronary Syndrome,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
1208,C0149871;C0205107;C0034065,Deep Vein Thrombosis Proximal Pulmonary Embolism,Deep Vein Thrombosis,,,Deep Vein Thrombosis,C0149871
1208,C0149871;C0205107;C0034065,Deep Vein Thrombosis Proximal Pulmonary Embolism,Pulmonary Embolism,,,Pulmonary Embolism,C0034065
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029942",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Colon <insect>,cancer location,,cancer location,"C0872338	  "
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029942",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Colon <insect>,cancer location,,cancer location,C0872338
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029939",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Lung,cancer location,,cancer location,"C0872338	  "
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029939",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Lung,cancer location,,cancer location,C0872338
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029943",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Ovary,cancer location,,cancer location,"C0872338	  "
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029943",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Ovary,cancer location,,cancer location,C0872338
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029940",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Pancreas,cancer location,,cancer location,"C0872338	  "
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029940",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Pancreas,cancer location,,cancer location,C0872338
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029941",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Stomach,cancer location,,cancer location,"C0872338	  "
1209,"C0872338	  ;C0024109;C0030274;C0038351;C3888384;C0029941",cancer location Lung Pancreas Stomach Colon <insect> Ovary,cancer location Stomach,cancer location,,cancer location,C0872338
1210,C2826292;C0036525,Related to Cancer Metastatic to,Metastatic Neoplasm,,,Metastatic Neoplasm,C2939420
1211,C0042469;C0279936;C1999216;C0332132,Venezuela tumor necrosis factor therapy Inhibitor Prior diagnosis,tumor necrosis factor therapy,,,tumor necrosis factor therapy,C0279936
1212,C0332157;C0279936;C1999216,Exposure to tumor necrosis factor therapy Inhibitor,tumor necrosis factor therapy,,,tumor necrosis factor therapy,C0279936
1213,C1519815;C4048285,"Upper Limit of Normal C-Reactive Protein, human",C-Reactive Protein,,,C-Reactive Protein,NA
1214,C0004096;C0018684,Asthma Health,Asthma,,,Asthma,C0004096
1215,C0005516;C0205250,Biological Markers High,Biological Marker,,,Biological Marker,NA
1216,C0005516;C0205251,Biological Markers low,Biological Marker,,,Biological Marker,NA
1217,C0014467;C0205250,eosinophil High,Eosinophil,,,Eosinophil,NA
1218,C0014467;C0205251,eosinophil low,Eosinophil,,,Eosinophil,NA
1219,C0205250;C3812270,High Periostin Measurement,Periostin Measurement,,,Periostin Measurement,C3812270
1220,C0205251;C3812270,low Periostin Measurement,Periostin Measurement,,,Periostin Measurement,C3812270
1221,C2746078;C1696465,Linagliptin placebo,Dipeptidyl-Peptidase IV Inhibitors,Antidiabetics,,Antidiabetics,C0935929
1222,C0007222;C0001925,Cardiovascular Diseases Albuminuria,Albuminuria,,,Albuminuria,C0001925
1222,C0007222;C0001925,Cardiovascular Diseases Albuminuria,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
1223,C0022658;C0443211,Kidney Diseases Established,Kidney Diseases,,,Kidney Diseases,C0022658
1224,C0025598;C0178602,Metformin Dosage,Metformin,Antidiabetics,,Antidiabetics,C0935929
1225,C0035647;C1565489,Risk Renal Insufficiency,Renal Insufficiency,,,Renal Insufficiency,C1565489
1225,C0035647;C1565489,Risk Renal Insufficiency,Risk,,,Risk,C0035647
1226,C1561643;C0035647,Chronic Kidney Diseases Risk,Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
1226,C1561643;C0035647,Chronic Kidney Diseases Risk,Risk,,,Risk,C0035647
1227,C0027430;C1442488,Nasal Polyps Baseline,Nasal Polyps,,,Nasal Polyps,C0027430
1228,C0239126;C1527415,corticosteroid use Oral Route of Drug administration,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1229,C0740304;C4086728,copd exacerbation Past Year,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1230,C1442488;C0392707,Baseline Atopy,Atopy,,,Atopy,C0392707
1231,C1514463;C0966225,Prior Therapy omalizumab,omalizumab,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
1232,C0027430;C1518422,Nasal Polyps Negation,Nasal Polyps,,,Nasal Polyps,C0027430
1233,C0239126;C0442027,corticosteroid use Oral,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1234,C0442027;C0239126;C1518422,Oral corticosteroid use Negation,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1235,C0936012;C0443225,Analysis Full,NA TO BE DELETED,,,NA TO BE DELETED,NA
1236,C1510829;C1828181,Age-Years Age at diagnosis,Age-Years,,,Age-Years,C1510829
1237,C1518422;C3714541;C1828181;C0239126;C0027430;C0442027;C2599602,Negation Forced Vital Capacity Age at diagnosis corticosteroid use Nasal Polyps Oral pre bronchodilator,Age-Years,,,Age-Years,C1510829
1237,C1518422;C3714541;C1828181;C0239126;C0027430;C0442027;C2599602,Negation Forced Vital Capacity Age at diagnosis corticosteroid use Nasal Polyps Oral pre bronchodilator,Bronchodilator Agents ,,,Bronchodilator Agents ,NA
1237,C1518422;C3714541;C1828181;C0239126;C0027430;C0442027;C2599602,Negation Forced Vital Capacity Age at diagnosis corticosteroid use Nasal Polyps Oral pre bronchodilator,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1237,C1518422;C3714541;C1828181;C0239126;C0027430;C0442027;C2599602,Negation Forced Vital Capacity Age at diagnosis corticosteroid use Nasal Polyps Oral pre bronchodilator,Forced Vital Capacity,,,Forced Vital Capacity,C3714541
1237,C1518422;C3714541;C1828181;C0239126;C0027430;C0442027;C2599602,Negation Forced Vital Capacity Age at diagnosis corticosteroid use Nasal Polyps Oral pre bronchodilator,Nasal Polyps,,,Nasal Polyps,C0027430
1238,C1828181;C1510829,Age at diagnosis Age-Years,Age-Years,,,Age-Years,C1510829
1239,C3714541;C2599602,Forced Vital Capacity pre bronchodilator,Bronchodilator Agents ,,,Bronchodilator Agents ,NA
1239,C3714541;C2599602,Forced Vital Capacity pre bronchodilator,Forced Vital Capacity,,,Forced Vital Capacity,C3714541
1240,C4086268;C0205448,Exacerbation Two,NA TO BE DELETED,,,NA TO BE DELETED,NA
1241,C4086268;C0205449,Exacerbation Three,NA TO BE DELETED,,,NA TO BE DELETED,NA
1242,eitheror;C2599602;C3714541;C0027430;C0239126;C0442027;C1828185,Either one or other pre bronchodilator Forced Vital Capacity Nasal Polyps corticosteroid use Oral Age at diagnosis,Age-Years,,,Age-Years,C1510829
1242,eitheror;C2599602;C3714541;C0027430;C0239126;C0442027;C1828184,Either one or other pre bronchodilator Forced Vital Capacity Nasal Polyps corticosteroid use Oral Age at diagnosis,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1242,eitheror;C2599602;C3714541;C0027430;C0239126;C0442027;C1828182,Either one or other pre bronchodilator Forced Vital Capacity Nasal Polyps corticosteroid use Oral Age at diagnosis,Forced Vital Capacity,,,Forced Vital Capacity,C3714541
1242,eitheror;C2599602;C3714541;C0027430;C0239126;C0442027;C1828183,Either one or other pre bronchodilator Forced Vital Capacity Nasal Polyps corticosteroid use Oral Age at diagnosis,Nasal Polyps,,,Nasal Polyps,C0027430
1242,eitheror;C2599602;C3714541;C0027430;C0239126;C0442027;C1828181,Either one or other pre bronchodilator Forced Vital Capacity Nasal Polyps corticosteroid use Oral Age at diagnosis,pre bronchodilator,Bronchodilator Agents,,Bronchodilator Agents,C0006280
1243,C0360714;C0231200,Hydroxymethylglutaryl-CoA Reductase Inhibitors intolerant,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1244,C0439092;C0876920,Less Than Median Statistical Measurement,NA TO BE DELETED,,,NA TO BE DELETED,NA
1245,C0876920;C0205172;C0205163,Median Statistical Measurement More Equal,NA TO BE DELETED,,,NA TO BE DELETED,NA
1246,C1442488;C0439810;C1100660;C2946261,Baseline Total Proprotein Convertases Level,Proprotein Convertases,,,Proprotein Convertases,C1100660
1247,C1442488;C1100660;C2946261;C0332296,Baseline Proprotein Convertases Level Free of (attribute),Proprotein Convertases,,,Proprotein Convertases,C1100660
1248,C0332181;C0349790;C4288115,Annual Exacerbation of asthma Total Number,Asthma,,,Asthma,C0004096
1249,C0392707;C1442488,Atopy Baseline,Atopy,,,Atopy,C0392707
1250,C0806481;C1442488,IgE.total Baseline,IgE.total,,,IgE.total,C0806481
1251,C0966225;C1514463,omalizumab Prior Therapy,omalizumab,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
1252,C0340293;C1518422,Anterior myocardial infarction Negation,Anterior myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
1253,C0449450;C1279919,Presentation Early,NA TO BE DELETED,,,NA TO BE DELETED,NA
1254,C0001645;C1524063,Adrenergic beta-Antagonists Use of,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
1255,C0018801;C3898876,Heart failure Hospitalization Due to Heart Failure,Heart failure,,,Heart failure,C0018801
1256,C0011849;C0262926;C1518422,Diabetes Mellitus Medical History Negation,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1256,C0011849;C0262926;C1518422,Diabetes Mellitus Medical History Negation,Medical History,,,Medical History,C0262926
1257,C0018801;C0015127,Heart failure Etiology aspects,Etiology aspects,,,Etiology aspects,C0015127
1257,C0018801;C0015127,Heart failure Etiology aspects,Heart failure,,,Heart failure,C0018801
1258,C0034656;C0369773,Randomization P Blood group antibodies,P Blood group antibodies,,,P Blood group antibodies,C0369773
1259,C0034656;C0369773;C1518422,Randomization P Blood group antibodies Negation,P Blood group antibodies,,,P Blood group antibodies,C0369773
1260,C0475224;C1518422,Ischemic Negation,Ischemia,,,Ischemia,C0022116
1261,C0003015;C1518422;C0815017,Angiotensin-Converting Enzyme Inhibitors Negation Angiotensin Receptor Antagonists,Angiotensin Receptor Antagonists,,,Angiotensin Receptor Antagonists,C0815017
1261,C0003015;C1518422;C0815017,Angiotensin-Converting Enzyme Inhibitors Negation Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
1262,C0017853;C0876920,"Hemoglobin, Glycosylated Median Statistical Measurement","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
1263,C0025598;C1518422,Metformin Negation,Metformin,Antidiabetics,,Antidiabetics,C0935929
1264,C0032042;C1706778,Placebos Allocation,placebo,,,placebo,C1696465
1265,C0205314;C0011847,New Diabetes,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1266,C0332152;C0011847,Before Diabetes,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1267,C0332152;C0441471;C0007226,Before Event Cardiovascular system,Cardiovascular system,,,Cardiovascular system,C0007226
1268,C0332152;C0441471;C0007226;C1518422,Before Event Cardiovascular system Negation,Cardiovascular system,,,Cardiovascular system,C0007226
1269,C0815017;C0003015,Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors,Angiotensin Receptor Antagonists,,,Angiotensin Receptor Antagonists,C0815017
1269,C0815017;C0003015,Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
1270,C1272092;C0271650,Impaired fasting glycaemia Impaired glucose tolerance,Impaired fasting glycaemia,,,Impaired fasting glycaemia,C1272092
1270,C1272092;C0271650,Impaired fasting glycaemia Impaired glucose tolerance,Impaired glucose tolerance,,,Impaired glucose tolerance,C0271650
1271,C0666743;C0205156,infliximab Previous,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
1272,C0666743;C0205156;C1518422,infliximab Previous Negation,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
1273,C1442488;C1518422;C0239126,Baseline Negation corticosteroid use,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1274,C0024117;C1306673,Chronic Obstructive Airway Disease Stage,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1275,C1514463;C1442488,Prior Therapy Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
1276,C0239126;C0004482;C0000618;C1442488,corticosteroid use Azathioprine mercaptopurine Baseline,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1276,C0239126;C0004482;C0000618;C1442488,corticosteroid use Azathioprine mercaptopurine Baseline,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1277,C0239126;C3844738,corticosteroid use No Response - Disease Response,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1278,C0450429;C0017446,Location Geographic Locations,Geographic Locations,,,Geographic Locations,C0017446
1279,C0543467;C0521362;C0009324,Operative Surgical Procedures gastrointestinal Ulcerative Colitis,gastrointestinal,,,gastrointestinal,C0521362
1279,C0543467;C0521362;C0009324,Operative Surgical Procedures gastrointestinal Ulcerative Colitis,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
1279,C0543467;C0521362;C0009324,Operative Surgical Procedures gastrointestinal Ulcerative Colitis,Ulcerative Colitis,,,Ulcerative Colitis,C0009324
1280,C1442488;C0004482;C0000618,Baseline Azathioprine mercaptopurine,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1281,C1442488;C0457451,Baseline Severity score,NA TO BE DELETED,,,NA TO BE DELETED,NA
1282,C1442488;C1519386,Baseline Smoking Status,Smoking Status,,,Smoking Status,C1519386
1283,C2926735;C0009324,Duration Ulcerative Colitis,Ulcerative Colitis,,,Ulcerative Colitis,C0009324
1284,C2987624;C0332152,Segmentectomy Before,Segmentectomy,,,Segmentectomy,C2987624
1285,C0039798;C1442488,therapeutic aspects Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
1286,C0205156;C0439234;C4086268,Previous year Exacerbation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1287,C1442488;C0087111,Baseline Therapeutic procedure,NA TO BE DELETED,,,NA TO BE DELETED,NA
1288,C1510829;C0001779,Age-Years Age,Age-Years,,,Age-Years,C1510829
1289,C3826977;C1442488,Modified Medical Research Council Dyspnea Scale Questionnaire Baseline,Modified Medical Research Council Dyspnea Scale Questionnaire,,,Modified Medical Research Council Dyspnea Scale Questionnaire,C3826977
1290,LABA,long-acting beta agonist ,long-acting beta agonist ,,,long-acting beta agonist ,LABA 
1291,C1882327;C2599594;C0429706,Percent of Predicted Value post bronchodilator Forced expiratory volume in 1 second finding,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
1291,C1882327;C2599594;C0429706,Percent of Predicted Value post bronchodilator Forced expiratory volume in 1 second finding,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
1292,C2599594;C0429706,post bronchodilator Forced expiratory volume in 1 second finding,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
1292,C2599594;C0429706,post bronchodilator Forced expiratory volume in 1 second finding,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
1293,C2964552;C4284282,Total score COPD Assessment Test Questionnaire,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1294,C4086268;C2360800;C4086728,Exacerbation Number of patients Past Year,NA TO BE DELETED,,,NA TO BE DELETED,NA
1295,C0025598;C0086027;C0332196;C1561607;C1705429,"Metformin Analysis, Cohort Exclude Overall User Group",Metformin,Antidiabetics,,Antidiabetics,C0935929
1296,C0086027;C0205225;C1561607,"Analysis, Cohort Primary Overall",NA TO BE DELETED,,,NA TO BE DELETED,NA
1297,C1561643;C0086027;C0025598;C0332196;C1705429,"Chronic Kidney Diseases Analysis, Cohort Metformin Exclude User Group",Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
1298,C1561643;C0086027;C0175668,"Chronic Kidney Diseases Analysis, Cohort Secondary to",Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
1299,C0497327;C0449820;C1292730,Dementia Score Condition severity,Dementia,,,Dementia,C0497327
1300,C0011849;C0030705,Diabetes Mellitus Patients,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1301,C0907402;C2973895,Insulin Glargine Lixisenatide,Insulin,,,Insulin,C0021641
1302,C0034065;C0149871,Pulmonary Embolism Deep Vein Thrombosis,Deep Vein Thrombosis,,,Deep Vein Thrombosis,C0149871
1302,C0034065;C0149871,Pulmonary Embolism Deep Vein Thrombosis,Pulmonary Embolism,,,Pulmonary Embolism,C0034065
1303,C0034656;C0332152;C2711563,Randomization Before Duration of anticoagulant therapy,Anticoagulants,,,Anticoagulants,C0003280
1304,C0035648;C0441471;C0918012,risk factors Event Index,risk factors,,,risk factors,C0035648
1305,C0149871;C0205171,Deep Vein Thrombosis Singular,Deep Vein Thrombosis,,,Deep Vein Thrombosis,C0149871
1306,C0205309;C0398623,Known Thrombophilia,Thrombophilia,,,Thrombophilia,C0398623
1307,C0439792;C0918012;C0441471,Extent Index Event,NA TO BE DELETED,,,NA TO BE DELETED,NA
1308,C0441471;C0918012;C0449450,Event Index Presentation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1309,C1518422;C1444748,Negation Triggered by,NA TO BE DELETED,,,NA TO BE DELETED,NA
1310,C1861172;C2945760;C0262926,Venous Thromboembolism Recurrent Medical History,Medical History,,,Medical History,C0262926
1310,C1861172;C2945760;C0262926,Venous Thromboembolism Recurrent Medical History,Thromboembolism,,,Thromboembolism,C0040038
1311,C0002598;C0457083;C1442488,Amiodarone Usage Baseline,Amiodarone,"Antiarrhythmics, class III",CARDIAC THERAPY,CARDIAC THERAPY,NA
1312,C0004057;C0457083;C1442488,Aspirin Usage Baseline,Aspirin,,,Aspirin,C0004057
1313,C0004238;C0332307,Atrial Fibrillation Type - attribute,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
1314,C0332152;C4554100,"Before Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
1315,C0449238;C0460097,Duration (temporal concept) Within therapeutic range,NA TO BE DELETED,,,NA TO BE DELETED,NA
1316,C0034656;C0442504,Randomization Place,NA TO BE DELETED,,,NA TO BE DELETED,NA
1317,C0439234;C0001779,year Age,Age-Years,,,Age-Years,C1510829
1318,C0441471;C1521828;C1561607,Event Rate Overall,NA TO BE DELETED,,,NA TO BE DELETED,NA
1319,C0680532;C0332152,Amendment Before,NA TO BE DELETED,,,NA TO BE DELETED,NA
1320,C1515974;C0021308;C0450429,Anatomic Site Infarction Location,Infarction Anatomic Site ,,,Infarction Anatomic Site ,NA
1321,C2697847;C2697845;C2697846,Killip Class IV Killip Class II Killip Class III,Killip Class,,,Killip Class,C1881332
1322,C0015982;C1518422,Fibrin Negation,Fibrin,,,Fibrin,C0015982
1323,C0016018;C0332307,Fibrinolytic Agents Type - attribute,Fibrinolytic Agents,,,Fibrinolytic Agents,C0016018
1324,C0021308;C0450429,Infarction Location,Infarction Anatomic Site ,,,Infarction Anatomic Site ,NA
1325,C0026385;C0205251,Molecular Weight low,Molecular Weight,,,Molecular Weight,C0026385
1326,C0007226;C3887460;C0035647;C2698872;C0237753,Cardiovascular system Cardiovascular Risk Predictor Numbers,cardiovascular disorder risk,,,cardiovascular disorder risk,C1113685
1327,C0010055;C1532338;C0332152,Coronary Artery Bypass Surgery Percutaneous Coronary Intervention Before,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
1327,C0010055;C1532338;C0332152,Coronary Artery Bypass Surgery Percutaneous Coronary Intervention Before,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1328,C0011900;C1514624,Diagnosis Qualifying,NA TO BE DELETED,,,NA TO BE DELETED,NA
1329,C0034656;C0040223;C0520886;C1518422;C1532338,Randomization Time ST segment elevation (finding) Negation Percutaneous Coronary Intervention,ST segment elevation (finding),,,ST segment elevation (finding),C0520886
1330,C0034656;C0040223;C1532338;C0520886,Randomization Time Percutaneous Coronary Intervention ST segment elevation (finding),Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1331,C0039798;C0237400,therapeutic aspects Actual,NA TO BE DELETED,,,NA TO BE DELETED,NA
1332,C0520886;C0027051,ST segment elevation (finding) Myocardial Infarction,ST segment elevation (finding),,,ST segment elevation (finding),C0520886
1333,C0520886;C1518422;C0027051,ST segment elevation (finding) Negation Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
1333,C0520886;C1518422;C0027051,ST segment elevation (finding) Negation Myocardial Infarction,ST segment elevation (finding),,,ST segment elevation (finding),C0520886
1334,C0599880;C0679199,Treatment Plan strategy,NA TO BE DELETED,,,NA TO BE DELETED,NA
1335,C0521983;C0281481,Absence of therapeutic response anti-tumor necrosis factor therapy,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1336,C1442488;C0151280,"Baseline Creatinine clearance, ml/min",Creatinine clearance,,,Creatinine clearance,C0812399
1337,C1442488;C0232804,Baseline Renal function,Renal function,,,Renal function,C0232804
1338,C0439393;C0004048;C0806909,Liter per Minute Inspiration function Maximum,NA TO BE DELETED,,,NA TO BE DELETED,NA
1339,C0439393;C0806909;C0004048,Liter per Minute Maximum Inspiration function,NA TO BE DELETED,,,NA TO BE DELETED,NA
1340,C1706907;C1524063;LABA,Background Use of NA,long-acting beta agonist,,,long-acting beta agonist,NA
1341,C1706907;LABA ;C1524063,Background long-acting beta agonist  Use of,long-acting beta agonist,,,long-acting beta agonist,NA
1342,C0429706;C1882327;C0439092,Forced expiratory volume in 1 second finding Percent of Predicted Value Less Than,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
1343,C0429706;C1882327;C0439093;C0205163,Forced expiratory volume in 1 second finding Percent of Predicted Value Greater Than Equal,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
1344,C0439090;C0439092;C0429706;C1882327,Less Than or Equal to Less Than Forced expiratory volume in 1 second finding Percent of Predicted Value,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
1345,C0155668;C0205160,Old myocardial infarction Negative,Old myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
1346,C0006684;C1442488,Calcium Channel Blockers Baseline,Calcium Channel Blockers,,,Calcium Channel Blockers,C0006684
1347,C0010294;C0456603,Creatinine Ratio,Urine albumin/creatinine ratio measurement,,,Urine albumin/creatinine ratio measurement,C0455271
1348,C0012798;C1442488,Diuretics Baseline,Diuretics,,,Diuretics,C0012798
1349,C0018801;C0332132,Heart failure Prior diagnosis,Heart failure,,,Heart failure,C0018801
1350,C0021641;C1442488,Insulin Baseline,Insulin,,,Insulin,C0021641
1351,C0025598;C1442488,Metformin Baseline,Metformin,Antidiabetics,,Antidiabetics,C0935929
1352,C0332132;C1963138,"Prior diagnosis Hypertension, CTCAE","Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
1353,C1257987;C1442488,Thiazolidinediones Baseline,Thiazolidinediones,Antidiabetics,,Antidiabetics,C0935929
1354,C1442488;C0003015;C1563745,Baseline Angiotensin-Converting Enzyme Inhibitors Selective Angiotensin II Receptor Antagonists,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
1354,C1442488;C0003015;C1563745,Baseline Angiotensin-Converting Enzyme Inhibitors Selective Angiotensin II Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
1355,C1442488;C2362049,Baseline Microalbumin,Microalbumin,,,Microalbumin,C2362049
1356,C3536898;C1442488,Sulfonylurea [EPC] Baseline,Sulfonylurea Compounds,Antidiabetics,,Antidiabetics,C0935929
1357,C0001924;C1442488,Albumins Baseline,Albumins,,,Albumins,C0001924
1358,C0005910;C0549183,Body Weight Midline (qualifier value),Body Weight,,,Body Weight,C0005910
1359,C0018801;C0332132;C1518422,Heart failure Prior diagnosis Negation,Heart failure,,,Heart failure,C0018801
1360,C0202041;C2939193;C3534430,"Glucose measurement, serum Median (qualifier value) Serum glucose",Glucose,,,Glucose,C0017725
1361,C0443211;C0333482;C0012634,Established atherosclerotic Disease,atherosclerotic,,,atherosclerotic,C0333482
1362,C0455271;C0567349;C2939193,Urine albumin/creatinine ratio measurement milligram/millimole (mg/mmol) Median (qualifier value),Urine albumin/creatinine ratio measurement,,,Urine albumin/creatinine ratio measurement,C0455271
1363,C0549183;C1510829,Midline (qualifier value) Age-Years,Age-Years,,,Age-Years,C1510829
1364,C0877341;C1514463,coronary revascularization Prior Therapy,coronary revascularization,,,coronary revascularization,C0877341
1365,C1442488;C0006684,Baseline Calcium Channel Blockers,Calcium Channel Blockers,,,Calcium Channel Blockers,C0006684
1366,C3811844;C0876920;C0439445,Estimated Glomerular Filtration Rate Median Statistical Measurement mL/min,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
1367,C0005823;C0871470,Blood Pressure Systolic Pressure,Blood Pressure,,,Blood Pressure,C0005823
1368,C0010068;C0332152,Coronary heart disease Before,Coronary heart disease,,,Coronary heart disease,C0010068
1369,C0011847;C2926735,Diabetes Duration,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1370,C0015031;C0086409;C0086528,Ethnic group Hispanics Latinos,Racial group,,,Racial group,C0034510
1371,C0018802;C0332152,Congestive heart failure Before,Congestive heart failure,Heart failure,,Heart failure,C0018801
1372,C0018802;C1882083;C1442488,Congestive heart failure New York Heart Association Class Baseline,Congestive heart failure,Heart failure,,Heart failure,C0018801
1372,C0018802;C1882083;C1442488,Congestive heart failure New York Heart Association Class Baseline,New York Heart Association Class,,,New York Heart Association Class,C1882083
1373,C1882083;C4319718;C1518422,New York Heart Association Class Reported Negation,New York Heart Association Class,,,New York Heart Association Class,C1882083
1374,C0004057;C0332152;C0457083,Aspirin Before Usage,Aspirin,,,Aspirin,C0004057
1375,C0019134;C0457083;C0441471;C0918012;C0444598,heparin Usage Event Index Middle,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1376,C0242000;C0441471;C0918012,morphine use Event Index,morphine use,tural opium alkaloids,ALGESICS,ANALGESICS,NA
1377,C0242000;C0918012;C0441471;C1532338,morphine use Index Event Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1378,C0332152;C1532338;C1522410;C1881332,Before Percutaneous Coronary Intervention Highest Killip Class,Killip Class,,,Killip Class,C1881332
1378,C0332152;C1532338;C1522410;C1881332,Before Percutaneous Coronary Intervention Highest Killip Class,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1379,C0332152;C1881332;C1532338;C1522410,Before Killip Class Percutaneous Coronary Intervention Highest,Killip Class,,,Killip Class,C1881332
1379,C0332152;C1881332;C1532338;C1522410,Before Killip Class Percutaneous Coronary Intervention Highest,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1380,C0457083;C1999216;C0016011;C0332152;C0085532,Usage Inhibitor Platelet Glycoprotein GPIIb-IIIa Complex Before Coronary angiography,Coronary angiography,,,Coronary angiography,C0085532
1380,C0457083;C1999216;C0016011;C0332152;C0085532,Usage Inhibitor Platelet Glycoprotein GPIIb-IIIa Complex Before Coronary angiography,Platelet Glycoprotein GPIIb-IIIa Complex,,,Platelet Glycoprotein GPIIb-IIIa Complex,C0016011
1381,C1098510;C0019134;C0168273;C0457083;C0918012;C0441471;C0444598,fondaparinux heparin bivalirudin Usage Index Event Middle,bivalirudin,Direct thrombin inhibitors,Antithrombotic Agents,Antithrombotic Agents,C1704311
1381,C1098510;C0019134;C0168273;C0457083;C0918012;C0441471;C0444598,fondaparinux heparin bivalirudin Usage Index Event Middle,fondaparinux,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1381,C1098510;C0019134;C0168273;C0457083;C0918012;C0441471;C0444598,fondaparinux heparin bivalirudin Usage Index Event Middle,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1382,C1515974;C0027051,Anatomic Site Myocardial Infarction,Infarction Anatomic Site ,,,Infarction Anatomic Site ,NA
1383,C1549445;C1705108;C1710701,Yes - Yes/no indicator Yes (indicator) YES1 wt Allele,Genotype,,,Genotype,C0017431
1384,C1999216;C0457083;C0016011;C0085532;C0332152,Inhibitor Usage Platelet Glycoprotein GPIIb-IIIa Complex Coronary angiography Before,Coronary angiography,,,Coronary angiography,C0085532
1384,C1999216;C0457083;C0016011;C0085532;C0332152,Inhibitor Usage Platelet Glycoprotein GPIIb-IIIa Complex Coronary angiography Before,Coronary angiography,,,Coronary angiography,C0085532
1384,C1999216;C0457083;C0016011;C0085532;C0332152,Inhibitor Usage Platelet Glycoprotein GPIIb-IIIa Complex Coronary angiography Before,Platelet Glycoprotein GPIIb-IIIa Complex,,,Platelet Glycoprotein GPIIb-IIIa Complex,C0016011
1385,C0005001;C0205082,Benign prostatic hypertrophy Severe (severity modifier),Benign prostatic hypertrophy,,,Benign prostatic hypertrophy,C0005001
1386,C0028125;C0444706,Nitrates Measured,Nitrates,,,Nitrates,C0028125
1387,C0009324;C2926735;C0439234,Ulcerative Colitis Duration year,Ulcerative Colitis,,,Ulcerative Colitis,C0009324
1388,C0021081;C0521115;C0281481,Immunosuppressive Agents Simultaneous anti-tumor necrosis factor therapy,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1389,C0021081;C0521115;C0281481;C1518422,Immunosuppressive Agents Simultaneous anti-tumor necrosis factor therapy Negation,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1390,C0162643;C0021081;C0205156;C0281481;C1518422,treatment failure Immunosuppressive Agents Previous anti-tumor necrosis factor therapy Negation,anti-tumor necrosis factor therapy,,,anti-tumor necrosis factor therapy,C0281481
1390,C0162643;C0021081;C0205156;C0281481;C1518422,treatment failure Immunosuppressive Agents Previous anti-tumor necrosis factor therapy Negation,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
1391,C0239126;C0162643;C0205156,corticosteroid use treatment failure Previous,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1392,C0239126;C0521115,corticosteroid use Simultaneous,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1393,C0332293;C0205156,Treated with Previous,NA TO BE DELETED,,,NA TO BE DELETED,NA
1394,C0521115;C1518422;C0239126,Simultaneous Negation corticosteroid use,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1395,C0021499;C0021641,Subcutaneous Injections Insulin,Insulin,,,Insulin,C0021641
1396,C0337438;C0549178,Glucose measurement Continuous,Glucose,,,Glucose,C0017725
1397,C1518422;C0337438;C0549178,Negation Glucose measurement Continuous,Glucose,,,Glucose,C0017725
1398,C0005680;C1518424,Black race Not Hispanic or Latino,Racial group,,,Racial group,C0034510
1399,C0585890;C1956346;C0750480;C1704436,History of cerebrovascular disease Coronary Artery Disease Count Peripheral Arterial Diseases,Cerebrovascular disease,,,Cerebrovascular disease,NA
1399,C0585890;C1956346;C0750480;C1704436,History of cerebrovascular disease Coronary Artery Disease Count Peripheral Arterial Diseases,Coronary Artery Disease,,,Coronary Artery Disease,C1956346
1399,C0585890;C1956346;C0750480;C1704436,History of cerebrovascular disease Coronary Artery Disease Count Peripheral Arterial Diseases,Medical History,,,Medical History,C0262926
1399,C0585890;C1956346;C0750480;C1704436,History of cerebrovascular disease Coronary Artery Disease Count Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
1399,C0585890;C1956346;C0750480;C1704436,History of cerebrovascular disease Coronary Artery Disease Count Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
1400,C1096021;C1442488,antiplatelet therapy Baseline,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
1401,C0038454;C4554100,"Cerebrovascular accident Stroke, CTCAE",Cerebrovascular accident,,,Cerebrovascular accident,C0038454
1401,C0038454;C4554101,"Cerebrovascular accident Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
1402,C0182158;C1704436,Pads Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
1402,C0182158;C1704436,Pads Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
1403,C0262926;C4554100,"Medical History Stroke, CTCAE",Medical History,,,Medical History,C0262926
1403,C0262926;C4554100,"Medical History Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
1404,C0002006;C0457083,Aldosterone Usage,Aldosterone,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",corticosteroid use,corticosteroid use,C0239126
1405,C0332183;C0549178;eitheror,Frequently Continuous Either one or other,NA TO BE DELETED,,,NA TO BE DELETED,NA
1406,C0522498;C1518422;eitheror,Rare Negation Either one or other,NA TO BE DELETED,,,NA TO BE DELETED,NA
1407,C0679646;C0444667,Participant Whole,NA TO BE DELETED,,,NA TO BE DELETED,NA
1408,C4541021;C0815017;eitheror;C1524063,Angiotensin-converting enzyme inhibitor (disposition) Angiotensin Receptor Antagonists Either one or other Use of,Angiotensin Receptor Antagonists,,,Angiotensin Receptor Antagonists,C0815017
1408,C4541021;C0815017;eitheror;C1524063,Angiotensin-converting enzyme inhibitor (disposition) Angiotensin Receptor Antagonists Either one or other Use of,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
1409,C0015127;C1518422;C0475224,Etiology aspects Negation Ischemic,Etiology aspect,,,Etiology aspect,NA
1409,C0015127;C1518422;C0475224,Etiology aspects Negation Ischemic,Ischemic,,,Ischemic,C0475224
1410,C0235480;C0262926,Paroxysmal atrial fibrillation Medical History,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
1410,C0235480;C0262926,Paroxysmal atrial fibrillation Medical History,Medical History,,,Medical History,C0262926
1411,C0262926;C0235480;C1518422,Medical History Paroxysmal atrial fibrillation Negation,Medical History,,,Medical History,C0262926
1411,C0262926;C0235480;C1518422,Medical History Paroxysmal atrial fibrillation Negation,Paroxysmal atrial fibrillation,,,Paroxysmal atrial fibrillation,C0235480
1412,C1140609;C1518422,Insulin pump Negation,Insulin,,,Insulin,C0021641
1413,C0043031;C2826257,Warfarin Prior Medication Usage,Warfarin,,Antithrombotic Agents,Antithrombotic Agents,C1704311
1414,C0444567;C0225861,Ostium Left auricular appendage,Left auricular appendage,,,Left auricular appendage,C0225861
1415,C1444754;C0225861,Length Left auricular appendage,Left auricular appendage,,,Left auricular appendage,C0225861
1416,C0003211;C1518422,"Anti-Inflammatory Agents, Non-Steroidal Negation",Anti-Inflammatory Agents,,,Anti-Inflammatory Agents,C0003209
1417,C0003211;C1524063,"Anti-Inflammatory Agents, Non-Steroidal Use of",Anti-Inflammatory Agents,,,Anti-Inflammatory Agents,C0003209
1418,C0004057;C1518422;C1524063,Aspirin Negation Use of,Aspirin,,,Aspirin,C0004057
1419,C0004057;C1524063,Aspirin Use of,Aspirin,,,Aspirin,C0004057
1420,C0004057;C2347852,Aspirin Concomitant Agent,Aspirin,,,Aspirin,C0004057
1421,C0019664;C1704436,History Peripheral Arterial Diseases,Medical History,,,Medical History,C0262926
1421,C0019664;C1704436,History Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
1421,C0019664;C1704436,History Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
1422,C0020443;C1518422,Hypercholesterolemia Negation,Hypercholesterolemia,,,Hypercholesterolemia,C0020443
1423,C0020538;C1518422,Hypertensive disease Negation,"Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
1424,C0035648;C1518422,risk factors Negation,risk factors,,,risk factors,C0035648
1425,C0035648;C1523987,risk factors Alternative,risk factors,,,risk factors,C0035648
1426,C0070166;C1524063;C1518422,clopidogrel Use of Negation,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
1427,C0070166;C2347852,clopidogrel Concomitant Agent,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
1428,C0205258;eitheror;C0079488;C1446409,Indeterminate Either one or other Helicobacter pylori Positive,Helicobacter pylori,,,Helicobacter pylori,C0079488
1429,C0360714;C2347852,Hydroxymethylglutaryl-CoA Reductase Inhibitors Concomitant Agent,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1430,C1518422;C0020538,Negation Hypertensive disease,Hypertensive disease,,,Hypertensive disease,C0020538
1431,C1518422;C0070166,Negation clopidogrel,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
1432,C1518422;C1704436,Negation Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
1432,C1518422;C1704436,Negation Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
1433,C1524063;C0070166,Use of clopidogrel,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
1434,"C1704436	  ;C1518422",Peripheral Arterial Diseases Negation,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
1434,"C1704436	  ;C1518422",Peripheral Arterial Diseases Negation,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
1435,C2347852;C0360714,Concomitant Agent Hydroxymethylglutaryl-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1436,C0002962;C1442488,Angina Pectoris Baseline,Angina Pectoris,Angi Pectoris,,Angina Pectoris,C0002962
1437,C0877341;C0205156,coronary revascularization Previous,coronary revascularization,,,coronary revascularization,C0877341
1438,C0007787;C0332257;C3665365,"Transient Ischemic Attack Including (qualifier) Arteriosclerotic cardiovascular disease, NOS",Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
1438,C0007787;C0332257;C3665365,"Transient Ischemic Attack Including (qualifier) Arteriosclerotic cardiovascular disease, NOS",Transient Ischemic Attack,,,Transient Ischemic Attack,C0007787
1439,C0011881;C0022658,Diabetic Nephropathy Kidney Diseases,Diabetic Nephropathy,,,Diabetic Nephropathy,C0011881
1440,C0021641;C1442488;C2348070,Insulin Baseline Daily Dose,Insulin,,,Insulin,C0021641
1441,C0025266;C0151691,Male population group Decreased HDL cholesterol concentration,Gender,,,Gender,C0079399
1441,C0025266;C0151691,Male population group Decreased HDL cholesterol concentration,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1442,C0034510;C1518422;C0043157,Racial group Negation Caucasians,Racial group,,,Racial group,C0034510
1443,C0040363,Togo,Geographic Locations,,,Geographic Locations,C0017446
1443,C0017853,"Hemoglobin, Glycosylated","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
1444,C0041004;C1508496;C1442488,Triglycerides Quintile Baseline,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1445,C0065058;C1442488,Lipoprotein (a) Baseline,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1446,C0205250;C0023822,High High Density Lipoprotein Cholesterol,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1447,C0360714;C0205171,Hydroxymethylglutaryl-CoA Reductase Inhibitors Singular,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1448,C0360714;C0585943,Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipid-lowering therapy,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1448,C0360714;C0585943,Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipid-lowering therapy,Lipid-lowering therapy,,,Lipid-lowering therapy,C0585943
1449,C0360714;C0596836;C3244283,Hydroxymethylglutaryl-CoA Reductase Inhibitors Light intensity medium exposure,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1450,C0360714;C1512698,Hydroxymethylglutaryl-CoA Reductase Inhibitors Yes or No Response,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1451,C0360714;C4081854;C0596836,Hydroxymethylglutaryl-CoA Reductase Inhibitors High intensity Light intensity,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1452,C0439269;C0065058,mg/dL Lipoprotein (a),lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1453,C0439269;C0202236,mg/dL Triglycerides measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1454,C0439269;C0729627,mg/dL Non-high density lipoprotein cholesterol (substance),lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1455,C0439275;C1100660,Microgram per Liter Proprotein Convertases,Proprotein Convertases,,,Proprotein Convertases,C1100660
1456,C0444686;C0202117,Calculated Low density lipoprotein cholesterol measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1457,C0456387;C3811844,Class Estimated Glomerular Filtration Rate,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
1458,C1100660;C1442488,Proprotein Convertases Baseline,Proprotein Convertases,,,Proprotein Convertases,C1100660
1459,C1300563;C0486293,Gram per Kilogram Albumin To Creatinine Protein Ratio Measurement,Albumin To Creatinine Protein Ratio Measurement,,,Albumin To Creatinine Protein Ratio Measurement,C0486293
1460,C1442488;C0876920;C1100660,Baseline Median Statistical Measurement Proprotein Convertases,Proprotein Convertases,,,Proprotein Convertases,C1100660
1461,C1532634;C0021641;C1442488,Unit/kilogram/day Insulin Baseline,Insulin,,,Insulin,C0021641
1462,C1532634;C1442488;C0021641,Unit/kilogram/day Baseline Insulin,Insulin,,,Insulin,C0021641
1463,C1698058;C3665365,"per protocol Arteriosclerotic cardiovascular disease, NOS","Arteriosclerotic cardiovascular disease, NOS",,,"Arteriosclerotic cardiovascular disease, NOS",C3665365
1464,C0006539;C0035970;C0041580,Belarus Russia Ukraine,Geographic Locations,,,Geographic Locations,C0017446
1465,C0010055;C0262926;C1549445,Coronary Artery Bypass Surgery Medical History Yes - Yes/no indicator,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
1465,C0010055;C0262926;C1549445,Coronary Artery Bypass Surgery Medical History Yes - Yes/no indicator,Medical History,,,Medical History,C0262926
1466,C0086582;C0079399;C0086287,Males Gender Females,Gender,,,Gender,C0079399
1467,C1532338;C0262926;C1549445,Percutaneous Coronary Intervention Medical History Yes - Yes/no indicator,Medical History,,,Medical History,C0262926
1467,C1532338;C0262926;C1549445,Percutaneous Coronary Intervention Medical History Yes - Yes/no indicator,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1468,C1442488;C0019016,Baseline Hemoglobin A,Hemoglobin A,,,Hemoglobin A,C0019016
1469,C0754710;C1317554,Amino-terminal pro-brain natriuretic peptide Natriuretic Peptides B,Amino-terminal pro-brain natriuretic peptide,,,Amino-terminal pro-brain natriuretic peptide,C0754710
1470,C0025598;C0178602;C0034656;C1704711,Metformin Dosage Randomization Distribution,Metformin,Antidiabetics,,Antidiabetics,C0935929
1471,C0039798;C2348164,therapeutic aspects Screening Study,NA TO BE DELETED,,,NA TO BE DELETED,NA
1472,C0078988;C1518422,Asians Negation,Racial group,,,Racial group,C0034510
1473,C0428475;C1442488,Triglyceride level - finding Baseline,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1474,C0585943;C4081855;C0286651,Lipid-lowering therapy Moderate intensity atorvastatin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1474,C0585943;C4081855;C0286651,Lipid-lowering therapy Moderate intensity atorvastatin,Lipid-lowering therapy,,,Lipid-lowering therapy,C0585943
1475,C1442488;C0428475;C1532563,Baseline Triglyceride level - finding Millimole per Liter,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1476,C1442488;C1532563;C0428475,Baseline Millimole per Liter Triglyceride level - finding,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1477,C4081854;C0286651;C0585943,High intensity atorvastatin Lipid-lowering therapy,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1477,C4081854;C0286651;C0585943,High intensity atorvastatin Lipid-lowering therapy,Lipid-lowering therapy,,,Lipid-lowering therapy,C0585943
1478,C0040363;C0439475,Togo mmHg,Geographic Locations,,,Geographic Locations,C0017446
1479,C2697845;C2697846;C2697847,Killip Class II Killip Class III Killip Class IV,Killip Class,,,Killip Class,C1881332
1480,C0003842;C0441998,Arteries Left anterior,Arteries,,,Arteries,C0003842
1481,C0003842;C0444454,Arteries Access,Arteries,,,Arteries,C0003842
1482,C0003842;C1518422,Arteries Negation,Arteries,,,Arteries,C0003842
1483,C0012634;C0005847,Disease Blood Vessel,Blood Vessel,,,Blood Vessel,C0005847
1484,C0012634;C0679225,Disease multiple pathologies,multiple pathologies,,,multiple pathologies,C0679225
1485,C0012634;C0856738,Disease triple vessel disease,triple vessel disease,,,triple vessel disease,C0856738
1486,C0205156;C0441471;C0007222,Previous Event Cardiovascular Diseases,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
1486,C0205156;C0441471;C0007222,Previous Event Cardiovascular Diseases,Medical History,,,Medical History,C0262926
1487,C0205156;C1880008,Previous Cardiovascular History,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
1487,C0205156;C1880008,Previous Cardiovascular History,Medical History,,,Medical History,C0262926
1488,C0444454;C0221464,Access Arterial,NA TO BE DELETED,,,NA TO BE DELETED,NA
1489,C0449820;C0002965,"Score Angina, Unstable","Angina, Unstable",Angi Pectoris,,Angina Pectoris,C0002962
1490,C0004057;C0521115,Aspirin Simultaneous,Aspirin,,,Aspirin,C0004057
1491,C0005910;C0034656,Body Weight Randomization,Body Weight,,,Body Weight,C0005910
1492,C0006826;C0034656,Malignant Neoplasms Randomization,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1493,C0006826;C0205177;C0034656,Malignant Neoplasms Active Randomization,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1494,C0006826;C0262926,Malignant Neoplasms Medical History,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1494,C0006826;C0262926,Malignant Neoplasms Medical History,Medical History,,,Medical History,C0262926
1495,C0006826;C1518422,Malignant Neoplasms Negation,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1496,C0011900;C0449450,Diagnosis Presentation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1497,C0019134;C0205265,heparin Initially,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1498,C0019134;C0205265;C0034656;C0444921,heparin Initially Randomization Duration of treatment,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1499,C0019134;C0205265;C0444921,heparin Initially Duration of treatment,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1500,C0019134;C1705685,heparin Initial Usage,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1501,C0019905;C1518422,Honduras Negation,Geographic Locations,,,Geographic Locations,C0017446
1502,C0035648;C1442488,risk factors Baseline,risk factors,,,risk factors,C0035648
1503,C0078988;1,Asians ethnicity- other,Racial group,,,Racial group,C0034510
1504,C0205374;C0035648,Transitory risk factors,risk factors,,,risk factors,C0035648
1505,C0439209;C0005910,Kilogram Body Weight,Body Weight,,,Body Weight,C0005910
1506,C0439228;C0549183,day Midline (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
1507,C0455471;C1518422,H/O: malignant neoplasm Negation,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1507,C0455471;C1518422,H/O: malignant neoplasm Negation,Medical History,,,Medical History,C0262926
1508,C0525032;C0043031;C0302350;C0441889;C0205099,International Normalized Ratio Warfarin Therapeutic Levels (qualifier value) Central,Warfarin,,Antithrombotic Agents,Antithrombotic Agents,C1704311
1509,C0525032;C0460097;C0040223,International Normalized Ratio Within therapeutic range Time,NA TO BE DELETED,,,NA TO BE DELETED,NA
1510,C0812399;C0034656,Creatinine clearance Randomization,Creatinine clearance,,,Creatinine clearance,C0812399
1511,C2975435;C0034656,edoxaban Randomization,edoxaban,Direct factor Xa inhibitors,Antithrombotic Agents,Antithrombotic Agents,C1704311
1512,C0000956,acenocoumarol,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1513,C0003280;C4522267;C0034656,Anticoagulants Parenteral (intended site) Randomization,Anticoagulants,,,Anticoagulants,C0003280
1514,C0003281;C2926735,Anticoagulation Therapy Duration,Anticoagulants,,,Anticoagulants,C0003280
1515,C0006826;C0998265;C0205177,Malignant Neoplasms Cancer Genus Active,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1516,C0006826;C0998265;C1518422,Malignant Neoplasms Cancer Genus Negation,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1517,C0020944;C1518422,Immobilization Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1518,C0205156;C0332189,Previous Episode of,NA TO BE DELETED,,,NA TO BE DELETED,NA
1519,C0205177;C0006826,Active Malignant Neoplasms,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1520,C0205231;C1518422,Extensive Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1521,C0232804;C0812399,Renal function Creatinine clearance,Creatinine clearance,,,Creatinine clearance,C0812399
1521,C0232804;C0812399,Renal function Creatinine clearance,Renal function,,,Renal function,C0232804
1522,C4282132;C0034656,Malignancy Randomization,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1523,C4318935;C0034656,Mobility Ability Randomization,Mobility Ability,,,Mobility Ability,C4318935
1524,C0242708;C0205460;C0521983,"Antirheumatic Drugs, Disease-Modifying biological Absence of therapeutic response","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
1525,C0205197;C0249529;C0332152,Complete febuxostat Before,febuxostat,,,febuxostat,C0249529
1526,C0221099;C0750532,Impaired MILDLY,NA TO BE DELETED,,,NA TO BE DELETED,NA
1527,C0455272;C1442488,Serum urate measurement Baseline,Serum urate measurement,,,Serum urate measurement,C0455272
1528,C1442488;C0221248,Baseline Tophus,Tophus,,,Tophus,C0221248
1529,C0205311;C0004238,Paroxysmal Atrial Fibrillation,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
1530,C0007820;C4554100,"Cerebrovascular Disorders Stroke, CTCAE",Cerebrovascular accident,,,Cerebrovascular accident,C0038454
1530,C0007820;C4554100,"Cerebrovascular Disorders Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
1531,C0011849;C0022877;C0262926,Diabetes Mellitus Laboratory Medical History,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1531,C0011849;C0022877;C0262926,Diabetes Mellitus Laboratory Medical History,Medical History,,,Medical History,C0262926
1532,C0011900;C0262926,Diagnosis Medical History,Medical History,,,Medical History,C0262926
1533,C0017725;C0439269,Glucose mg/dL,Glucose,,,Glucose,C0017725
1534,C0027996;C0205156;C1524063,Niacin Previous Use of,Niacin,,,Niacin,C0027996
1535,C0085826;C0003280,Antiplatelet Agents Anticoagulants,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
1536,C0332152;C0444917,Before Duration of therapy,NA TO BE DELETED,,,NA TO BE DELETED,NA
1537,C0457083;C1442488,Usage Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
1538,C0205156;C1518422;C4554100,"Previous Negation Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
1539,C0205156;C4554100,"Previous Stroke, CTCAE","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
1540,C4554100;C0205156,"Stroke, CTCAE Previous","Stroke, CTCAE",,,"Stroke, CTCAE",C4554100
1541,C0205177;C1442488;C0998265,Active Baseline Cancer Genus,Cancer Genus,,,Cancer Genus,C0998265
1542,C0205265;C0231220,Initially Symptomatic,NA TO BE DELETED,,,NA TO BE DELETED,NA
1543,C1861172;C0205156,Venous Thromboembolism Previous,Thromboembolism,,,Thromboembolism,C0040038
1544,C0200760;C0037949,Morphometric analysis Vertebral column,Morphometric analysis,,,Morphometric analysis,C0200760
1544,C0200760;C0037949,Morphometric analysis Vertebral column,Vertebral column,,,Vertebral column,C0037949
1545,C1518422;C0037949,Negation Vertebral column,Vertebral column,,,Vertebral column,C0037949
1546,C0034656;C0449244;C1457887,Randomization Time of onset Symptoms,NA TO BE DELETED,,,NA TO BE DELETED,NA
1547,C0205437;C0439834,Third Slow,NA TO BE DELETED,,,NA TO BE DELETED,NA
1548,C0205437;C0456962,Third Rapid,NA TO BE DELETED,,,NA TO BE DELETED,NA
1549,C0021641;C1518422,Insulin Negation,Insulin,,,Insulin,C0021641
1550,C0021641;C1549445,Insulin Yes - Yes/no indicator,Insulin,,,Insulin,C0021641
1551,C0205163;C0439093,Equal Greater Than,NA TO BE DELETED,,,NA TO BE DELETED,NA
1552,C0205163;C0439093;C0439475,Equal Greater Than mmHg,NA TO BE DELETED,,,NA TO BE DELETED,NA
1553,C0360714;C1524063,Hydroxymethylglutaryl-CoA Reductase Inhibitors Use of,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1554,C0439092;C0439475,Less Than mmHg,NA TO BE DELETED,,,NA TO BE DELETED,NA
1555,C0549183;C0876920,Midline (qualifier value) Median Statistical Measurement,NA TO BE DELETED,,,NA TO BE DELETED,NA
1556,C0032285;C0205156,Pneumonia Previous,Pneumonia,,,Pneumonia,C0032285
1557,C0231999;C0439793;C0449295,Airflow Severities Limitation,Airflow,,,Airflow,C0231999
1558,C0740304;C0205156;C0439234;C4330837,copd exacerbation Previous year Number of Events,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1559,C0999593;C1710032;C1524063,Lama Screening Use of,Lama,,,Lama,C0999593
1560,C1518422;C1524063,Negation Use of,NA TO BE DELETED,,,NA TO BE DELETED,NA
1561,C1519386;C1710032,Smoking Status Screening,Smoking Status,,,Smoking Status,C1519386
1562,C1524063;C1518422,Use of Negation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1563,C1710032;C1524063;LABA,Screening Use of NA,long-acting beta agonist,,,long-acting beta agonist,NA
1564,C3540778;C1710032;C1524063,Glucocorticoid inhalants for obstructive airway disease Screening Use of,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
1565,C3540778;LABA ;C1710032;C1524063,Glucocorticoid inhalants for obstructive airway disease long-acting beta agonist  Screening Use of,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
1565,C3540778;LABA ;C1710032;C1524064,Glucocorticoid inhalants for obstructive airway disease long-acting beta agonist  Screening Use of,long-acting beta agonist,,,long-acting beta agonist,NA
1566,C1306673;C0024117;C0521117,Stage Chronic Obstructive Airway Disease Severity of illness,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
1567,C0004238;C1998417;C0019664,Atrial Fibrillation History of atrial flutter History,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
1567,C0004238;C1998417;C0019664,Atrial Fibrillation History of atrial flutter History,Medical History,,,Medical History,C0262926
1568,C0006280;C1710032;LABA,Bronchodilator Agents Screening long-acting beta agonist,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
1568,C0006280;C1710032;LABA,Bronchodilator Agents Screening long-acting beta agonist,long-acting beta agonist,,,long-acting beta agonist,NA
1569,C0028778;C0231999;C0439793,Obstruction Airflow Severities,Airflow,,,Airflow,C0231999
1570,C1442488;C0457083;C0586793,Baseline Usage Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
1571,C1442488;C0683519;C3887460;C1880018;C0348080,Baseline disease history Cardiovascular Cerebrovascular Condition,Cardiovascular system,,,Cardiovascular system,C0007226
1571,C1442488;C0683519;C3887460;C1880018;C0348080,Baseline disease history Cardiovascular Cerebrovascular Condition,Cerebrovascular disease,,,Cerebrovascular disease,NA
1571,C1442488;C0683519;C3887460;C1880018;C0348080,Baseline disease history Cardiovascular Cerebrovascular Condition,Medical History,,,Medical History,C0262926
1572,C0010068;C0205171,Coronary heart disease Singular,Coronary heart disease,,,Coronary heart disease,C0010068
1573,C0011849;C0011900;C0040223,Diabetes Mellitus Diagnosis Time,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1574,C0871470;C1305849,Systolic Pressure Diastolic blood pressure measurement,Blood Pressure,,,Blood Pressure,C0005823
1575,C1306620;C1305849,Systolic blood pressure measurement Diastolic blood pressure measurement,Blood Pressure,,,Blood Pressure,C0005823
1576,C4319571;C0007226,High risk Cardiovascular system,Cardiovascular system,,,Cardiovascular system,C0007226
1577,C0035647;C3272266;C0027051;C0449820,Risk Thrombolysis in Myocardial Infarction Flow Myocardial Infarction Score,Myocardial Infarction,,,Myocardial Infarction,C0027051
1577,C0035647;C3272266;C0027051;C0449820,Risk Thrombolysis in Myocardial Infarction Flow Myocardial Infarction Score,Risk,,,Risk,C0035647
1577,C0035647;C3272266;C0027051;C0449820,Risk Thrombolysis in Myocardial Infarction Flow Myocardial Infarction Score,Thrombolysis in Myocardial Infarction Flow,,,Thrombolysis in Myocardial Infarction Flow,C3272266
1578,C0070166;C1283828;C1279919,clopidogrel intent Early,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
1579,C0259945;C0332307,hospital care Type - attribute,NA TO BE DELETED,,,NA TO BE DELETED,NA
1580,C0027978;C0004340;C0332287;C0028405,New Zealand Australia In addition to North America,Geographic Locations,,,Geographic Locations,C0017446
1581,C0439475;C1306620;C1305849,mmHg Systolic blood pressure measurement Diastolic blood pressure measurement,Blood Pressure,,,Blood Pressure,C0005823
1582,C1306620;C1305849;C0439475,Systolic blood pressure measurement Diastolic blood pressure measurement mmHg,Blood Pressure,,,Blood Pressure,C0005823
1583,C4319571;C0850624,High risk cardiovascular risk factor,cardiovascular risk factor,,,cardiovascular risk factor,C0850624
1584,C0007787;C0205156,Transient Ischemic Attack Previous,Transient Ischemic Attack,,,Transient Ischemic Attack,C0007787
1585,C0070166;C0178602,clopidogrel Dosage,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
1586,C0070166;C3714444;C0449243,clopidogrel Loading dose Timing,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
1587,C0001779;C1333400,Age Gadolinium-Enhancing Lesion,Age-Years,,,Age-Years,C1510829
1588,C1510829;C1333400,Age-Years Gadolinium-Enhancing Lesion,Gadolinium-Enhancing Lesion,,,Gadolinium-Enhancing Lesion,C1333400
1589,C0205250;C1515021,High Subgroup,NA TO BE DELETED,,,NA TO BE DELETED,NA
1590,C0205251;C1515021,low Subgroup,NA TO BE DELETED,,,NA TO BE DELETED,NA
1591,C0004057;C4696290,Aspirin Aspirin dose,Aspirin,,,Aspirin,C0004057
1592,C0012634;C1518422,Disease Negation,Disease,,,Disease,C0012634
1593,C0027051;C0040223,Myocardial Infarction Time,Myocardial Infarction,,,Myocardial Infarction,C0027051
1594,C0205436;C0027051,second (number) Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
1595,C0205436;C0027051;C0332152,second (number) Myocardial Infarction Before,Myocardial Infarction,,,Myocardial Infarction,C0027051
1596,C0205436;C0027051;C1518422,second (number) Myocardial Infarction Negation,Myocardial Infarction,,,Myocardial Infarction,C0027051
1597,C0439209;C2939193,Kilogram Median (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
1598,C1532338;C0019664,Percutaneous Coronary Intervention History,Medical History,,,Medical History,C0262926
1598,C1532338;C0019664,Percutaneous Coronary Intervention History,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
1599,C1565489;C0205088;C1518422,Renal Insufficiency End-stage Negation,Renal Insufficiency,,,Renal Insufficiency,C1565489
1600,C1565489;C1518422,Renal Insufficiency Negation,Renal Insufficiency,,,Renal Insufficiency,C1565489
1601,C0377265;C2826257;C1705108,Levetiracetam Prior Medication Usage Yes (indicator),Levetiracetam,ANTIEPILEPTICS,,ANTIEPILEPTICS,NA
1602,C0521116;C1444637,Current (present time) In the past,NA TO BE DELETED,,,NA TO BE DELETED,NA
1603,C1518422;C4284232;C0359086,Negation Medications oral hypoglycemic,oral hypoglycemic,,,oral hypoglycemic,C0359086
1604,C4284232;C0359086,Medications oral hypoglycemic,oral hypoglycemic,,,oral hypoglycemic,C0359086
1605,C0242339;C1442488,Dyslipidemias Baseline,Dyslipidemias,,,Dyslipidemias,C0242339
1606,C0543414;C1442488,Tobacco use Baseline,Smoking Status,,,Smoking Status,C1519386
1607,C0239126;C1518422,corticosteroid use Negation,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1608,C2926735;C0011847,Duration Diabetes,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012800,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,Age-Years,,,Age-Years,C1510829
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012802,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,Benzodiazepines,,,Benzodiazepines,C0005064
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012805,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012799,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,Gender,,,Gender,C0079399
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012798,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,Geographic Locations,,,Geographic Locations,C0017446
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012803,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,Left ventricular ejection fraction,,,Left ventricular ejection fraction,C0428772
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012805,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,New York Heart Association Class,,,New York Heart Association Class,C1882083
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012801,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,Racial group,,,Racial group,C0034510
1609,C0017446;C0079399;C1510829;C3853635;C0005064;C0428772;C0600061;C1882083;C0011849;C0012804,Geographic Locations Gender Age-Years Race Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Diuretics,Serum creatinine level,,,Serum creatinine level,C0600061
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,Age-Years,,,Age-Years,C1510829
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,Benzodiazepines,,,Benzodiazepines,C0005064
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,Gender,,,Gender,C0079399
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,Geographic Locations,,,Geographic Locations,C0017446
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,Left ventricular ejection fraction,,,Left ventricular ejection fraction,C0428772
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,New York Heart Association Class,,,New York Heart Association Class,C1882083
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,Racial group,,,Racial group,C0034510
1610,C0017446;C0086582;C0086287;C1510829;C1533021;C0086409;C0005064;C0428772;C0600061;C1882083;C0011849;C1549445;C0012798,Geographic Locations Males Females Age-Years Hispanic white racial group Hispanics Benzodiazepines Left ventricular ejection fraction Serum creatinine level New York Heart Association Class Diabetes Mellitus Yes - Yes/no indicator Diuretics,Serum creatinine level,,,Serum creatinine level,C0600061
1611,C0001779;C2347635;C1711350,Age Population Median Interquartile Range,Age-Years,,,Age-Years,C1510829
1612,C0010055;C1514463,Coronary Artery Bypass Surgery Prior Therapy,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
1613,C0023822;C1711350;C2347635,High Density Lipoprotein Cholesterol Interquartile Range Population Median,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1614,C0023824;C1711350;C2347635,LDL Cholesterol Lipoproteins Interquartile Range Population Median,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1615,C0023824;C2348144,LDL Cholesterol Lipoproteins Sample Median,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1616,C0032821;C0870261,Potassium channel blockers,Anti-Arrhythmia Agents,,,Anti-Arrhythmia Agents,C0003195
1617,C0034656;C0040223;C0948089;C2347635;C1711350,Randomization Time Acute Coronary Syndrome Population Median Interquartile Range,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
1618,C0038454;C0332132,Cerebrovascular accident Prior diagnosis,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
1619,C0038454;C0332132;C1518422,Cerebrovascular accident Prior diagnosis Negation,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
1620,C0041004;C1711350;C2347635,Triglycerides Interquartile Range Population Median,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1621,C0332152;C0027051;C0332132;C0918012;C0948089,Before Myocardial Infarction Prior diagnosis Index Acute Coronary Syndrome,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
1621,C0332152;C0027051;C0332132;C0918012;C0948089,Before Myocardial Infarction Prior diagnosis Index Acute Coronary Syndrome,Myocardial Infarction,,,Myocardial Infarction,C0027051
1622,C0332152;C3539119;C2826257,"Before HMG CoA reductase inhibitors, plain lipid modifying drugs Prior Medication Usage","HMG CoA reductase inhibitors, plain lipid modifying drugs","LIPID MODIFYING AGENTS, PLAIN",,"LIPID MODIFYING AGENTS, PLAIN",NA
1623,C0441471;C0918012;C0332152;C0948089,Event Index Before Acute Coronary Syndrome,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
1624,C0441471;C0948089;C0918012;C0587081,Event Acute Coronary Syndrome Index Laboratory test finding,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
1625,C0441471;C1637833;C0948089,Event % index Acute Coronary Syndrome,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
1626,C0543421;C2347635;C1711350,Total cholesterol Population Median Interquartile Range,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1627,C0596019;C1382187,Chloride Ion Clearance of substance,Chloride Ion,,,Chloride Ion,C0596019
1628,C1277291;C0449820,Stroke risk Score,Risk,,,Risk,C0035647
1628,C1277291;C0449820,Stroke risk Score,Stroke,,,Stroke,NA
1629,C1305855;C2347635;C1711350,Body mass index Population Median Interquartile Range,Body mass index,,,Body mass index,C1305855
1630,C1536221;C0948089,Non ST elevation myocardial infarction Acute Coronary Syndrome,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
1630,C1536221;C0948089,Non ST elevation myocardial infarction Acute Coronary Syndrome,Non ST elevation myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
1631,C2347635;C1711350;C1441604;C4048285,"Population Median Interquartile Range High sensitivity C-Reactive Protein, human",C-Reactive Protein,,,C-Reactive Protein,NA
1632,C2348144;C0023824,Sample Median LDL Cholesterol Lipoproteins,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1633,C2826257;C3539119,"Prior Medication Usage HMG CoA reductase inhibitors, plain lipid modifying drugs","HMG CoA reductase inhibitors, plain lipid modifying drugs","LIPID MODIFYING AGENTS, PLAIN",,"LIPID MODIFYING AGENTS, PLAIN",NA
1634,C3811844;C2347635;C1711350,Estimated Glomerular Filtration Rate Population Median Interquartile Range,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
1635,C0017853;C1442488;C0439165,"Hemoglobin, Glycosylated Baseline Percent (qualifier value)","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
1636,C0549178;C0337438,Continuous Glucose measurement,Glucose,,,Glucose,C0017725
1637,C0019664;C0027051;C0332152,History Myocardial Infarction Before,Medical History,,,Medical History,C0262926
1637,C0019664;C0027051;C0332152,History Myocardial Infarction Before,Myocardial Infarction,,,Myocardial Infarction,C0027051
1638,C0205160;C0027051;C0333482;C0007223,Negative Myocardial Infarction atherosclerotic Cardiovascular Diseases,atherosclerotic,,,atherosclerotic,C0333482
1638,C0205160;C0027051;C0333482;C0007224,Negative Myocardial Infarction atherosclerotic Cardiovascular Diseases,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
1638,C0205160;C0027051;C0333482;C0007222,Negative Myocardial Infarction atherosclerotic Cardiovascular Diseases,Myocardial Infarction,,,Myocardial Infarction,C0027051
1639,C0850624;C0027051,cardiovascular risk factor Myocardial Infarction,cardiovascular risk factor,,,cardiovascular risk factor,C0850624
1639,C0850624;C0027051,cardiovascular risk factor Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
1640,C3665365;C0027051,"Arteriosclerotic cardiovascular disease, NOS Myocardial Infarction","Arteriosclerotic cardiovascular disease, NOS",,,"Arteriosclerotic cardiovascular disease, NOS",C3665365
1641,C1306673;C0205450,Stage Four,NA TO BE DELETED,,,NA TO BE DELETED,NA
1642,C0011847;C1442488,Diabetes Baseline,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1643,C0017654;C0750572;C1442488,Glomerular Filtration Rate Estimated Baseline,Glomerular Filtration Rate,,,Glomerular Filtration Rate,C0017654
1644,C0024671;C1442488;C4048285,"Mammography Baseline C-Reactive Protein, human",C-Reactive Protein,,,C-Reactive Protein,NA
1644,C0024671;C1442488;C4048285,"Mammography Baseline C-Reactive Protein, human",Mammography,,,Mammography,C0024671
1645,C1142985;C0042153;C0457083,ezetimibe utilization qualifier Usage,ezetimibe,Other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
1646,C1442488;C0041004,Baseline Triglycerides,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1647,C1442488;C0202117,Baseline Low density lipoprotein cholesterol measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1648,C1442488;C0202236,Baseline Triglycerides measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1649,C1442488;C1278454;C0522510,Baseline Statin prophylaxis With intensity,Statin prophylaxis,,,Statin prophylaxis,C1278454
1650,C0205156;C2003901,Previous Never (frequency),NA TO BE DELETED,,,NA TO BE DELETED,NA
1651,C1561607;C1704436,Overall Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
1651,C1561607;C1704436,Overall Peripheral Arterial Diseases,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
1652,"C1704436	  ;C0023216",Peripheral Arterial Diseases Lower Extremity,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
1652,"C1704436	  ;C0023216",Peripheral Arterial Diseases Lower Extremity,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
1653,"C1704436	  ;C0231220",Peripheral Arterial Diseases Symptomatic,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,"C1704436	  "
1653,"C1704436	  ;C0231220",Peripheral Arterial Diseases Symptomatic,Peripheral Arterial Diseases,,,Peripheral Arterial Diseases,C1704436
1654,C0001925;C3811844,Albuminuria Estimated Glomerular Filtration Rate,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
1655,C0730345;C0001925,Microalbuminuria Albuminuria,Albuminuria,,,Albuminuria,C0001925
1655,C0730345;C0001925,Microalbuminuria Albuminuria,Microalbuminuria,,,Microalbuminuria,C0730345
1656,C1442488;C1448177;C0449438,"Baseline TNF protein, human Status","TNF protein, human",,,"TNF protein, human",C1448177
1657,C0001779;C1710032,Age Screening,Age-Years,,,Age-Years,C1510829
1658,C0019664;C0264716,History Chronic heart failure,Heart failure,,,Heart failure,C0018801
1658,C0019664;C0264716,History Chronic heart failure,Medical History,,,Medical History,C0262926
1659,C3811844;C3839656,Estimated Glomerular Filtration Rate Modification of diet in renal disease formula,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
1660,C4319718;C4551412,Reported Electronic case report form,NA TO BE DELETED,,,NA TO BE DELETED,NA
1661,C4551412;C1518422;C4319718,Electronic case report form Negation Reported,NA TO BE DELETED,,,NA TO BE DELETED,NA
1662,C4551412;C4319718,Electronic case report form Reported,NA TO BE DELETED,,,NA TO BE DELETED,NA
1663,C0439605;C1705492,Random Missing,NA TO BE DELETED,,,NA TO BE DELETED,NA
1664,C1705492;C0439605,Missing Random,NA TO BE DELETED,,,NA TO BE DELETED,NA
1665,C1706462;C1948062;C0439605,Reference Object Copy (object) Random,NA TO BE DELETED,,,NA TO BE DELETED,NA
1666,C1948062;C1706462;C0439605,Copy (object) Reference Object Random,NA TO BE DELETED,,,NA TO BE DELETED,NA
1667,C1948062;C1706462,Copy (object) Reference Object,NA TO BE DELETED,,,NA TO BE DELETED,NA
1668,C1510829,Age-Years,Age-Years,,,Age-Years,C1510829
1669,C0439234,year,NA TO BE DELETED,,,NA TO BE DELETED,NA
1670,C0011849,Diabetes Mellitus,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
1671,C1549445,Yes - Yes/no indicator,NA TO BE DELETED,,,NA TO BE DELETED,NA
1672,C0439269,mg/dL,NA TO BE DELETED,,,NA TO BE DELETED,NA
1673,C0337664,Smoker,Smoking Status,,,Smoking Status,C1519386
1674,C0034510,Racial group,Racial group,,,Racial group,C0034510
1675,C0521116,Current (present time),NA TO BE DELETED,,,NA TO BE DELETED,NA
1676,C0001645,Adrenergic beta-Antagonists,Adrenergic beta-Antagonists,,,Adrenergic beta-Antagonists,C0001645
1677,C0155668,Old myocardial infarction,Old myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
1678,C0428471,HDL - High density lipoprotein cholesterol level result,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1679,C0241889,Family history,Family history,,,Family history,C0241889
1680,C0004057,Aspirin,Aspirin,,,Aspirin,C0004057
1681,C1963138,"Hypertension, CTCAE","Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
1682,C0023824,LDL Cholesterol Lipoproteins,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1683,C0041004,Triglycerides,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1684,C0229671,Serum,NA TO BE DELETED,,,NA TO BE DELETED,NA
1685,C0007806,Cerebrospinal Fluid,Cerebrospinal Fluid,,,Cerebrospinal Fluid,C0007806
1686,C0008377,Cholesterol,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1687,C0064673,lathosterol,lathosterol,,,lathosterol,C0064673
1688,C0439231,month,NA TO BE DELETED,,,NA TO BE DELETED,NA
1689,C0584960,Factor V Leiden mutation,Factor V Leiden mutation,,,Factor V Leiden mutation,C0584960
1690,C0332197,Absent,NA TO BE DELETED,,,NA TO BE DELETED,NA
1691,C0079399,Gender,Gender,,,Gender,C0079399
1692,C0150312,Present,NA TO BE DELETED,,,NA TO BE DELETED,NA
1693,C0001948,Alcohol consumption,Alcohol consumption,,,Alcohol consumption,C0001948
1694,C0002962,Angina Pectoris,Angina Pectoris,Angi Pectoris,,Angina Pectoris,C0002962
1695,C1305855,Body mass index,Body mass index,,,Body mass index,C1305855
1696,C0017446,Geographic Locations,Geographic Locations,,,Geographic Locations,C0017446
1697,C0428883,Diastolic blood pressure,Blood Pressure,,,Blood Pressure,C0005823
1698,C0232306,Electrocardiogram: left ventricle hypertrophy (finding),Electrocardiogram: left ventricle hypertrophy (finding),,,Electrocardiogram: left ventricle hypertrophy (finding),C0232306
1699,C0015259,Exercise,Exercise,Physical activity,,Physical activity,C0026606
1700,C0018801,Heart failure,Heart failure,,,Heart failure,C0018801
1701,C0852149,Ischaemic coronary artery disease,Ischaemic coronary artery disease,Corory Artery Disease,,Coronary Artery Disease,C1956346
1702,C0745133,isolated systolic hypertension,isolated systolic hypertension,"Hypertension, CTCAE",,"Hypertension, CTCAE",C1963138
1703,C0027051,Myocardial Infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
1704,C0730345,Microalbuminuria,Microalbuminuria,,,Microalbuminuria,C0730345
1705,C0007820,Cerebrovascular Disorders,Cerebrovascular accident,,,Cerebrovascular accident,C0038454
1706,C0871470,Systolic Pressure,Blood Pressure,,,Blood Pressure,C0005823
1707,C0543421,Total cholesterol,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1708,C1709380,P-Value,NA TO BE DELETED,,,NA TO BE DELETED,NA
1709,C2985465,Hazard Ratio,NA TO BE DELETED,,,NA TO BE DELETED,NA
1710,C1521828,Rate,NA TO BE DELETED,,,NA TO BE DELETED,NA
1711,C2360800,Number of patients,NA TO BE DELETED,,,NA TO BE DELETED,NA
1712,C0032385,Pollen,Pollen,,,Pollen,C0032385
1713,C0006560,C-reactive protein,C-Reactive Protein,,,C-Reactive Protein,NA
1714,C0205160,Negative,NA TO BE DELETED,,,NA TO BE DELETED,NA
1715,C1536220,ST segment elevation myocardial infarction,ST segment elevation myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
1715,C1536220,ST segment elevation myocardial infarction,ST segment elevation myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
1716,C0439070,Roman Numeral III,NA TO BE DELETED,,,NA TO BE DELETED,NA
1717,C3811844,Estimated Glomerular Filtration Rate,Estimated Glomerular Filtration Rate,,,Estimated Glomerular Filtration Rate,C3811844
1718,C0439810,Total,NA TO BE DELETED,,,NA TO BE DELETED,NA
1719,C1532737,ezetimibe / Simvastatin,ezetimibe / Simvastatin,HMG CoA reductase inhibitors in combition with other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
1720,C0074554,Simvastatin,Simvastatin,HMG CoA reductase inhibitors,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
1721,C1711350,Interquartile Range,NA TO BE DELETED,,,NA TO BE DELETED,NA
1722,C0750194,Non-Sustained Ventricular Tachycardia by ECG Finding,Non-Sustained Ventricular Tachycardia by ECG Finding,,,Non-Sustained Ventricular Tachycardia by ECG Finding,C0750194
1723,C2939193,Median (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
1724,C0018810,heart rate,heart rate,,,heart rate,C0018810
1725,C1516879,Enrollment,NA TO BE DELETED,,,NA TO BE DELETED,NA
1726,C0039070,Syncope,Syncope,,,Syncope,C0039070
1727,C0010294,Creatinine,Creatinine clearance,,,Creatinine clearance,C0812399
1728,C0024115,Lung diseases,Lung diseases,,,Lung diseases,C0024115
1729,C0523891,Serum sodium measurement,Serum sodium measurement,,,Serum sodium measurement,C0523891
1730,C0012798,Diuretics,Diuretics,,,Diuretics,C0012798
1731,C0020473,Hyperlipidemia,Hyperlipidemia,,,Hyperlipidemia,C0020473
1732,C0013227,Pharmaceutical Preparations,Pharmaceutical Preparations,,,Pharmaceutical Preparations,C0013227
1733,C0428772,Left ventricular ejection fraction,Left ventricular ejection fraction,,,Left ventricular ejection fraction,C0428772
1734,C0439223,millisecond,NA TO BE DELETED,,,NA TO BE DELETED,NA
1735,C0206158,Premenopause,Menopausal Status,,,Menopausal Status,C1513126
1736,C4085655,Uncertain - Response,NA TO BE DELETED,,,NA TO BE DELETED,NA
1737,C0005823,Blood Pressure,Blood Pressure,,,Blood Pressure,C0005823
1738,C0439475,mmHg,NA TO BE DELETED,,,NA TO BE DELETED,NA
1739,C1561607,Overall,NA TO BE DELETED,,,NA TO BE DELETED,NA
1740,C0205094,Anterior,NA TO BE DELETED,,,NA TO BE DELETED,NA
1741,C0015982,Fibrin,Fibrin,,,Fibrin,C0015982
1742,C0019134,heparin,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1743,C0439175,% of total,NA TO BE DELETED,,,NA TO BE DELETED,NA
1744,C0017654,Glomerular Filtration Rate,Glomerular Filtration Rate,,,Glomerular Filtration Rate,C0017654
1745,C1532563,Millimole per Liter,NA TO BE DELETED,,,NA TO BE DELETED,NA
1746,C0237753,Numbers,NA TO BE DELETED,,,NA TO BE DELETED,NA
1747,C2003901,Never (frequency),NA TO BE DELETED,,,NA TO BE DELETED,NA
1748,C1444637,In the past,NA TO BE DELETED,,,NA TO BE DELETED,NA
1749,C0332177,Monthly (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
1750,C0010068,Coronary heart disease,Coronary heart disease,,,Coronary heart disease,C0010068
1751,C0856742,post mi,post mi,,,post mi,C0856742
1752,C1271104,Blood pressure finding,Blood Pressure,,,Blood Pressure,C0005823
1753,C1287371,Finding of serum cholesterol level,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1754,C0007222,Cardiovascular Diseases,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
1755,C1513916,Negative Finding,NA TO BE DELETED,,,NA TO BE DELETED,NA
1756,C0041199,Troponin,Troponin,,,Troponin,C0041199
1757,C0439275,Microgram per Liter,NA TO BE DELETED,,,NA TO BE DELETED,NA
1758,C0564385,/hour,NA TO BE DELETED,,,NA TO BE DELETED,NA
1759,C0877341,coronary revascularization,coronary revascularization,,,coronary revascularization,C0877341
1760,C0205447,One,NA TO BE DELETED,,,NA TO BE DELETED,NA
1761,C0205448,Two,NA TO BE DELETED,,,NA TO BE DELETED,NA
1762,C0086440,Hypolipidemic Agents,Hypolipidemic Agents,,,Hypolipidemic Agents,C0086440
1763,C1282910,Upper,NA TO BE DELETED,,,NA TO BE DELETED,NA
1764,C0004153,Atherosclerosis,Atherosclerosis,,,Atherosclerosis,C0004153
1765,C0972314,etoricoxib,etoricoxib,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",NA
1766,C0042153,utilization qualifier,NA TO BE DELETED,,,NA TO BE DELETED,NA
1767,C0003873,Rheumatoid Arthritis,Rheumatoid Arthritis,,,Rheumatoid Arthritis,C0003873
1768,C0012634,Disease,Disease,,,Disease,C0012634
1769,D010003,osteoarthritis,osteoarthritis,,,osteoarthritis,D010003
1770,C0340293,Anterior myocardial infarction,Anterior myocardial infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
1771,C0449450,Presentation,NA TO BE DELETED,,,NA TO BE DELETED,NA
1772,C0358591,Proton Pump Inhibitors,Proton Pump Inhibitors,,,Proton Pump Inhibitors,C0358591
1773,C1314792,Etiology,Etiology aspect,,,Etiology aspect,NA
1774,C1095989,Brain natriuretic peptide measurement,Brain natriuretic peptide measurement,,,Brain natriuretic peptide measurement,C1095989
1775,C0700148,Congestion,Congestion,,,Congestion,C0700148
1776,C0013404,Dyspnea,Dyspnea,,,Dyspnea,C0013404
1777,C2700378,Ejection fraction (finding),Ejection fraction (finding),,,Ejection fraction (finding),C2700378
1778,C0022116,Ischemia,Ischemia,,,Ischemia,C0022116
1779,C1882083,New York Heart Association Class,New York Heart Association Class,,,New York Heart Association Class,C1882083
1780,C4316743,Not severe,NA TO BE DELETED,,,NA TO BE DELETED,NA
1781,C0856666,serum urea,serum urea,,,serum urea,C0856666
1782,C0205082,Severe (severity modifier),NA TO BE DELETED,,,NA TO BE DELETED,NA
1783,C1098706,human AVP protein,human AVP protein,,,human AVP protein,C1098706
1784,C0035647,Risk,Risk,,,Risk,C0035647
1785,C0011900,Diagnosis,NA TO BE DELETED,,,NA TO BE DELETED,NA
1786,C0812399,Creatinine clearance,Creatinine clearance,,,Creatinine clearance,C0812399
1787,C0520887,ST segment depression (finding),ST segment depression (finding),,,ST segment depression (finding),C0520887
1788,C0286651,atorvastatin,atorvastatin,,,atorvastatin,C0286651
1789,C3258257,Total population,NA TO BE DELETED,,,NA TO BE DELETED,NA
1790,C0017853,"Hemoglobin, Glycosylated","Hemoglobin, Glycosylated",,,"Hemoglobin, Glycosylated",C0017853
1791,C0443258,Microvascular,Microvascular,,,Microvascular,C0443258
1792,C0085826,Antiplatelet Agents,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
1793,C0085672,Microbiology procedure,Microbiology procedure,,,Microbiology procedure,C0085672
1794,C0003364,Antihypertensive Agents,Antihypertensive Agents,,,Antihypertensive Agents,C0003364
1795,C0136123,Perindopril,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
1796,C0360714,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
1797,C1442488,Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
1798,C1318293,Albumin/creatinine ration result,Urine albumin/creatinine ratio measurement,,,Urine albumin/creatinine ratio measurement,C0455271
1799,C1705492,Missing,NA TO BE DELETED,,,NA TO BE DELETED,NA
1800,C0752046,Single Nucleotide Polymorphism,Single Nucleotide Polymorphism,,,Single Nucleotide Polymorphism,C0752046
1801,C0850624,cardiovascular risk factor,cardiovascular risk factor,,,cardiovascular risk factor,C0850624
1802,C0042381,Vascular Surgical Procedures,Vascular Surgical Procedures,,,Vascular Surgical Procedures,C0042381
1803,C0030705,Patients,NA TO BE DELETED,,,NA TO BE DELETED,NA
1804,C2700280,World,NA TO BE DELETED,,,NA TO BE DELETED,NA
1805,C0442050,Middle third,NA TO BE DELETED,,,NA TO BE DELETED,NA
1806,C0439673,Unknown,NA TO BE DELETED,,,NA TO BE DELETED,NA
1807,C0205145,Site,NA TO BE DELETED,,,NA TO BE DELETED,NA
1808,C0017725,Glucose,Glucose,,,Glucose,C0017725
1809,C2242682,Recurrent Cerebral Ischemia,Recurrent Cerebral Ischemia,,,Recurrent Cerebral Ischemia,C2242682
1810,C0850708,History of disease,Medical History,,,Medical History,C0262926
1811,C4319571,High risk,Risk,,,Risk,C0035647
1812,C0558293,Once a week,NA TO BE DELETED,,,NA TO BE DELETED,NA
1813,C0439228,day,NA TO BE DELETED,,,NA TO BE DELETED,NA
1814,C0302891,Native (qualifier value),Racial group,,,Racial group,C0034510
1815,C1696465,placebo,placebo,,,placebo,C1696465
1816,C0248719,telmisartan,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
1817,C0028754,Obesity,Obesity,,,Obesity,C0028754
1818,C0034656,Randomization,NA TO BE DELETED,,,NA TO BE DELETED,NA
1819,C0001168,Complete obstruction,NA TO BE DELETED,,,NA TO BE DELETED,NA
1820,C1836785,Recurrent strokes,Recurrent Cerebral Ischemia,,,Recurrent Cerebral Ischemia,C2242682
1821,C3538919,Low Risk,Risk,,,Risk,C0035647
1822,C3536709,Corticosteroid [EPC],corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1823,C3665365,"Arteriosclerotic cardiovascular disease, NOS","Arteriosclerotic cardiovascular disease, NOS",,,"Arteriosclerotic cardiovascular disease, NOS",C3665365
1824,C0599755,Cohort,NA TO BE DELETED,,,NA TO BE DELETED,NA
1825,C0205156,Previous,NA TO BE DELETED,,,NA TO BE DELETED,NA
1826,C0021966,Iodides,Iodides,,,Iodides,C0021966
1827,C0449261,Reversibility,NA TO BE DELETED,,,NA TO BE DELETED,NA
1828,C3540778,Glucocorticoid inhalants for obstructive airway disease,Glucocorticoid inhalants for obstructive airway disease,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,NA
1829,C0815320,Impaired Control Scale,Impaired Control Scale,,,Impaired Control Scale,C0815320
1830,C0242896,Anticholinergic Agents,Anticholinergic Agents,,,Anticholinergic Agents,C0242896
1831,C4049919,Insulin Sensitivity Measurement,Insulin Sensitivity,,,Insulin Sensitivity,C0920563
1832,C2911690,Disease Controlled,NA TO BE DELETED,,,NA TO BE DELETED,NA
1833,C0205318,Uncontrolled,NA TO BE DELETED,,,NA TO BE DELETED,NA
1834,C0062152,HDL-triglyceride,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
1835,C0004238,Atrial Fibrillation,Atrial Fibrillation,,,Atrial Fibrillation,C0004238
1836,C0205355,Permanent,NA TO BE DELETED,,,NA TO BE DELETED,NA
1837,C1696073,enrollment - ResearchSubjectRoleBasis,NA TO BE DELETED,,,NA TO BE DELETED,NA
1838,C0376409,Patient Preference,NA TO BE DELETED,,,NA TO BE DELETED,NA
1839,C0037712,South Africa,Geographic Locations,,,Geographic Locations,C0017446
1840,CHADS,CHADS2 - risk prediction score,CHADS2 - risk prediction score,Risk,,Risk,C0035647
1841,C0018802,Congestive heart failure,Congestive heart failure,Heart failure,,Heart failure,C0018801
1842,C3653316,Vitamin K antagonists,Vitamin K antagonists,Antithrombotic Agents,,Antithrombotic Agents,C1704311
1843,C3251812,Bleeding risk,Bleeding risk,,,Bleeding risk,C3251812
1844,C0205311,Paroxysmal,NA TO BE DELETED,,,NA TO BE DELETED,NA
1845,C3146298,Indication,NA TO BE DELETED,,,NA TO BE DELETED,NA
1846,C0340489,Lone atrial fibrillation,Lone atrial fibrillation,Atrial Fibrillation,,Atrial Fibrillation,C0004238
1847,C0003195,Anti-Arrhythmia Agents,Anti-Arrhythmia Agents,,,Anti-Arrhythmia Agents,C0003195
1848,C0002598,Amiodarone,Amiodarone,"Antiarrhythmics, class III",CARDIAC THERAPY,CARDIAC THERAPY,NA
1849,C0205370,Unspecified,NA TO BE DELETED,,,NA TO BE DELETED,NA
1850,C0025598,Metformin,Metformin,Antidiabetics,,Antidiabetics,C0935929
1851,C1611934,saxagliptin,Dipeptidyl-Peptidase IV Inhibitors,Antidiabetics,,Antidiabetics,C0935929
1852,C0449279,Extent of disease,NA TO BE DELETED,,,NA TO BE DELETED,NA
1853,C0040808,Treatment Protocols,NA TO BE DELETED,,,NA TO BE DELETED,NA
1854,C2603343,Study,NA TO BE DELETED,,,NA TO BE DELETED,NA
1855,C0439209,Kilogram,NA TO BE DELETED,,,NA TO BE DELETED,NA
1856,C0449820,Score,NA TO BE DELETED,,,NA TO BE DELETED,NA
1857,C0005910,Body Weight,Body Weight,,,Body Weight,C0005910
1858,C0175566,Open,NA TO BE DELETED,,,NA TO BE DELETED,NA
1859,C0205251,low,NA TO BE DELETED,,,NA TO BE DELETED,NA
1860,C0524425,inside the blood vessel,Blood Vessel,,,Blood Vessel,C0005847
1861,C0205250,High,NA TO BE DELETED,,,NA TO BE DELETED,NA
1862,C1444662,Discontinued,NA TO BE DELETED,,,NA TO BE DELETED,NA
1863,C0205103,Intermediate,NA TO BE DELETED,,,NA TO BE DELETED,NA
1864,C0439526,/mL,NA TO BE DELETED,,,NA TO BE DELETED,NA
1865,C0015179,European Union,Geographic Locations,,,Geographic Locations,C0017446
1866,C1279986,Procedure on heart,NA TO BE DELETED,,,NA TO BE DELETED,NA
1867,C0085532,Coronary angiography,Coronary angiography,,,Coronary angiography,C0085532
1868,C4049621,Peritoneal Cancer Index,Peritoneal Cancer Index,,,Peritoneal Cancer Index,C4049621
1869,C1514463,Prior Therapy,NA TO BE DELETED,,,NA TO BE DELETED,NA
1870,C0445550,Low dose,NA TO BE DELETED,,,NA TO BE DELETED,NA
1871,C0038766,Sulfonylurea Compounds,Sulfonylurea Compounds,Antidiabetics,,Antidiabetics,C0935929
1872,C0019020,Hemoglobin C,Hemoglobin C,,,Hemoglobin C,C0019020
1873,C0232804,Renal function,Renal function,,,Renal function,C0232804
1874,C0205081,Moderate (severity modifier),NA TO BE DELETED,,,NA TO BE DELETED,NA
1875,C0205307,Normal,NA TO BE DELETED,,,NA TO BE DELETED,NA
1876,C0178602,Dosage,NA TO BE DELETED,,,NA TO BE DELETED,NA
1877,C0543467,Operative Surgical Procedures,Operative Surgical Procedures,,,Operative Surgical Procedures,C0543467
1878,C0441889,Levels (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
1879,C0181074,Graft material,Graft material,,,Graft material,C0181074
1880,C0042449,Veins,Veins,,,Veins,C0042449
1881,C0750523,FORMER,NA TO BE DELETED,,,NA TO BE DELETED,NA
1882,C0369773,P Blood group antibodies,P Blood group antibodies,,,P Blood group antibodies,C0369773
1883,C4688581,Helicobacter pylori Negative,Helicobacter pylori,,,Helicobacter pylori,C0079488
1884,C0085096,Peripheral Vascular Diseases,Peripheral Vascular Diseases,,,Peripheral Vascular Diseases,C0085096
1885,C0079488,Helicobacter pylori,Helicobacter pylori,,,Helicobacter pylori,C0079488
1886,C0003211,"Anti-Inflammatory Agents, Non-Steroidal",Anti-Inflammatory Agents,,,Anti-Inflammatory Agents,C0003209
1887,C0043031,Warfarin,Warfarin,,Antithrombotic Agents,Antithrombotic Agents,C1704311
1888,C0022271,Israel,Geographic Locations,,,Geographic Locations,C0017446
1889,C0003280,Anticoagulants,Anticoagulants,,,Anticoagulants,C0003280
1890,C0450429,Location,NA TO BE DELETED,,,NA TO BE DELETED,NA
1891,C0175668,Secondary to,NA TO BE DELETED,,,NA TO BE DELETED,NA
1892,C0205231,Extensive,NA TO BE DELETED,,,NA TO BE DELETED,NA
1893,C0020944,Immobilization,NA TO BE DELETED,,,NA TO BE DELETED,NA
1894,C0027978,New Zealand,Geographic Locations,,,Geographic Locations,C0017446
1895,C0018799,Heart Diseases,Heart Diseases,Cardiovascular Diseases,,Cardiovascular Diseases,C0007222
1896,C0439445,mL/min,NA TO BE DELETED,,,NA TO BE DELETED,NA
1897,C0686905,Unavailability,NA TO BE DELETED,,,NA TO BE DELETED,NA
1898,C0368663,aminosalicylate,aminosalicylate,Aminosalicylic acid and derivatives,ANTIMYCOBACTERIALS,ANTIMYCOBACTERIALS,NA
1899,C1527392,Immunomodulators,Immunomodulators,,,Immunomodulators,C1527392
1900,C0457451,Severity score,NA TO BE DELETED,,,NA TO BE DELETED,NA
1901,C1998280,International Prostate Symptom Score,International Prostate Symptom Score,,,International Prostate Symptom Score,C1998280
1902,D017430,Prostate specific antigen,Prostate specific antigen,,,Prostate specific antigen,D017430
1903,C0429784,Maximal urinary flow rate,Maximal urinary flow rate,,,Maximal urinary flow rate,C0429784
1904,C1306673,Stage,NA TO BE DELETED,,,NA TO BE DELETED,NA
1905,C0018026,Gold,NA TO BE DELETED,,,NA TO BE DELETED,NA
1906,C0455829,Waist Circumference,Waist Circumference,,,Waist Circumference,C0455829
1907,C1548221,Bed Status - Isolated,NA TO BE DELETED,,,NA TO BE DELETED,NA
1908,C0220938,White color,Racial group,,,Racial group,C0034510
1909,C1328504,Hormone refractory prostate cancer,Hormone refractory prostate cancer,,,Hormone refractory prostate cancer,C1328504
1910,C0019046,Hemoglobin,Hemoglobin,,,Hemoglobin,C0019046
1911,C0010054,Coronary Arteriosclerosis,Coronary Arteriosclerosis,,,Coronary Arteriosclerosis,C0010054
1912,C0166128,rolofylline,rolofylline,,,rolofylline,C0166128
1913,C0004340,Australia,Geographic Locations,,,Geographic Locations,C0017446
1914,C0004348,Austria,Geographic Locations,,,Geographic Locations,C0017446
1915,C0004950,Belgium,Geographic Locations,,,Geographic Locations,C0017446
1916,C0006137,Brazil,Geographic Locations,,,Geographic Locations,C0017446
1917,C0206578,Czech Republic,Geographic Locations,,,Geographic Locations,C0017446
1918,C0014908,Estonia,Geographic Locations,,,Geographic Locations,C0017446
1919,C0017480,Germany,Geographic Locations,,,Geographic Locations,C0017446
1920,C0020174,Hungary,Geographic Locations,,,Geographic Locations,C0017446
1921,C0022277,Italy,Geographic Locations,,,Geographic Locations,C0017446
1922,C0023128,Latvia,Geographic Locations,,,Geographic Locations,C0017446
1923,C0032356,Country of Poland,Geographic Locations,,,Geographic Locations,C0017446
1924,C0035826,Romania,Geographic Locations,,,Geographic Locations,C0017446
1925,C0232970,Postmenopausal state,Postmenopausal state,Menopausal Status,,Menopausal Status,C1513126
1926,C1704711,Distribution,NA TO BE DELETED,,,NA TO BE DELETED,NA
1927,C0010055,Coronary Artery Bypass Surgery,Coronary Artery Bypass Surgery,,,Coronary Artery Bypass Surgery,C0010055
1928,C0021641,Insulin,Insulin,,,Insulin,C0021641
1929,C0003015,Angiotensin-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
1930,C1275835,History of myocardial infarction,Medical History,,,Medical History,C0262926
1930,C1275835,History of myocardial infarction,Myocardial Infarction,,,Myocardial Infarction,C0027051
1931,C0524620,Metabolic Syndrome X,Metabolic Syndrome X,,,Metabolic Syndrome X,C0524620
1932,C3272907,Percent Change From Baseline,NA TO BE DELETED,,,NA TO BE DELETED,NA
1933,C1861172,Venous Thromboembolism,Thromboembolism,,,Thromboembolism,C0040038
1934,C0035648,risk factors,risk factors,,,risk factors,C0035648
1935,C1120149,thienopyridine,thienopyridine,,,thienopyridine,C1120149
1936,C0232809,Glomerular filtration,Glomerular Filtration Rate,,,Glomerular Filtration Rate,C0017654
1937,C0035448,Rheumatoid Factor,Rheumatoid Factor,,,Rheumatoid Factor,C0035448
1938,C1446409,Positive,NA TO BE DELETED,,,NA TO BE DELETED,NA
1939,C4318437,Anti-Cyclic Citrullinated Protein Antibodies,Anti-Cyclic Citrullinated Protein Antibodies,,,Anti-Cyclic Citrullinated Protein Antibodies,C4318437
1940,C0948089,Acute Coronary Syndrome,Acute Coronary Syndrome,,,Acute Coronary Syndrome,C0948089
1941,C0441471,Event,NA TO BE DELETED,,,NA TO BE DELETED,NA
1942,C0149871,Deep Vein Thrombosis,Deep Vein Thrombosis,,,Deep Vein Thrombosis,C0149871
1943,C1565489,Renal Insufficiency,Renal Insufficiency,,,Renal Insufficiency,C1565489
1944,C2945599,Mild (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
1945,C0232805,Normal renal function,Renal function,,,Renal function,C0232804
1946,C0205322,Persistent,NA TO BE DELETED,,,NA TO BE DELETED,NA
1947,C4330985,Per Millimeter,NA TO BE DELETED,,,NA TO BE DELETED,NA
1948,C0542339,Inferior,NA TO BE DELETED,,,NA TO BE DELETED,NA
1949,C1881332,Killip Class,Killip Class,,,Killip Class,C1881332
1950,C2697844,Killip Class I,Killip Class,,,Killip Class,C1881332
1951,C0002422,Ambulances,NA TO BE DELETED,,,NA TO BE DELETED,NA
1952,C0020003,"Hospitals, Community",NA TO BE DELETED,,,NA TO BE DELETED,NA
1953,C0680532,Amendment,NA TO BE DELETED,,,NA TO BE DELETED,NA
1954,C0040223,Time,NA TO BE DELETED,,,NA TO BE DELETED,NA
1955,C3537168,Antianginals,Antianginals,,,Antianginals,C3537168
1956,C0332189,Episode of,NA TO BE DELETED,,,NA TO BE DELETED,NA
1957,C0439422,milligram/day,NA TO BE DELETED,,,NA TO BE DELETED,NA
1958,C0054201,Budesonide,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
1959,C0868908,pancolitis,pancolitis,,,pancolitis,C0868908
1960,C0439211,microgram,NA TO BE DELETED,,,NA TO BE DELETED,NA
1961,C2887821,Colitis,Colitis,,,Colitis,C0009319
1962,C1514983,Stratification,NA TO BE DELETED,,,NA TO BE DELETED,NA
1963,C0070939,phosphoethanolamine,phosphoethanolamine,,,phosphoethanolamine,C0070939
1964,C0302113,Fragility,Fragility,,,Fragility,C0302113
1965,C0331873,nordic,Racial group,,,Racial group,C0034510
1966,C0242191,Pacific Islander Americans,Racial group,,,Racial group,C0034510
1967,C0037724,Southern Europe,Geographic Locations,,,Geographic Locations,C0017446
1968,C4282132,Malignancy,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1969,C0682125,Alaska Natives,Racial group,,,Racial group,C0034510
1970,C2825026,Unfractionated Heparin [EPC],Unfractionated Heparin [EPC],Heparin group,Antithrombotic Agents,Antithrombotic Agents,C1704311
1971,C0206460,Enoxaparin,Enoxaparin,Heparin group,Antithrombotic Agents,Antithrombotic Agents,C1704311
1972,C0455471,H/O: malignant neoplasm,Malignant Neoplasms,,,Malignant Neoplasms,C0006826
1972,C0455471,H/O: malignant neoplasm,Medical History,,,Medical History,C0262926
1973,C1955473,Others - Allergy,Others - Allergy,,,Others - Allergy,C1955473
1974,C0443211,Established,NA TO BE DELETED,,,NA TO BE DELETED,NA
1975,C0332307,Type - attribute,NA TO BE DELETED,,,NA TO BE DELETED,NA
1976,C0032923,Prealbumin,Prealbumin,,,Prealbumin,C0032923
1977,C0332152,Before,NA TO BE DELETED,,,NA TO BE DELETED,NA
1978,C0949236,Pulse Pressure,Pulse Pressure,,,Pulse Pressure,C0949236
1979,C0439092,Less Than,NA TO BE DELETED,,,NA TO BE DELETED,NA
1980,C0441885,Class 1,NA TO BE DELETED,,,NA TO BE DELETED,NA
1981,C0441886,Class 2,NA TO BE DELETED,,,NA TO BE DELETED,NA
1982,C1279919,Early,NA TO BE DELETED,,,NA TO BE DELETED,NA
1983,C0205421,Deferred,NA TO BE DELETED,,,NA TO BE DELETED,NA
1984,C0567349,milligram/millimole (mg/mmol),NA TO BE DELETED,,,NA TO BE DELETED,NA
1985,C0521942,Angiotensin II receptor antagonist,Angiotensin II receptor antagonist,,,Angiotensin II receptor antagonist,C0521942
1986,C0006684,Calcium Channel Blockers,Calcium Channel Blockers,,,Calcium Channel Blockers,C0006684
1987,C0242339,Dyslipidemias,Dyslipidemias,,,Dyslipidemias,C0242339
1988,C1518425,Not Otherwise Specified,NA TO BE DELETED,,,NA TO BE DELETED,NA
1989,C1257987,Thiazolidinediones,Thiazolidinediones,Antidiabetics,,Antidiabetics,C0935929
1990,C1442792,State,NA TO BE DELETED,,,NA TO BE DELETED,NA
1991,C2926735,Duration,NA TO BE DELETED,,,NA TO BE DELETED,NA
1992,C1627892,Microgram per Kilogram,NA TO BE DELETED,,,NA TO BE DELETED,NA
1993,C3490348,empagliflozin,empagliflozin,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,Antidiabetics,Antidiabetics,C0935929
1994,C4255010,Non-ST Elevated Myocardial Infarction,Non-ST Elevated Myocardial Infarction,Myocardial Infarction,,Myocardial Infarction,C0027051
1995,C4321396,MG,NA TO BE DELETED,,,NA TO BE DELETED,NA
1996,C0456387,Class,NA TO BE DELETED,,,NA TO BE DELETED,NA
1997,C0002871,Anemia,Anemia,,,Anemia,C0002871
1998,C0442038,Radial,NA TO BE DELETED,,,NA TO BE DELETED,NA
1999,C0449618,Target vessel,Target vessel,,,Target vessel,C0449618
2000,C0003842,Arteries,Arteries,,,Arteries,C0003842
2001,C4086878,Symptom Onset,NA TO BE DELETED,,,NA TO BE DELETED,NA
2002,C0205107,Proximal,NA TO BE DELETED,,,NA TO BE DELETED,NA
2003,C0087086,Thrombus,Thrombus,,,Thrombus,C0087086
2004,C1549488,Amount type - Percentage,NA TO BE DELETED,,,NA TO BE DELETED,NA
2005,C1300563,Gram per Kilogram,NA TO BE DELETED,,,NA TO BE DELETED,NA
2006,D054873,Dipeptidyl-Peptidase IV Inhibitors,Dipeptidyl-Peptidase IV Inhibitors,Antidiabetics,,Antidiabetics,C0935929
2007,C4086268,Exacerbation,NA TO BE DELETED,,,NA TO BE DELETED,NA
2008,C3641272,Very severe,NA TO BE DELETED,,,NA TO BE DELETED,NA
2009,C4522078,Group B,NA TO BE DELETED,,,NA TO BE DELETED,NA
2010,C0441838,Group D,NA TO BE DELETED,,,NA TO BE DELETED,NA
2011,C0457083,Usage,NA TO BE DELETED,,,NA TO BE DELETED,NA
2012,C0024117,Chronic Obstructive Airway Disease,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
2013,C0003811,Cardiac Arrhythmia,Cardiac Arrhythmia,,,Cardiac Arrhythmia,C0003811
2014,C0034787,Angiotensin Receptor,Angiotensin Receptor,,,Angiotensin Receptor,C0034787
2015,C0004604,Back Pain,Back Pain,,,Back Pain,C0004604
2016,C0441800,Grade,NA TO BE DELETED,,,NA TO BE DELETED,NA
2017,C0021400,Influenza,Influenza,,,Influenza,C0021400
2018,C0027441,Nasopharyngitis,Nasopharyngitis,,,Nasopharyngitis,C0027441
2019,C0205404,Serious,NA TO BE DELETED,,,NA TO BE DELETED,NA
2020,C0041912,Upper Respiratory Infections,Upper Respiratory Infections,,,Upper Respiratory Infections,C0041912
2021,C0869039,Unit dose,NA TO BE DELETED,,,NA TO BE DELETED,NA
2022,C2709270,Natriuretic peptide,Natriuretic peptide,,,Natriuretic peptide,C2709270
2023,C0754710,Amino-terminal pro-brain natriuretic peptide,Amino-terminal pro-brain natriuretic peptide,,,Amino-terminal pro-brain natriuretic peptide,C0754710
2024,C0008677,"Bronchitis, Chronic",Bronchitis,,,Bronchitis,C0006277
2025,C0014457,Eosinophilia,Eosinophilia,,,Eosinophilia,C0014457
2026,C0013990,Pathological accumulation of air in tissues,Pathological accumulation of air in tissues,,,Pathological accumulation of air in tissues,C0013990
2027,C0205430,Mixed (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
2028,C0006277,Bronchitis,Bronchitis,,,Bronchitis,C0006277
2029,C3494202,Time-to-Treatment,NA TO BE DELETED,,,NA TO BE DELETED,NA
2030,C1568891,"HGS protein, human","HGS protein, human",,,"HGS protein, human",C1568891
2031,C0557651,Room of building - Study,NA TO BE DELETED,,,NA TO BE DELETED,NA
2032,C3281223,"CEREBELLAR ATAXIA, NEUROPATHY, AND VESTIBULAR AREFLEXIA SYNDROME","CEREBELLAR ATAXIA, NEUROPATHY, AND VESTIBULAR AREFLEXIA SYNDROME",,,"CEREBELLAR ATAXIA, NEUROPATHY, AND VESTIBULAR AREFLEXIA SYNDROME",C3281223
2033,C0205090,Right,NA TO BE DELETED,,,NA TO BE DELETED,NA
2034,C1881056,History of peripheral vascular disease,Medical History,,,Medical History,C0262926
2034,C1881056,History of peripheral vascular disease,Peripheral Vascular Diseases,,,Peripheral Vascular Diseases,C0085096
2035,C1704311,Antithrombotic Agents,Antithrombotic Agents,,,Antithrombotic Agents,C1704311
2036,C0002688,Amputation,Amputation,,,Amputation,C0002688
2037,C2917241,Renin Inhibitors,Renin Inhibitors,,,Renin Inhibitors,C2917241
2038,C2348561,Study Population (group),NA TO BE DELETED,,,NA TO BE DELETED,NA
2039,C0002965,"Angina, Unstable","Angina, Unstable",Angi Pectoris,,Angina Pectoris,C0002962
2040,C0585943,Lipid-lowering therapy,Lipid-lowering therapy,,,Lipid-lowering therapy,C0585943
2041,C0679225,multiple pathologies,multiple pathologies,,,multiple pathologies,C0679225
2042,C0011298,Demography,Demography,,,Demography,C0011298
2043,C0596019,Chloride Ion,Chloride Ion,,,Chloride Ion,C0596019
2044,C1328319,Ankle brachial pressure index (observable entity),Ankle brachial pressure index (observable entity),,,Ankle brachial pressure index (observable entity),C1328319
2045,C0369718,N not otherwise specified Antibody,N not otherwise specified Antibody,,,N not otherwise specified Antibody,C0369718
2046,C1963154,"Renal Failure, CTCAE","Renal Failure, CTCAE",,,"Renal Failure, CTCAE",C1963154
2047,C0585890,History of cerebrovascular disease,Cerebrovascular disease,,,Cerebrovascular disease,NA
2047,C0585890,History of cerebrovascular disease,Medical History,,,Medical History,C0262926
2048,C3529352,evolocumab,evolocumab,"LIPID MODIFYING AGENTS, PLAIN",,"LIPID MODIFYING AGENTS, PLAIN",NA
2049,C1140609,Insulin pump,Insulin,,,Insulin,C0021641
2050,C0455531,H/O: heart failure,Heart failure,,,Heart failure,C0018801
2050,C0455531,H/O: heart failure,Medical History,,,Medical History,C0262926
2051,C0242444,Population at Risk,NA TO BE DELETED,,,NA TO BE DELETED,NA
2052,C0033144,Primary Prevention,NA TO BE DELETED,,,NA TO BE DELETED,NA
2053,C0149721,Left Ventricular Hypertrophy,Left Ventricular Hypertrophy,,,Left Ventricular Hypertrophy,C0149721
2054,C0581603,Revascularization - action,Revascularization - action,,,Revascularization - action,C0581603
2055,C1619634,erythrocyte sedimentation rate result,erythrocyte sedimentation rate result,,,erythrocyte sedimentation rate result,C1619634
2056,C0679646,Participant,NA TO BE DELETED,,,NA TO BE DELETED,NA
2057,C0439219,Pounds,NA TO BE DELETED,,,NA TO BE DELETED,NA
2058,C1521970,Characteristics,NA TO BE DELETED,,,NA TO BE DELETED,NA
2059,C0007430,Catheterization,Catheterization,,,Catheterization,C0007430
2060,C0003872,"Arthritis, Psoriatic","Arthritis, Psoriatic",,,"Arthritis, Psoriatic","C0003872	"
2060,C0003872,"Arthritis, Psoriatic","Arthritis, Psoriatic",,,"Arthritis, Psoriatic",C0003872
2061,C0005902,Body Surface Area,Body Surface Area,,,Body Surface Area,C0005902
2062,C0278947,prior biologic therapy,prior biologic therapy,,,prior biologic therapy,C0278947
2063,C0010594,Cyclosporins,Cyclosporins,,,Cyclosporins,C0010594
2064,C3899393,Dermatology Life Quality Index Questionnaire,Dermatology Life Quality Index Questionnaire,,,Dermatology Life Quality Index Questionnaire,C3899393
2065,C0050559,Acitretin,Acitretin,Retinoids for treatment of psoriasis,ANTIPSORIATICS,ANTIPSORIATICS,NA
2066,C0332237,Topical surface,NA TO BE DELETED,,,NA TO BE DELETED,NA
2067,C0454530,Ultraviolet B therapy,Ultraviolet B therapy,,,Ultraviolet B therapy,C0454530
2068,C0853073,PUVA Photochemotherapy,PUVA Photochemotherapy,,,PUVA Photochemotherapy,C0853073
2069,C0025677,Methotrexate,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
2070,C1872109,certolizumab pegol,certolizumab pegol,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
2071,C1290384,Structural disorder of heart,Structural disorder of heart,,,Structural disorder of heart,C1290384
2072,C4013784,"Hypertension, severe","Hypertension, CTCAE",,,"Hypertension, CTCAE",C1963138
2073,C0017431,Genotype,Genotype,,,Genotype,C0017431
2074,C0239945,heparin use,heparin,Antithrombotic Agents,,Antithrombotic Agents,C1704311
2075,C0205171,Singular,NA TO BE DELETED,,,NA TO BE DELETED,NA
2076,C0205225,Primary,NA TO BE DELETED,,,NA TO BE DELETED,NA
2077,C0439178,percent positive cells,NA TO BE DELETED,,,NA TO BE DELETED,NA
2078,C0026385,Molecular Weight,Molecular Weight,,,Molecular Weight,C0026385
2079,C0205372,Tertiary,NA TO BE DELETED,,,NA TO BE DELETED,NA
2080,C0439232,Minute of time,NA TO BE DELETED,,,NA TO BE DELETED,NA
2081,C0340288,Stable angina,Stable angina,,,Stable angina,C0340288
2082,C0015811,Femur,Femur,,,Femur,C0015811
2083,C4696290,Aspirin dose,Aspirin,,,Aspirin,C0004057
2084,C0024671,Mammography,Mammography,,,Mammography,C0024671
2085,C0449442,Marker status,Marker status,,,Marker status,C0449442
2086,C0742343,Acute Chest Syndrome,Acute Chest Syndrome,,,Acute Chest Syndrome,C0742343
2087,C0392877,infusion of drug,infusion of drug,,,infusion of drug,C0392877
2088,C0702093,Per Minute,NA TO BE DELETED,,,NA TO BE DELETED,NA
2089,C0011854,"Diabetes Mellitus, Insulin-Dependent",Diabetes Mellitus,,,Diabetes Mellitus,C0011849
2090,C0005847,Blood Vessel,Blood Vessel,,,Blood Vessel,C0005847
2091,C0168273,bivalirudin,bivalirudin,Direct thrombin inhibitors,Antithrombotic Agents,Antithrombotic Agents,C1704311
2092,C0038257,"Stent, device","Stent, device",,,"Stent, device",C0038257
2093,C2825200,Bare metal stent,"Stent, device",,,"Stent, device",C0038257
2094,C1322815,Drug-Eluting Stents,Drug-Eluting Stents,,,Drug-Eluting Stents,C1322815
2095,C3829066,Millimole per Mole,NA TO BE DELETED,,,NA TO BE DELETED,NA
2096,C1561643,Chronic Kidney Diseases,Chronic Kidney Diseases,Kidney Diseases,,Kidney Diseases,C0022658
2097,C4081854,High intensity,NA TO BE DELETED,,,NA TO BE DELETED,NA
2098,C0020615,Hypoglycemia,Hypoglycemia,,,Hypoglycemia,C0020615
2099,C3203102,Idiopathic pulmonary arterial hypertension,Idiopathic pulmonary arterial hypertension,,,Idiopathic pulmonary arterial hypertension,C3203102
2100,C0009782,Connective Tissue Diseases,Connective Tissue Diseases,,,Connective Tissue Diseases,C0009782
2101,C1134681,Endothelin receptor antagonist,Endothelin receptor antagonist,,,Endothelin receptor antagonist,C1134681
2102,C0031638,Phosphodiesterase Inhibitors,Phosphodiesterase Inhibitors,CARDIAC THERAPY,,CARDIAC THERAPY,NA
2103,C1272705,Unsuccessful,NA TO BE DELETED,,,NA TO BE DELETED,NA
2104,C0451521,Swollen joint count,NA TO BE DELETED,,,NA TO BE DELETED,NA
2105,C0451530,Tender joint count,NA TO BE DELETED,,,NA TO BE DELETED,NA
2106,C0449462,Length of stent,"Stent, device",,,"Stent, device",C0038257
2107,C0006949,Carbamazepine,Carbamazepine,ANTIEPILEPTICS,,ANTIEPILEPTICS,NA
2108,C0023556,Levamisole,Levamisole,Imidazothiazole derivatives,ANTINEMATODAL AGENTS,ANTINEMATODAL AGENTS,NA
2109,C0332157,Exposure to,NA TO BE DELETED,,,NA TO BE DELETED,NA
2110,C0076829,topiramate,topiramate,ANTIEPILEPTICS,,ANTIEPILEPTICS,NA
2111,C0005821,Blood Platelets,Blood Platelets,,,Blood Platelets,C0005821
2112,C0205682,Waist-Hip Ratio,Waist-Hip Ratio,,,Waist-Hip Ratio,C0205682
2113,C0009458,Communications Media,NA TO BE DELETED,,,NA TO BE DELETED,NA
2114,C0065058,Lipoprotein (a),lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
2115,C0418981,Medical therapy,NA TO BE DELETED,,,NA TO BE DELETED,NA
2116,C0016522,"Foramen Ovale, Patent","Foramen Ovale, Patent",,,"Foramen Ovale, Patent",C0016522
2117,C0232180,Cardiac shunt,Cardiac shunt,,,Cardiac shunt,C0232180
2118,C2986535,Primary Endpoint,NA TO BE DELETED,,,NA TO BE DELETED,NA
2119,C0016327,Fluorides,Fluorides,,,Fluorides,C0016327
2120,C0439297,Nanogram per Liter,NA TO BE DELETED,,,NA TO BE DELETED,NA
2121,C0042963,Vomiting,Vomiting,,,Vomiting,C0042963
2122,C0007584,Cell Count,NA TO BE DELETED,,,NA TO BE DELETED,NA
2123,C1415800,HTN1 gene,Genotype,,,Genotype,C0017431
2124,C1558950,Adverse Event Associated with Vascular,NA TO BE DELETED,,,NA TO BE DELETED,NA
2125,C0302350,Therapeutic,NA TO BE DELETED,,,NA TO BE DELETED,NA
2126,C0015684,Fatty Acids,Fatty Acids,,,Fatty Acids,C0015684
2127,C0033687,Proteinuria,Proteinuria,,,Proteinuria,C0033687
2128,C0001925,Albuminuria,Albuminuria,,,Albuminuria,C0001925
2129,C1142985,ezetimibe,ezetimibe,Other lipid modifying agents,LIPID MODIFYING AGENTS,LIPID MODIFYING AGENTS,NA
2130,C1449704,Fibrates,Fibrates,"LIPID MODIFYING AGENTS, PLAIN",,"LIPID MODIFYING AGENTS, PLAIN",NA
2131,C0683312,Categories,NA TO BE DELETED,,,NA TO BE DELETED,NA
2132,C0443343,Unstable status,NA TO BE DELETED,,,NA TO BE DELETED,NA
2133,C0428621,High density/low density lipoprotein ratio result,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
2134,C1171408,High density/low density lipoprotein ratio measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
2135,C0586793,Inhaled steroids use,Inhaled steroids use,,,Inhaled steroids use,C0586793
2136,C0681842,prediction,NA TO BE DELETED,,,NA TO BE DELETED,NA
2137,C0232187,Cardiac rhythm type,Cardiac rhythm type,,,Cardiac rhythm type,C0232187
2138,C0232201,Sinus rhythm,Sinus rhythm,,,Sinus rhythm,C0232201
2139,C0669479,pro-brain natriuretic peptide (1-76),pro-brain natriuretic peptide (1-76),,,pro-brain natriuretic peptide (1-76),C0669479
2140,C0522498,Rare,NA TO BE DELETED,,,NA TO BE DELETED,NA
2141,C0019930,Postmenopausal Hormone Replacement Therapy,Hormone Therapy,,,Hormone Therapy,C0279025
2141,C0019930,Postmenopausal Hormone Replacement Therapy,Postmenopausal state,Menopausal Status,,Menopausal Status,C1513126
2142,C0042874,Vitamin E,Vitamin E,,,Vitamin E,C0042874
2143,C0205177,Active,NA TO BE DELETED,,,NA TO BE DELETED,NA
2144,C0679699,Secondary Prevention,NA TO BE DELETED,,,NA TO BE DELETED,NA
2145,C1317301,diabetes status,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
2146,C0521117,Severity of illness,NA TO BE DELETED,,,NA TO BE DELETED,NA
2147,C0087130,Uncertainty,NA TO BE DELETED,,,NA TO BE DELETED,NA
2148,C2699193,Cholesterol to HDL-Cholesterol Ratio Measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
2149,C1535899,Non-High Density Lipoprotein Cholesterol Measurement,lipoprotein cholesterol,,,lipoprotein cholesterol,C0065055
2150,C1313937,Family history of diabetes mellitus,Diabetes Mellitus,,,Diabetes Mellitus,C0011849
2150,C1313937,Family history of diabetes mellitus,Family history,,,Family history,C0241889
2151,C0085201,Apolipoprotein A-I,Apolipoprotein A-I,,,Apolipoprotein A-I,C0085201
2152,C0039411,Technetium,Technetium,,,Technetium,C0039411
2153,C0073633,ranolazine,ranolazine,CARDIAC THERAPY,,CARDIAC THERAPY,NA
2154,C0271650,Impaired glucose tolerance,Impaired glucose tolerance,,,Impaired glucose tolerance,C0271650
2155,C0441074,Meters (physical object),NA TO BE DELETED,,,NA TO BE DELETED,NA
2156,C0252643,bosentan,bosentan,Antihypertensives for pulmory arterial hypertension,Antihypertensive Agents,Antihypertensive Agents,C0003364
2157,C0152171,Idiopathic pulmonary hypertension,Idiopathic pulmonary hypertension,,,Idiopathic pulmonary hypertension,C0152171
2158,C0235828,Lack of Efficacy,NA TO BE DELETED,,,NA TO BE DELETED,NA
2159,C0424641,Decrease in height,NA TO BE DELETED,,,NA TO BE DELETED,NA
2160,C0451306,Mini-mental state examination,Mental state,,,Mental state,C0278060
2161,C1508496,Quintile,NA TO BE DELETED,,,NA TO BE DELETED,NA
2162,C0337954,Tertiary care hospital,NA TO BE DELETED,,,NA TO BE DELETED,NA
2163,C0063034,huperzine B,huperzine B,,,huperzine B,C0063034
2164,C1442160,Cutoff,NA TO BE DELETED,,,NA TO BE DELETED,NA
2165,C1257890,Population Group,NA TO BE DELETED,,,NA TO BE DELETED,NA
2166,C0016018,Fibrinolytic Agents,Fibrinolytic Agents,,,Fibrinolytic Agents,C0016018
2167,C0038418,Streptokinase,Streptokinase,Antithrombotic Agents,,Antithrombotic Agents,C1704311
2168,C0965129,rosuvastatin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,,,Hydroxymethylglutaryl-CoA Reductase Inhibitors,C0360714
2169,C0728475,ultra,NA TO BE DELETED,,,NA TO BE DELETED,NA
2170,C0031437,Phenotype,Phenotype,,,Phenotype,C0031437
2171,C2700379,Poor - qualifier,NA TO BE DELETED,,,NA TO BE DELETED,NA
2172,C1516050,Assignment - action,NA TO BE DELETED,,,NA TO BE DELETED,NA
2173,C0154723,Migraine with Aura,Migraine Disorders,,,Migraine Disorders,C0149931
2174,C1532338,Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,,,Percutaneous Coronary Intervention,C1532338
2175,C1319441,Body mass index 40+ - severely obese,Body mass index,,,Body mass index,C1305855
2176,C0392756,Reduced,NA TO BE DELETED,,,NA TO BE DELETED,NA
2177,C0205217,Increased,NA TO BE DELETED,,,NA TO BE DELETED,NA
2178,C0151699,Intracranial Hemorrhage,Intracranial Hemorrhage,,,Intracranial Hemorrhage,C0151699
2179,C2746079,Anti-dsDNA Antibody,Anti-dsDNA Antibody,,,Anti-dsDNA Antibody,C2746079
2180,C0036043,Safety,NA TO BE DELETED,,,NA TO BE DELETED,NA
2181,C1565750,sitagliptin,Dipeptidyl-Peptidase IV Inhibitors,Antidiabetics,,Antidiabetics,C0935929
2182,C0205195,Combined,NA TO BE DELETED,,,NA TO BE DELETED,NA
2183,C0002915,General Anesthesia,Anesthesia procedures,,,Anesthesia procedures,C0002903
2184,C0002903,Anesthesia procedures,Anesthesia procedures,,,Anesthesia procedures,C0002903
2185,C3714938,Baseline Dyspnea Index Questionnaire,Baseline Dyspnea Index Questionnaire,,,Baseline Dyspnea Index Questionnaire,C3714938
2186,C0429706,Forced expiratory volume in 1 second finding,Forced expiratory volume in 1 second finding,Forced expiratory volume function,,Forced expiratory volume function,C0016529
2187,C3842462,On pump,NA TO BE DELETED,,,NA TO BE DELETED,NA
2188,C1883710,Clamping Activity,Clamping Activity,Physical activity,,Physical activity,C0026606
2189,C0543465,Serum Potassium result,potassium measurement,Potassium,,Potassium,C0032821
2190,C1519269,Serving,NA TO BE DELETED,,,NA TO BE DELETED,NA
2191,D019918,Heart Valve Prosthesis Implantation,Heart Valve Prosthesis Implantation,,,Heart Valve Prosthesis Implantation,D019918
2192,C0225860,Left atrial structure,Left atrial structure,,,Left atrial structure,C0225860
2193,C0003761,Country of Argentina,Geographic Locations,,,Geographic Locations,C0017446
2194,XXXXXX,Drug loading,NA TO BE DELETED,,,NA TO BE DELETED,NA
2195,C0948008,Ischemic stroke,Ischemic stroke,"Stroke, CTCAE",,"Stroke, CTCAE",C4554100
2196,C2348066,dabigatran,Anticoagulants,,,Anticoagulants,C0003280
2197,D059168,Carotid intimal medial thickness,Carotid intimal medial thickness,,,Carotid intimal medial thickness,D059168
2198,C0011570,Mental Depression,Mental state,,,Mental state,C0278060
2199,C0424594,Frailty,Fragility,,,Fragility,C0302113
2200,C0871754,Frail,Fragility,,,Fragility,C0302113
2201,C1522541,Protocol Treatment Arm,NA TO BE DELETED,,,NA TO BE DELETED,NA
2202,C4553389,Study Control,NA TO BE DELETED,,,NA TO BE DELETED,NA
2203,C0213771,tiotropium,Bronchodilator Agents,,,Bronchodilator Agents,C0006280
2204,C0037747,Spain,Geographic Locations,,,Geographic Locations,C0017446
2205,C0007294,Genetic Carriers,Genetic Carriers,,,Genetic Carriers,C0007294
2206,C0019904,Homozygote,Homozygote,,,Homozygote,C0019904
2207,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",Diabetes Mellitus,,,Diabetes Mellitus,C0011849
2208,C0168634,BaseLine dental cement,BaseLine dental cement,,,BaseLine dental cement,C0168634
2209,C0005382,Biguanides,Biguanides,Antidiabetics,,Antidiabetics,C0935929
2210,C0221099,Impaired,NA TO BE DELETED,,,NA TO BE DELETED,NA
2211,C3146289,Anatomic bifurcation,Infarction Anatomic Site ,,,Infarction Anatomic Site ,NA
2212,C0205435,First (number),NA TO BE DELETED,,,NA TO BE DELETED,NA
2213,C0205436,second (number),NA TO BE DELETED,,,NA TO BE DELETED,NA
2214,C0184906,Bifurcation (procedure),NA TO BE DELETED,,,NA TO BE DELETED,NA
2215,C1121991,cangrelor,Antiplatelet Agents,,,Antiplatelet Agents,C0085826
2216,C0070166,clopidogrel,clopidogrel,Platelet aggregation inhibitors excl. heparin,Antithrombotic Agents,Antithrombotic Agents,C1704311
2217,C1257882,Australasia,Geographic Locations,,,Geographic Locations,C0017446
2218,C0549409,Packed cell volume increased,Packed cell volume increased,,,Packed cell volume increased,C0549409
2219,C0220908,Screening procedure,NA TO BE DELETED,,,NA TO BE DELETED,NA
2220,C0008120,Chinese Language,Racial group,,,Racial group,C0034510
2221,C0429886,Walking distance,Walking (activity),Physical activity,,Physical activity,C0026606
2222,C0439227,Hour,NA TO BE DELETED,,,NA TO BE DELETED,NA
2223,C0520997,"Thrombolysis, function",Thrombolysis,,,Thrombolysis,NA
2224,C0018787,Heart,Heart,Cardiovascular system,,Cardiovascular system,C0007226
2225,C0035124,Reperfusion Therapy,Reperfusion Therapy,,,Reperfusion Therapy,C0035124
2226,C0428302,Calcium level result,Calcium level result,,,Calcium level result,C0428302
2227,C4546361,Charlson Comorbidity Index,Charlson Comorbidity Index,,,Charlson Comorbidity Index,C4546361
2228,C0080331,Walking (activity),Walking (activity),Physical activity,,Physical activity,C0026606
2229,C0019557,Hip Fractures,Hip Fractures,,,Hip Fractures,C0019557
2230,C0278060,Mental state,Mental state,,,Mental state,C0278060
2231,C0745355,intertrochanteric,intertrochanteric,,,intertrochanteric,C0745355
2232,C0439230,week,NA TO BE DELETED,,,NA TO BE DELETED,NA
2233,C0016658,Fracture,Fracture,,,Fracture,C0016658
2234,C4318935,Mobility Ability,Mobility Ability,,,Mobility Ability,C4318935
2235,C0497406,Overweight,Overweight,,,Overweight,C0497406
2236,C1225105,Sia,NA TO BE DELETED,,,NA TO BE DELETED,NA
2237,C0487652,Thyroperoxidase Antibody,Thyroperoxidase Antibody,,,Thyroperoxidase Antibody,C0487652
2238,C0011702,Desmosine,Desmosine,,,Desmosine,C0011702
2239,C0597484,Sodium Cation,Sodium Cation,,,Sodium Cation,C0597484
2240,C0037982,Spironolactone,Spironolactone,Aldosterone antagonists,DIURETICS,DIURETICS,NA
2241,C1739768,rivaroxaban,rivaroxaban,Direct factor Xa inhibitors,Antithrombotic Agents,Antithrombotic Agents,C1704311
2242,C0004482,Azathioprine,Immunosuppressive Agents,,,Immunosuppressive Agents,C0021081
2243,C0666743,infliximab,infliximab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
2244,C0332324,Sensitive,NA TO BE DELETED,,,NA TO BE DELETED,NA
2245,C0054015,Nesiritide,Nesiritide,VASODILATORS USED IN CARDIAC DISEASES,CARDIAC THERAPY,CARDIAC THERAPY,NA
2246,C0077401,Troponin I,Troponin,,,Troponin,C0041199
2247,C0444504,Statistical mean,NA TO BE DELETED,,,NA TO BE DELETED,NA
2248,C3887460,Cardiovascular,Cardiovascular Diseases,,,Cardiovascular Diseases,C0007222
2249,C0085805,Androgen Binding Protein,Androgen Binding Protein,,,Androgen Binding Protein,C0085805
2250,C0205170,Good,NA TO BE DELETED,,,NA TO BE DELETED,NA
2251,C3826998,Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire,Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire,,,Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire,C3826998
2252,C0544452,Disease remission,NA TO BE DELETED,,,NA TO BE DELETED,NA
2253,C0073992,salmeterol,long-acting beta agonist,,,long-acting beta agonist,NA
2254,C3869583,Clinical disease activity index,NA TO BE DELETED,,,NA TO BE DELETED,NA
2255,C0439165,Percent (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
2256,C0031001,Perfusion (procedure),Perfusion (procedure),,,Perfusion (procedure),C0031001
2257,C0060323,Fibrin fragment D,Fibrin,,,Fibrin,C0015982
2258,C0398623,Thrombophilia,Thrombophilia,,,Thrombophilia,C0398623
2259,C0038348,Compression Stockings,NA TO BE DELETED,,,NA TO BE DELETED,NA
2260,C0242707,Right Ventricular Dysfunction,Right Ventricular Dysfunction,,,Right Ventricular Dysfunction,C0242707
2261,C1167956,Cardiac Resynchronization Therapy,Cardiac Resynchronization Therapy,,,Cardiac Resynchronization Therapy,C1167956
2262,C0012265,Digoxin,Digoxin,Digitalis glycosides,CARDIAC THERAPY,CARDIAC THERAPY,NA
2263,C0162589,Implantable defibrillator,Implantable defibrillator,,,Implantable defibrillator,C0162589
2264,C1579268,Mineralocorticoid Receptor Antagonists,Mineralocorticoid Receptor Antagonists,,,Mineralocorticoid Receptor Antagonists,C1579268
2265,C0014025,Enalapril,Angiotensin-Converting Enzyme Inhibitors,,,Angiotensin-Converting Enzyme Inhibitors,C0003015
2266,C4033631,sacubitril / valsartan,Angiotensin Receptor Antagonists,,,Angiotensin Receptor Antagonists,C0815017
2267,C1620287,prasugrel,prasugrel,Antithrombotic Agents,,Antithrombotic Agents,C1704311
2268,C1261287,Stenosis,Stenosis,,,Stenosis,C1261287
2269,C0039155,Systole,NA TO BE DELETED,,,NA TO BE DELETED,NA
2270,C1272092,Impaired fasting glycaemia,Impaired fasting glycaemia,,,Impaired fasting glycaemia,C1272092
2271,C1442989,Standard (qualifier),NA TO BE DELETED,,,NA TO BE DELETED,NA
2272,C0362046,Prediabetes syndrome,Prediabetes syndrome,,,Prediabetes syndrome,C0362046
2273,C0918012,Index,NA TO BE DELETED,,,NA TO BE DELETED,NA
2274,C2364172,Adherence To Medication Regime,NA TO BE DELETED,,,NA TO BE DELETED,NA
2275,C0205281,Invasive,NA TO BE DELETED,,,NA TO BE DELETED,NA
2276,C0199168,Medical service,NA TO BE DELETED,,,NA TO BE DELETED,NA
2277,C1998004,Bath ankylosing spondylitis disease activity index,Bath ankylosing spondylitis disease activity index,,,Bath ankylosing spondylitis disease activity index,C1998004
2278,C0239161,Dactylitis,Dactylitis,,,Dactylitis,C0239161
2279,C1282952,Enthesitis,Enthesitis,,,Enthesitis,C1282952
2280,C0038012,Spondylitis,Spondylitis,,,Spondylitis,C0038012
2281,C0003506,Replacement of aortic valve (procedure),Replacement of aortic valve (procedure),,,Replacement of aortic valve (procedure),C0003506
2282,C0683469,surgical methods,surgical methods,,,surgical methods,C0683469
2283,C0184661,Interventional procedure,NA TO BE DELETED,,,NA TO BE DELETED,NA
2284,C0004916,Beds,NA TO BE DELETED,,,NA TO BE DELETED,NA
2285,C0005775,Blood Circulation,Blood Circulation,,,Blood Circulation,C0005775
2286,C0001613,Adrenal Cortex,Adrenal Cortex,,,Adrenal Cortex,C0001613
2287,C0149566,Structure of middle cerebral artery,Structure of middle cerebral artery,,,Structure of middle cerebral artery,C0149566
2288,C0311277,"Obesity, Abdominal",Obesity,,,Obesity,C0028754
2289,C0001701,"Exercise, Aerobic",Exercise,Physical activity,,Physical activity,C0026606
2290,C0018017,objective (goal),NA TO BE DELETED,,,NA TO BE DELETED,NA
2291,C4528685,Psoriasis Area and Severity Index Clinical Classification,Psoriasis Area and Severity Index Clinical Classification,Psoriasis,,Psoriasis,C0033860
2292,C3279454,Renal dysfunction,Renal dysfunction,,,Renal dysfunction,C3279454
2293,C0021027,Immunoglobulins,Immunoglobulins,,,Immunoglobulins,C0021027
2294,C0439457,International Unit per Liter,NA TO BE DELETED,,,NA TO BE DELETED,NA
2295,C4053960,Systemic Corticosteroid Therapy,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
2296,C0027430,Nasal Polyps,Nasal Polyps,,,Nasal Polyps,C0027430
2297,C0024091,Bone structure of lumbar vertebra,Bone structure of lumbar vertebra,,,Bone structure of lumbar vertebra,C0024091
2298,C0019552,Hip structure,Hip structure,,,Hip structure,C0019552
2299,C0015815,Structure of neck of femur,Structure of neck of femur,,,Structure of neck of femur,C0015815
2300,C0080179,Spinal Fractures,Spinal Fractures,,,Spinal Fractures,C0080179
2301,C0037949,Vertebral column,Vertebral column,,,Vertebral column,C0037949
2302,C0008976,Clinical Trials,NA TO BE DELETED,,,NA TO BE DELETED,NA
2303,C0015663,Fasting,NA TO BE DELETED,,,NA TO BE DELETED,NA
2304,C3714541,Forced Vital Capacity,Forced Vital Capacity,,,Forced Vital Capacity,C3714541
2305,C0205390,Phase,NA TO BE DELETED,,,NA TO BE DELETED,NA
2306,C0392366,Tests (qualifier value),NA TO BE DELETED,,,NA TO BE DELETED,NA
2307,D054143,Systolic Heart Failure (HFrEF),Systolic Heart Failure (HFrEF),Heart failure,,Heart failure,C0018801
2308,C0014939,Estrogens,Estrogens,,,Estrogens,C0014939
2309,C0451071,Crohn's disease activity index,Crohn Disease,,,Crohn Disease,C0010346
2310,C0009368,Colon structure (body structure),Colon structure (body structure),,,Colon structure (body structure),C0009368
2311,C0020885,ileum,ileum,,,ileum,C0020885
2312,C2828255,Quartile,NA TO BE DELETED,,,NA TO BE DELETED,NA
2313,C0221690,Syndesmophyte,Syndesmophyte,,,Syndesmophyte,C0221690
2314,C0451528,Systemic lupus erythematosus disease activity index,"Lupus Erythematosus, Systemic",,,"Lupus Erythematosus, Systemic",C0024141
2315,C1456820,Tumor Necrosis Factor-alpha,Tumor Necrosis Factor-alpha,,,Tumor Necrosis Factor-alpha,C1456820
2316,C0021764,Interleukins,Interleukins,IMMUNOSTIMULANTS,,IMMUNOSTIMULANTS,NA
2317,D008274,Magnesium,Magnesium,,,Magnesium,D008274
2318,C4330837,Number of Events,NA TO BE DELETED,,,NA TO BE DELETED,NA
2319,C1452534,"ACE protein, human","ACE protein, human",,,"ACE protein, human",C1452534
2320,C2603360,T prime,NA TO BE DELETED,,,NA TO BE DELETED,NA
2321,C0456081,Adjustment Action,NA TO BE DELETED,,,NA TO BE DELETED,NA
2322,C1439367,unadjusted,NA TO BE DELETED,,,NA TO BE DELETED,NA
2323,C0439378,cells/uL,NA TO BE DELETED,,,NA TO BE DELETED,NA
2324,C0018824,Heart valve disease,Heart valve disease,,,Heart valve disease,C0018824
2325,C1444748,Triggered by,NA TO BE DELETED,,,NA TO BE DELETED,NA
2326,C0439801,Limited (extensiveness),NA TO BE DELETED,,,NA TO BE DELETED,NA
2327,C0439294,Kilogram per Cubic Meter,NA TO BE DELETED,,,NA TO BE DELETED,NA
2328,C3536830,beta-Adrenergic Blocker [EPC],beta-Adrenergic Blocker [EPC],,,beta-Adrenergic Blocker [EPC],C3536830
2329,C1306577,Death (finding),NA TO BE DELETED,,,NA TO BE DELETED,NA
2330,C0033860,Psoriasis,Psoriasis,,,Psoriasis,C0033860
2331,C0041980,Uric Acid,Uric Acid,,,Uric Acid,C0041980
2332,C0444956,High dose,NA TO BE DELETED,,,NA TO BE DELETED,NA
2333,C0232100,Exsanguination,Exsanguination,,,Exsanguination,C0232100
2334,C1276807,Budesonide / formoterol,corticosteroid use,Anti-Inflammatory Agents,,Anti-Inflammatory Agents,C0003209
2335,C0024141,"Lupus Erythematosus, Systemic","Lupus Erythematosus, Systemic",,,"Lupus Erythematosus, Systemic",C0024141
2336,C0205172,More,NA TO BE DELETED,,,NA TO BE DELETED,NA
2337,C4284282,COPD Assessment Test Questionnaire,Chronic Obstructive Airway Disease,,,Chronic Obstructive Airway Disease,C0024117
2338,C2733224,Asthma control test score,Asthma,,,Asthma,C0004096
2339,C0359086,oral hypoglycemic,oral hypoglycemic,,,oral hypoglycemic,C0359086
2340,C0003537,Aphasia,Aphasia,,,Aphasia,C0003537
2341,C0007282,Carotid Stenosis,Carotid Stenosis,,,Carotid Stenosis,C0007282
2342,C0009488,Comorbidity,Comorbidity,,,Comorbidity,C0009488
2343,C4505301,Anti-Citrullinated Protein Antibodies,Anti-Citrullinated Protein Antibodies,,,Anti-Citrullinated Protein Antibodies,C4505301
2344,C0872146,disease length,NA TO BE DELETED,,,NA TO BE DELETED,NA
2345,C0451208,Health assessment questionnaire,Health assessment questionnaire,,,Health assessment questionnaire,C0451208
2346,C3871128,SDAI,SDAI,,,SDAI,C3871128
2347,C0806481,IgE.total,IgE.total,,,IgE.total,C0806481
2348,C3812270,Periostin Measurement,Periostin Measurement,,,Periostin Measurement,C3812270
2349,C0521143,Seropositive,NA TO BE DELETED,,,NA TO BE DELETED,NA
2350,C1122087,adalimumab,adalimumab,Tumor necrosis factor alpha (TNF-?) inhibitors,Immunosuppressive Agents,Immunosuppressive Agents,C0021081
2351,C0014758,Erythrityl Tetranitrate,Erythrityl Tetranitrate,,,Erythrityl Tetranitrate,C0014758
2352,C0680240,Agreement,NA TO BE DELETED,,,NA TO BE DELETED,NA
2353,C3826977,Modified Medical Research Council Dyspnea Scale Questionnaire,Modified Medical Research Council Dyspnea Scale Questionnaire,,,Modified Medical Research Council Dyspnea Scale Questionnaire,C3826977
2354,C0242960,Genetic Heterogeneity,Genetic Heterogeneity,,,Genetic Heterogeneity,C0242960
2355,C0443252,Long-term,NA TO BE DELETED,,,NA TO BE DELETED,NA
2356,C0443303,short-term,NA TO BE DELETED,,,NA TO BE DELETED,NA
2357,C0521983,Absence of therapeutic response,NA TO BE DELETED,,,NA TO BE DELETED,NA
2358,C1523987,Alternative,NA TO BE DELETED,,,NA TO BE DELETED,NA
2359,C1113685,cardiovascular disorder risk,cardiovascular disorder risk,,,cardiovascular disorder risk,C1113685
2360,C0242708,"Antirheumatic Drugs, Disease-Modifying","Antirheumatic Drugs, Disease-Modifying",,,"Antirheumatic Drugs, Disease-Modifying",C0242708
2361,C0010346,Crohn Disease,Crohn Disease,,,Crohn Disease,C0010346
2362,C0009324,Ulcerative Colitis,Ulcerative Colitis,,,Ulcerative Colitis,C0009324
2363,C2986416,Noncarrier,NA TO BE DELETED,,,NA TO BE DELETED,NA
2364,C2746078,Linagliptin,Dipeptidyl-Peptidase IV Inhibitors,Antidiabetics,,Antidiabetics,C0935929
2365,C0011816,Dextromethorphan,Dextromethorphan,Opium alkaloids and derivatives,,Opium alkaloids and derivatives,NA
2366,C0439393,Liter per Minute,NA TO BE DELETED,,,NA TO BE DELETED,NA
2367,C0027496,Nauru,Geographic Locations,,,Geographic Locations,C0017446
2368,C0022658,Kidney Diseases,Kidney Diseases,,,Kidney Diseases,C0022658
2369,C1709269,North,NA TO BE DELETED,,,NA TO BE DELETED,NA
2370,C1321567,hyperglycemic agent,hyperglycemic agent,,,hyperglycemic agent,C1321567
2371,C0451148,Enthesitis index,Enthesitis,,,Enthesitis,C1282952
2372,C1292734,Treatment intent,NA TO BE DELETED,,,NA TO BE DELETED,NA
2373,C0205087,Late,NA TO BE DELETED,,,NA TO BE DELETED,NA
2374,C0029408,Degenerative polyarthritis,Degenerative polyarthritis,,,Degenerative polyarthritis,C0029408
